High-purity steviol glycosides

ABSTRACT

Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.14/894,084, filed Nov. 25, 2015, which is a national phase applicationunder 35 U.S.C. § 371 of International Application No.PCT/US2014/039758, filed on 28 May 2014, which claims the benefit ofU.S. Provisional Patent Application No. 61/827,922, filed May 28, 2013;U.S. Provisional Patent Application No. 61/843,544, filed Jul. 8, 2013;U.S. Provisional Patent Application No. 61/861,528, filed Aug. 2, 2013;U.S. Provisional Patent Application No. 61/881,166, filed Sep. 23, 2013;U.S. Provisional Patent Application No. 61/885,084, filed Oct. 1, 2013;U.S. Provisional Patent Application No. 61/904,751, filed Nov. 15, 2013;U.S. Provisional Patent Application No. 61/913,482, filed Dec. 9, 2013;U.S. Provisional Patent Application No. 61/921,635, filed Dec. 30, 2013;U.S. Provisional Patent Application No. 61/925,329, filed Jan. 9, 2014and U.S. Provisional Patent Application No. 61/939,855, filed Feb. 14,2014, the disclosures of all of which are incorporated herein byreference.

JOINT RESEARCH AGREEMENT

The present disclosure was made by or on behalf of the below listedparties to a joint research agreement. The joint research agreement wasin effect on or before the date the present disclosure was made and thepresent disclosure was made as a result of activities undertaken withinthe scope of the joint research agreement. The parties to the jointresearch agreement are 1) PURECIRCLE SDN BHD and 2) THE COCA-COLACOMPANY.

TECHNICAL FIELD

The present invention relates to a biocatalytic process for preparingcompositions comprising steviol glycosides, including highly purifiedsteviol glycoside compositions. The present invention also relates tonovel steviol glycosides, methods for isolation of the same and uses forthe novel steviol glycosides.

BACKGROUND OF THE INVENTION

High intensity sweeteners possess a sweetness level that is many timesgreater than the sweetness level of sucrose. They are essentiallynon-caloric and are commonly used in diet and reduced-calorie products,including foods and beverages. High intensity sweeteners do not elicit aglycemic response, making them suitable for use in products targeted todiabetics and others interested in controlling for their intake ofcarbohydrates.

Steviol glycosides are a class of compounds found in the leaves ofStevia rebaudiana Bertoni, a perennial shrub of the Asteraceae(Compositae) family native to certain regions of South America. They arecharacterized structurally by a single base, steviol, differing by thepresence of carbohydrate residues at positions C13 and C19. Theyaccumulate in Stevia leaves, composing approximately 10%-20% of thetotal dry weight. On a dry weight basis, the four major glycosides foundin the leaves of Stevia typically include stevioside (9.1%),rebaudioside A (3.8%), rebaudioside C (0.6-1.0%) and dulcoside A (0.3%).Other known steviol glycosides include rebaudioside B, C, D, E, F and M,steviolbioside and rubusoside.

Although methods are known for preparing steviol glycosides from Steviarebaudiana, many of these methods are unsuitable for use commercially.

Accordingly, there remains a need for simple, efficient, and economicalmethods for preparing compositions comprising steviol glycosides,including highly purified steviol glycoside compositions.

Additionally, there remains a need for novel steviol glycosides andmethods of preparing and isolating the same.

SUMMARY OF THE INVENTION

The present invention provides a biocatalytic process for preparing acomposition comprising a target steviol glycoside comprising contactinga medium containing a starting composition comprising an organiccompound comprising at least one carbon atom with a biocatalyst, therebyproducing a composition comprising a target steviol glycoside.

In another embodiment, the present invention provides a method forproducing a target steviol glycoside comprising contacting an organiccompound and at least one enzyme selected from a steviol biosynthesisenzymes and a UDP-glycosyltransferases, thereby producing a compositioncomprising the target steviol glycoside.

The organic compound comprising at least one carbon atom is thesubstrate for the biotransformation. In one embodiment, the organiccompound is selected from the group consisting of polyols or sugaralcohols, or various carbohydrates. In another embodiment, the organiccompound at least one steviol glycoside.

The target steviol glycoside can be any steviol glycoside that is notthe same as the substrate steviol glycoside. In one embodiment, thetarget steviol glycoside is steviolmonoside, steviolbioside, rubusoside,dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, stevioside,rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I,rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K,rebaudioside J, rebaudioside M, rebaudioside M2, rebaudioside D,rebaudioside D2, rebaudioside N, rebaudioside O or a synthetic steviolglycoside.

In one embodiment, the target steviol glycoside is stevioside.

In another embodiment, the target steviol glycoside is rebaudioside A.

In still another embodiment, the target steviol glycoside isrebaudioside D.

In yet another embodiment, the target steviol glycoside is rebaudiosideM (also known as rebaudioside X).

In a preferred embodiments, the biocatalyst is an enzyme, or a cellcomprising one or more enzyme, capable of converting the organiccompound to target steviol glycosides. The biocatalyst can be located onthe surface and/or inside the cell. The biocatalyst can be provided inthe form of a whole cell suspension, a crude lysate or as purifiedenzyme(s). The biocatalyst can be in free form or immobilized to a solidsupport made from inorganic or organic materials.

In some embodiments, a microorganism comprises the necessarybiocatalyst(s) for converting the organic compound to target steviolglycosides. Accordingly, the present invention also provides abiocatalytic process for preparing a composition comprising a targetsteviol glycoside by contacting a starting composition comprising anorganic compound with a microorganism comprising at least one enzymecapable of converting the organic compound to target steviol glycosides,thereby producing a medium comprising at least one target steviolglycoside.

The enzymes necessary for converting the organic compound to targetsteviol glycosides include the steviol biosynthesis enzymes,UDP-glycosyltransferases (UGTs) and/or UDP-recycling enzyme.

In one embodiment the steviol biosynthesis enzymes are selected from thegroup consisting of geranylgeranyl diphosphate synthase, copalyldiphosphate synthase, kaurene synthase, kaurene oxidase, kaurenoic acid13-hydroxylase (KAH), steviol synthetase, deoxyxylulose 5-phosphatesynthase (DXS), D-1-deoxyxylulose 5-phosphate reductoisomerase (DXR),4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (CMS),4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK),4-diphosphocytidyl-2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase(MCS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate synthase (HDS),1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate reductase (HDR),acetoacetyl-CoA thiolase, truncated HMG-CoA reductase, mevalonatekinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylaseand cytochrome P450 reductase.

The UDP-glucosyltransferase can be any UDP-glucosyltransferase capableof adding at least one glucose unit to the steviol and or steviolglycoside substrate to provide the target steviol glycoside.

In one embodiment, steviol biosynthesis enzymes andUDP-glucosyltransferases are produced in a microorganism. Themicroorganism may be, for example, E. coli, Saccharomyces sp.,Aspergillus sp., Pichia sp., Bacillus sp., Yarrowia sp. etc. In anotherembodiment, the UDP-glucosyltransferases are synthesized.

In one embodiment, the UDP-glucosyltransferase is selected from groupconsisting of UGT74G1, UGT85C2, UGT76G1, UGT91D2, UGTSL, UGTSL_Sc,UGTSL2 (GI No. 460410132 version XP_004250485.1), UGTLB, GI No.460409128 (UGTSL) version XP_004249992.1, GI No. 115454819 versionNP_001051010.1, GI No. 187373030, version ACD03249.1, GI No. 222619587version EEE55719.1, GI No. 297795735 version XP_002865752.1 or EUGT11and UGTs having substantial (>85%) identity to these polypeptides aswell as isolated nucleic acid molecules that code for these UGTs.

In one embodiment, steviol biosynthesis enzymes, UGTs and UDP-glucoserecycling system are present in one microorganism. The microorganism maybe for example, E. coli, Saccharomyces sp., Aspergillus sp., Pichia sp.,Bacillus sp., Yarrowia sp.

In one embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit torubusoside to form stevioside. In a particular embodiment, theUDP-glucosyltransferase is UGT91D2.

In one embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit tostevioside to form rebaudioside A. In a particular embodiment, theUDP-glucosyltransferase is UGT76G1.

In another embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit torebaudioside A to form rebaudioside D. In a particular embodiment, theUDP-glucosyltransferase is UGT91D2. In another embodiment, the UGT is animproved variant of UGT91D2 with higher activity and/or selectivityproduced by directed evolution.

In yet another embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit torebaudioside D to form rebaudioside M. In a particular embodiment, theUDP-glucosyltransferase is UGT76G1. In another embodiment, the UGT is animproved variant of UGT76G1 with higher activity and/or selectivityproduced by directed evolution.

Optionally, the method of the present invention further comprisesrecycling UDP to provide UDP-glucose. In one embodiment, the methodcomprises recycling UDP by providing a recycling catalyst and arecycling substrate, such that the biotransformation of the steviolglycoside substrate to the target steviol glycoside is carried out usingcatalytic amounts of UDP-glucosyltransferase and UDP-glucose.

In one embodiment, the recycling catalyst is sucrose synthase.

In one embodiment, the recycling substrate is sucrose.

Optionally, the method of the present invention further comprisesseparating the target steviol glycoside from the medium to provide ahighly purified target steviol glycoside composition. The target steviolglycoside can be separated by at least one suitable method, such as, forexample, crystallization, separation by membranes, centrifugation,extraction, chromatographic separation or a combination of such methods.

In one embodiment, the target steviol glycoside can be produced withinthe microorganism. In another embodiment, the target steviol glycosidecan be secreted out in the medium. In one another embodiment, thereleased steviol glycoside can be continuously removed from the medium.In yet another embodiment, the target steviol glycoside is separatedafter the completion of the reaction.

In one embodiment, separation produces a composition comprising greaterthan about 80% by weight of the target steviol glycoside on an anhydrousbasis, i.e., a highly purified steviol glycoside composition. In anotherembodiment, separation produces a composition comprising greater thanabout 90% by weight of the target steviol glycoside. In particularembodiments, the composition comprises greater than about 95% by weightof the target steviol glycoside. In other embodiments, the compositioncomprises greater than about 99% by weight of the target steviolglycoside.

The target steviol glycoside can be in any polymorphic or amorphousform, including hydrates, solvates, anhydrous or combinations thereof.

Purified target steviol glycosides can be used in consumable products asa sweetener. Suitable consumer products include, but are not limited to,food, beverages, pharmaceutical compositions, tobacco products,nutraceutical compositions, oral hygiene compositions, and cosmeticcompositions.

The present invention also provides steviol glycosides rebaudioside D2(reb D2, isomer of rebaudioside D) and rebaudioside M2 (reb M2, isomerof rebaudioside M). In one embodiment, isolated and purified reb D2 isprovided. In another embodiment, isolated and purified reb M2 isprovided. Reb D2 and reb M2 may also be present in any consumableproducts disclosed herein. In a particular embodiment, beveragescomprising reb D2 and/or reb M2 are provided.

Methods of preparing reb D2 and reb M2 are also provided herein. Bothare formed during the biotransformation of reb A to reb D. Reb M2 isbelieved to form from biotransformation of reb D2 in situ.

In one embodiment, the present invention is a method for the preparationof a composition comprising reb D2 comprising: (a) contacting a startingcomposition comprising reb A with an enzyme capable of transforming rebA to reb D2, UDP-glucose, and optionally UDP-glucose recycling enzymes,to produce a composition comprising reb D2, and (b) isolating thecomposition comprising reb D2.

In another embodiment, the present invention is a method for thepreparation of a composition comprising reb M2 comprising (a) contactinga starting composition comprising reb D2 with an enzyme capable oftransforming reb D2 to reb M2, UDP-glucose, and optionally UDP-glucoserecycling enzymes, to produce a composition comprising reb M2, and (b)and isolating the composition comprising reb M2.

A further method for the preparation of a composition comprising reb M2comprises (a) contacting a starting composition comprising reb A with anenzyme capable of transforming reb A to reb D2, UDP-glucose, andoptionally UDP-glucose recycling enzymes, to produce a compositioncomprising reb D2, (b) optionally, isolating the composition comprisingreb D2, (c) contacting the composition comprising reb D2 with an enzymecapable of transforming reb D2 to reb M2, UDP-glucose, and optionallyUDP-glucose recycling enzymes to produce a composition comprising rebM2, and (d) isolating the composition comprising reb M2.

The composition can be further purified to provide reb D2 or reb M2 withpurities greater than about 95% by weight on a dry basis.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are included to provide a furtherunderstanding of the invention. The drawings illustrate embodiments ofthe invention and together with the description serve to explain theprinciples of the embodiments of the invention.

FIG. 1 shows the biocatalytic production of reb M from stevioside.

FIG. 2 shows the biocatalytic production of reb A from stevioside usingthe enzyme UGT76G1 and concomitant recycling of UDP to UDP glucose viasucrose synthase.

FIG. 3 shows the HPLC chromatogram of the product of the biocatalyticproduction of reb M from reb D, as detailed in Example 14. The peak withretention time of 24.165 minutes corresponds to unreacted reb D. Thepeak with retention time of 31.325 minutes corresponds to reb M.

FIG. 4 shows the UGT76G1 catalyzed transformation of stevioside to rebA.

FIG. 5 shows the UGT76G1 catalyzed transformation of reb D to reb M.

FIG. 6 shows LC-MS analysis of semi-synthetic steviol glycoside mixture,Lot number CB-2977-106, showing TIC (A), MS of peak at 1.8 min (B), MSof reb M2 peak at 4.1 min (C), MS of reb D peak at 6.0 min (D), MS ofreb D2 peak at 7.7 min (E), MS of peak at 9.4 min (F), MS ofrebaudioside Apeak at 15.2 min (G), MS of peak at 16.5 min (H), and MSof peak at 18.3 min (I).

FIG. 7 shows HPLC analysis of semi-synthetic steviol glycoside mixture,Lot number CB-2977-106 (A), Isolated reb M2 (B), isolated reb D (C) andisolated reb D2 (D).

FIG. 8 shows the ¹H NMR spectrum of reb D2 (500 MHz, pyridine-d₅).

FIG. 9 shows the ¹³C NMR spectrum of reb D2(125 MHz, pyridine-d₅).

FIG. 10 shows an expansion of the ¹³C NMR spectrum of reb D2 (125 MHz,pyridine-d₅).

FIG. 11 shows the ¹H-¹H COSY Spectrum of reb D2 (500 MHz, pyridine-d₅).

FIG. 12 shows the HSQC-DEPT spectrum of reb D2(500 MHz, pyridine-d₅).

FIG. 13 shows the HMBC spectrum of reb D2.

FIG. 14 shows an expansion of HMBC spectrum of reb D2 (500 MHz,pyridine-d₅).

FIG. 15 shows the NOESY spectrum of reb D2.

FIG. 16 shows ¹H NMR spectrum of reb D2 (500 MHz, pyridine-d₅) acquiredafter ˜46 hours.

FIG. 17 shows and expansion of ¹H NMR spectrum of reb D2 (500 MHz,pyridine-d₅) acquired after ˜46 hours.

FIG. 18 shows the ¹H NMR spectrum of reb M2(500 MHz, D₂O).

FIG. 19 shows the ¹³C NMR spectrum of reb M2 (125 MHz, D₂O/TSP).

FIG. 20 shows an expansion of the ¹³C NMR spectrum of reb M2 (125 MHz,D₂O/TSP).

FIG. 21 shows the ¹H-¹H COSY spectrum of reb M2 (500 MHz, D₂O).

FIG. 22 shows the HSQC-DEPT spectrum of reb M2(500 MHz, D₂O).

FIG. 23 shows the HMBC spectrum of reb M2 (500 MHz, D₂O).

FIG. 24 shows an expansion of HMBC spectrum of reb M2 (500 MHz, D₂O).

DETAILED DESCRIPTION

The present invention provides a biocatalytic process for preparing acomposition comprising a target steviol glycoside by contacting a mediumcontaining a starting composition comprising an organic compoundcomprising at least one carbon atom with a biocatalyst, therebyproducing a medium comprising a target steviol glycoside.

In another embodiment, the present invention provides a method forproducing a target steviol glycoside comprising contacting an organiccompound and at least one enzyme selected from a steviol biosynthesisenzymes and a UDP-glycosyltransferases, thereby producing a compositioncomprising the target steviol glycoside.

One object of the invention is to provide an efficient biocatalyticmethod for preparing steviol glycosides, particularly stevioside, reb E,reb A, reb D, reb D2, reb M, and reb M2 from various organic compoundsin starting compositions.

As used herein, “biocatalysis” or “biocatalytic” refers to the use ofnatural or genetically engineered biocatalysts, such as enzymes, orcells comprising one or more enzyme, capable of single or multiple stepchemical transformations on organic compounds. Biocatalysis processesinclude fermentation, biosynthesis and biotransformation processes. Bothisolated enzyme and whole-cell biocatalysis methods are known in theart. Biocatalyst protein enzymes can be naturally occurring orrecombinant proteins.

As used herein, the term “steviol glycoside(s)” refers to a glycoside ofsteviol, including, but not limited to, naturally occurring steviolglycosides, e.g. steviolmonoside, steviolbioside, rubusoside, dulcosideB, dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudiosideC, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E,rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J,rebaudioside M, rebaudioside M2, rebaudioside D, rebaudioside D2,rebaudioside N, rebaudioside 0, synthetic steviol glycosides, e.g.enzymatically glucosylated steviol glycosides and combinations thereof.

Starting Composition

As used herein, “starting composition” refers to any composition(generally an aqueous solution) containing one or more organic compoundcomprising at least one carbon atom.

In one embodiment, the organic compound is selected from the groupconsisting of polyols and various carbohydrates. Such organic compounds,and starting compositions comprising the same, are particularly usefulwhen the present method is a fermentation method.

The term “polyol” refers to a molecule that contains more than onehydroxyl group. A polyol may be a diol, triol, or a tetraol whichcontain 2, 3, and 4 hydroxyl groups, respectively. A polyol also maycontain more than four hydroxyl groups, such as a pentaol, hexaol,heptaol, or the like, which contain 5, 6, or 7 hydroxyl groups,respectively. Additionally, a polyol also may be a sugar alcohol,polyhydric alcohol, or polyalcohol which is a reduced form ofcarbohydrate, wherein the carbonyl group (aldehyde or ketone, reducingsugar) has been reduced to a primary or secondary hydroxyl group.Examples of polyols include, but are not limited to, erythritol,maltitol, mannitol, sorbitol, lactitol, xylitol, inositol, isomalt,propylene glycol, glycerol, threitol, galactitol, hydrogenatedisomaltulose, reduced isomalto-oligosaccharides, reducedxylo-oligosaccharides, reduced gentio-oligosaccharides, reduced maltosesyrup, reduced glucose syrup, hydrogenated starch hydrolyzates,polyglycitols and sugar alcohols or any other carbohydrates capable ofbeing reduced.

The term “carbohydrate” refers to aldehyde or ketone compoundssubstituted with multiple hydroxyl groups, of the general formula(CH₂O)_(n), wherein n is 3-30, as well as their oligomers and polymers.The carbohydrates of the present invention can, in addition, besubstituted or deoxygenated at one or more positions. Carbohydrates, asused herein, encompass unmodified carbohydrates, carbohydratederivatives, substituted carbohydrates, and modified carbohydrates. Asused herein, the phrases “carbohydrate derivatives”, “substitutedcarbohydrate”, and “modified carbohydrates” are synonymous. Modifiedcarbohydrate means any carbohydrate wherein at least one atom has beenadded, removed, or substituted, or combinations thereof. Thus,carbohydrate derivatives or substituted carbohydrates includesubstituted and unsubstituted monosaccharides, disaccharides,oligosaccharides, and polysaccharides. The carbohydrate derivatives orsubstituted carbohydrates optionally can be deoxygenated at anycorresponding C-position, and/or substituted with one or more moietiessuch as hydrogen, halogen, haloalkyl, carboxyl, acyl, acyloxy, amino,amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, aryloxy, nitro, cyano, sulfo, mercapto, imino, sulfonyl,sulfenyl, sulfinyl, sulfamoyl, carboalkoxy, carboxamido, phosphonyl,phosphinyl, phosphoryl, phosphino, thioester, thioether, oximino,hydrazino, carbamyl, phospho, phosphonato, or any other viablefunctional group provided the carbohydrate derivative or substitutedcarbohydrate functions to improve the sweet taste of the sweetenercomposition.

Examples of carbohydrates which may be used in accordance with thisinvention include, but are not limited to, tagatose, trehalose,galactose, rhamnose, various cyclodextrins, cyclic oligosaccharides,various types of maltodextrins, dextran, sucrose, glucose, ribulose,fructose, threose, arabinose, xylose, lyxose, allose, altrose, mannose,idose, lactose, maltose, invert sugar, isotrehalose, neotrehalose,isomaltulose, erythrose, deoxyribose, gulose, idose, talose,erythrulose, xylulose, psicose, turanose, cellobiose, amylopectin,glucosamine, mannosamine, fucose, glucuronic acid, gluconic acid,glucono-lactone, abequose, galactosamine, beet oligosaccharides,isomalto-oligosaccharides (isomaltose, isomaltotriose, panose and thelike), xylo-oligosaccharides (xylotriose, xylobiose and the like),xylo-terminated oligosaccharides, gentio-oligosaccharides (gentiobiose,gentiotriose, gentiotetraose and the like), sorbose,nigero-oligosaccharides, palatinose oligosaccharides,fructooligosaccharides (kestose, nystose and the like), maltotetraol,maltotriol, malto-oligosaccharides (maltotriose, maltotetraose,maltopentaose, maltohexaose, maltoheptaose and the like), starch,inulin, inulo-oligosaccharides, lactulose, melibiose, raffinose, ribose,isomerized liquid sugars such as high fructose corn syrups, couplingsugars, and soybean oligosaccharides. Additionally, the carbohydrates asused herein may be in either the D- or L-configuration.

The starting composition may be synthetic or purified (partially orentirely), commercially available or prepared.

In one embodiment, the organic compound is glycerol. In anotherembodiment, the starting composition comprises glycerol.

In one embodiment, the organic compound is glucose. In anotherembodiment, the starting composition comprises glucose.

In one embodiment, the organic compound is sucrose. In anotherembodiment, the starting composition comprises sucrose.

In one embodiment, the organic compound is starch. In anotherembodiment, the starting composition comprises starch.

In one embodiment, the organic compound is maltodextrin. In anotherembodiment, the starting composition comprises maltodextrin.

The organic compound(s) serve as a substrate(s) for the production ofthe target steviol glycoside(s), as described herein.

The present method also provides methods of biocatalytic conversion onesteviol glycoside to another steviol glycoside. Accordingly, in someembodiments, the organic compound is a steviol glycoside including, butnot limited to, steviolmonoside, steviolbioside, rubusoside, dulcosideB, dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudiosideC, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E,rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J,rebaudioside M, rebaudioside M2, rebaudioside D, rebaudioside D2,rebaudioside N or rebaudioside 0, or other glycoside of steviol.

Notably, the substrate steviol glycoside for biocatalytic conversion isnot the same as the target steviol glycoside, discussed below. However,the starting composition may contain steviol glycosides other than thesubstrate steviol glycoside and, in some cases, may contain some amountof target steviol glycoside.

Target Steviol Glycoside

The target steviol glycoside of the present method can be any steviolglycoside that can be prepared by the process disclosed herein. In oneembodiment, the target steviol glycoside is selected from the groupconsisting of steviolmonoside, steviolbioside, rubusoside, dulcoside B,dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudioside C,rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E,rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J,rebaudioside M, rebaudioside M2, rebaudioside D, rebaudioside D2,rebaudioside N or rebaudioside 0, or other glycoside of steviol.

In one embodiment, the target steviol glycoside is stevioside. Inanother embodiment, the target steviol glycoside is reb A. In stillanother embodiment, the target steviol glycoside is reb E. In yetanother embodiment, the target steviol glycoside is reb D.

In yet another embodiment, the target steviol glycoside is reb D2. In afurther embodiment, the target steviol glycoside is reb M. In a stillfurther another embodiment, the target steviol glycoside is reb M2.

The target steviol glycoside can be in any polymorphic or amorphousform, including hydrates, solvates, anhydrous or combinations thereof.

In one embodiment, the present invention is a biocatalytic process forthe production of reb A. In a more particular embodiment, the presentinvention is a fermentation process for the production of reb A from astarting composition comprising, e.g., glucose.

In another embodiment, the present invention is a biocatalytic processfor the production of reb E. In a more particular embodiment, thepresent invention is a fermentation process for the production of reb Efrom a starting composition comprising, e.g., glucose.

In still another embodiment, the present invention is a biocatalyticprocess for the production of reb D. In a more particular embodiment,the present invention is a fermentation process for the production ofreb D from a starting composition comprising, e.g., glucose.

In yet another embodiment, the present invention is a biocatalyticprocess for the production of reb D2. In a more particular embodiment,the present invention is a fermentation process for the production ofreb D2 from a starting composition comprising, e.g., glucose.

In a further embodiment, the present invention is a biocatalytic processfor the production of reb M. In a more particular embodiment, thepresent invention is a fermentation process for the production of reb Mfrom a starting composition comprising, e.g., glucose.

In a still further embodiment, the present invention is a biocatalyticprocess for the production of reb M2. In a more particular embodiment,the present invention is a fermentation process for the production ofreb M2 from a starting composition comprising, e.g., glucose.

In another further embodiment, the present invention is a biocatalyticprocess for the production of stevioside. In a more particularembodiment, the present invention is a fermentation process for theproduction of stevioside from a starting composition comprising, e.g.,glucose.

Optionally, the method of the present invention further comprisesseparating the target steviol glycoside from the medium to provide ahighly purified target steviol glycoside composition. The target steviolglycoside can be separated by any suitable method, such as, for example,crystallization, separation by membranes, centrifugation, extraction,chromatographic separation or a combination of such methods.

In particular embodiments, the process described herein results in ahighly purified target steviol glycoside composition. The term “highlypurified”, as used herein, refers to a composition having greater thanabout 80% by weight of the target steviol glycoside on an anhydrousbasis. In one embodiment, the highly purified target steviol glycosidecomposition contains greater than about 90% by weight of the targetsteviol glycoside on an anhydrous basis, such as, for example, greaterthan about 91%, greater than about 92%, greater than about 93%, greaterthan about 94%, greater than about 95%, greater than about 96%, greaterthan about 97%, greater than about 98% or greater than about 99% targetsteviol glycoside content on a dry basis.

In one embodiment, when the target steviol glycoside is reb M, theprocess described herein provides a composition having greater thanabout 90% reb M content by weight on a dry basis. In another particularembodiment, when the target steviol glycoside is reb M, the processdescribed herein provides a composition comprising greater than about95% reb M content by weight on a dry basis.

In another embodiment, when the target steviol glycoside is reb M2, theprocess described herein provides a composition having greater thanabout 90% reb M2 content by weight on a dry basis. In another particularembodiment, when the target steviol glycoside is reb M2, the processdescribed herein provides a composition comprising greater than about95% reb M2 content by weight on a dry basis.

In yet another embodiment, when the target steviol glycoside is reb D,the process described herein provides a composition greater than about90% reb D content by weight on a dry basis. In another particularembodiment, when the target steviol glycoside is reb D, the processdescribed herein provides a composition comprising greater than about95% reb D content by weight on a dry basis.

In still another embodiment, when the target steviol glycoside is rebD2, the process described herein provides a composition greater thanabout 90% reb D2 content by weight on a dry basis. In another particularembodiment, when the target steviol glycoside is reb D2, the processdescribed herein provides a composition comprising greater than about95% reb D2 content by weight on a dry basis.

In a further embodiment, when the target steviol glycoside is reb A, theprocess described herein provides a composition comprising greater thanabout 90% reb A content by weight on a dry basis. In another particularembodiment, when the target steviol glycoside is reb A, the processdescribed herein provides a composition comprising greater than about95% reb A content by weight on a dry basis.

In a still further embodiment, when the target steviol glycoside is rebE, the process described herein provides a composition comprisinggreater than about 90% reb E content by weight on a dry basis. Inanother particular embodiment, when the target steviol glycoside is rebE, the process described herein provides a composition comprisinggreater than about 95% reb E content by weight on a dry basis.

In yet a further embodiment, when the target steviol glycoside isstevioside, the process described herein provides a compositioncomprising greater than about 90% stevioside content by weight on a drybasis. In another particular embodiment, when the target steviolglycoside is stevioside, the process described herein provides acomposition comprising greater than about 95% stevioside content byweight on a dry basis.

Microorganism and Biocatalysts

In one embodiment of present invention, a biocatalyst is contacted witha medium containing the starting composition to produce target steviolglycosides. In certain embodiments, the biocatalyst is an enzyme, or acell comprising one or more enzyme, capable of converting the organiccompound to the target steviol glycoside.

In one embodiment, the biocatalyst is an enzyme capable of convertingthe organic compound to the target steviol glycoside. The enzyme can beprovided in the form of a whole cell suspension, a crude lysate, apurified enzyme or a combination thereof. In one embodiment, thebiocatalyst is a purified enzyme capable of converting the organiccompound to the target steviol glycoside. In another embodiment, thebiocatalyst is a crude lysate comprising at least one enzyme capable ofconverting the organic compound to the target steviol glycoside. Instill another embodiment, the biocatalyst is a whole cell suspensioncomprising at least one enzyme capable of converting the organiccompound to the target steviol glycoside.

In another embodiment, the biocatalyst is one or more cells comprisingan enzyme capable of converting the organic compound to the targetsteviol glycoside. The enzyme can be located on the surface of the cell,inside the cell or located both on the surface of the cell and insidethe cell.

In one embodiment, one biocatalyst enzyme is used per conversion oforganic compound to target steviol glycoside. In another embodiment, twoor more biocatalyst enzymes are used per conversion.

Suitable enzymes for converting the organic compound to target steviolglycosides include, but are not limited to, steviol biosynthesis enzymesand UDP-glycosyltransferases (UGTs).

In one embodiment, the steviol biosynthesis enzymes include mevalonate(MVA) pathway enzymes.

In another embodiment, the steviol biosynthesis enzymes includenon-mevalonate 2-C-methyl-D-erythritol-4-phosphate pathway (MEP/DOXP)enzymes.

In one embodiment, the steviol biosynthesis enzymes are selected fromthe group consisting of geranylgeranyl diphosphate synthase, copalyldiphosphate synthase, kaurene synthase, kaurene oxidase, kaurenoic acid13-hydroxylase (KAH), steviol synthetase, deoxyxylulose 5-phosphatesynthase (DXS), D-1-deoxyxylulose 5-phosphate reductoisomerase (DXR),4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (CMS),4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK),4-diphosphocytidyl-2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase(MCS), 1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate synthase (HDS),1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate reductase (HDR),acetoacetyl-CoA thiolase, truncated HMG-CoA reductase, mevalonatekinase, phosphomevalonate kinase, mevalonate pyrophosphate decarboxylaseand cytochrome P450 reductase.

The UDP-glucosyltransferase can be any UDP-glucosyltransferase capableof adding at least one glucose unit to the steviol and or steviolglycoside substrate to provide the target steviol glycoside.

In one embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit torubusoside, thereby producing stevioside.

The UDP-glucosyltransferase may be, for example, UGT91D2.

In another embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit torubusoside, thereby producing rebaudioside E. TheUDP-glucosyltransferase may be, for example, UGTSL, UGTSL2 or UGTLB.

In still another embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit torebaudioside E, thereby producing rebaudioside D. TheUDP-glucosyltransferase may be, for example, UGT76G1.

In yet embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit tostevioside, thereby producing rebaudioside A. TheUDP-glucosyltransferase may be, for example, UGT76G1.

In a further embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit torebaudioside A, thereby producing rebaudioside D and/or rebaudioside D2and/or rebaudioside M2. The UDP-glucosyltransferase may be, for example,UGT91D2, UGTSL2, UGTLB or EUGT11.

In another embodiment, the UDP-glucosyltransferase capable of adding atleast one glucose unit to rebaudioside A is selected from the followinglisting of GenInfo identifier numbers, preferably from the grouppresented in Table 1, and more preferably the group presented in Table2.

397567 30680413 115480946 147798902 218193594 225443294 454245 32816174116310259 147811764 218193942 225444853 1359905 32816178 116310985147827151 219885307 225449296 1685003 34393978 116788066 147836230222615927 225449700 1685005 37993665 116788606 147839909 222619587225454338 2191136 37993671 116789315 147846163 222623142 2254543402501497 37993675 119394507 147855977 222625633 225454342 291104939104603 119640480 148905778 222625635 225454473 4218003 41469414122209731 148905999 222636620 225454475 4314356 41469452 125526997148906835 222636621 225458362 13492674 42566366 125534279 148907340222636628 225461551 13492676 42570280 125534461 148908935 222636629225461556 15217773 42572855 125540090 148909182 224053242 22546155815217796 44890129 125541516 148909920 224053386 225469538 1522339646806235 125545408 148910082 224055535 225469540 15223589 50284482125547340 148910154 224056138 226316457 15227766 51090402 125547520148910612 224056160 226492603 15230017 51090594 125554547 148910769224067918 226494221 15231757 52839682 125557592 156138791 224072747226495389 15234056 56550539 125557593 156138797 224080189 22649594515234195 62734263 125557608 156138799 224091845 226502400 1523419662857204 125559566 156138803 224094703 226507980 15238503 62857206125563266 165972256 224100653 226531147 15239523 62857210 125571055168016721 224100657 226532094 15239525 62857212 125579728 171674071224101569 238477377 15239543 75265643 125588307 171906258 224103105240254512 15239937 75285934 125589492 183013901 224103633 24203261515240305 75288884 125599469 183013903 224103637 242032621 1524053477550661 125601477 186478321 224109218 242038423 15982889 77556148126635837 187373030 224114583 242043290 18086351 82791223 126635845187373042 224116284 242044836 18418378 83778990 126635847 190692175224120552 242051252 18418380 89953335 126635863 194701936 224121288242056217 18418382 110741436 126635867 195620060 224121296 24205621919743740 110743955 126635883 209954691 224121300 242056663 19911201115438196 126635887 209954719 224130358 242059339 20149064 115438785133874210 209954725 224140703 242059341 20260654 115441237 133874212209954733 224143404 242060922 21435782 115454819 145358033 210063105224143406 242067411 21553613 115456047 147772508 210063107 224144306242067413 21593514 115457492 147776893 212275846 224285244 24207625822759895 115459312 147776894 216296854 225431707 242076396 23955910115464719 147776895 217074506 225435532 242084750 26452040 115471069147786916 218185693 225436321 242091005 28393204 115471071 147798900218187075 225440041 242095206 30679796 115474009 147798901 218189427225441116 242345159 242345161 297724601 326492035 356523945 357140904359486938 255536859 297725463 326493430 356523957 357165849 359487055255538228 297728331 326500410 356523959 357165852 359488135 255541676297738632 326506816 356523961 357168415 359488708 255547075 297745347326507826 356523963 357437837 359493630 255552620 297745348 326508394356524387 357442755 359493632 255552622 297795735 326509445 356524403357442757 359493634 255555343 297796253 326511261 356527181 357445729359493636 255555361 297796257 326511866 356533209 357445731 359493815255555363 297796261 326512412 356533852 357445733 359495856 255555365297797587 326517673 356534718 357446799 359495858 255555369 297798502326518800 356535480 357446805 359495869 255555373 297799226 326521124356542996 357452779 359495871 255555377 297805988 326525567 356543136357452781 359497638 255556812 297807499 326525957 356543932 357452783359807261 255556818 297809125 326526607 356549841 357452787 374256637255563008 297809127 326527141 356549843 357452789 377655465 255564074297811403 326530093 356554358 357452791 378405177 255564531 297820040326534036 356554360 357452797 378829085 255572878 297821483 326534312356558606 357452799 387135070 255577901 297825217 332071132 356560333357470367 387135072 255583249 297832276 339715876 356560599 357472193387135078 255583253 297832280 342306012 356560749 357472195 387135092255583255 297832518 342306016 356566018 357474295 387135094 255585664297832520 343457675 356566169 357474493 387135098 255585666 297840825343457677 356566173 357474497 387135100 255634688 297840827 350534960356567761 357474499 387135134 255644801 297847402 356498085 356574704357490035 387135136 255645821 297849372 356499771 356576401 357493567387135174 255647456 300078590 356499777 356577660 357497139 387135176255648275 300669727 356499779 357114993 357497581 387135184 260279126302142947 356501328 357115447 357497671 387135186 260279128 302142948356502523 357115451 357500579 387135188 261343326 302142950 356503180357115453 357504663 387135190 283132367 302142951 356503184 357116080357504691 387135192 283362112 302765302 356503295 357116928 357504699387135194 289188052 302796334 356504436 357117461 357504707 387135282295841350 302811470 356504523 357117463 357505859 387135284 296088529302821107 356504765 357117829 357510851 387135294 296090415 302821679356511113 357117839 357516975 387135298 296090524 319759260 356515120357125059 359477003 387135300 296090526 319759266 356517088 357126015359477998 387135302 297599503 320148814 356520732 357134488 359478043387135304 297601531 326489963 356522586 357135657 359478286 387135312297611791 326490273 356522588 357138503 359484299 387135314 297722841326491131 356522590 357139683 359486936 387135316 387135318 449440433460376293 460413408 462423864 475546199 387135320 449445896 460378310460416351 470101924 475556485 387135322 449446454 460380744 462394387470102280 475559699 387135324 449447657 460381726 462394433 470102858475578293 387135326 449449002 460382093 462394557 470104211 475591753387135328 449449004 460382095 462395646 470104264 475593742 388493506449449006 460382754 462395678 470104266 475612072 388495496 449451379460384935 462396388 470106317 475622476 388498446 449451589 460384937462396389 470106357 475622507 388499220 449451591 460385076 462396419470115448 475623787 388502176 449451593 460385872 462396542 470130404482550481 388517521 449453712 460386018 462397507 470131550 482550499388519407 449453714 460389217 462399998 470136482 482550740 388521413449453716 460394872 462400798 470136484 482550999 388827901 449453732460396139 462401217 470136488 482552352 388827903 449457075 460397862462402118 470136492 482554970 388827907 449467555 460397864 462402237470137933 482555336 388827909 449468742 460398541 462402284 470137937482555478 388827913 449495638 460403139 462402416 470140422 482556454393887637 449495736 460403141 462404228 470140426 482557289 393887646449499880 460403143 462406358 470140908 482558462 393887649 449502786460403145 462408262 470141232 482558508 393990627 449503471 460405998462409325 470142008 482558547 397746860 449503473 460407578 462409359470142010 482561055 397789318 449515857 460407590 462409777 470142012482561555 413924864 449518643 460409128 462411467 470143607 482562795414590349 449519559 460409134 462414311 470143939 482562850 414590661449522783 460409136 462414416 470145404 482565074 414591157 449524530460409459 462414476 473923244 482566269 414879558 449524591 460409461462415526 474114354 482566296 414879559 449528823 460409463 462415603474143634 482566307 414879560 449528825 460409465 462415731 474202268482568689 414888074 449534021 460409467 462416307 474299266 482570049431812559 460365546 460410124 462416920 474363119 482570572 449432064460366882 460410126 462416922 474366157 482575121 449432066 460369823460410128 462416923 474429346 449433069 460369829 460410130 462416924475432777 449436944 460369831 460410132 462417401 475473002 449438665460369833 460410134 462419769 475489790 449438667 460370755 460410213462420317 475511330 449440431 460374714 460411200 462423366 475516200

TABLE 1 GI number Accession Origin 190692175 ACE87855.1 Steviarebaudiana 41469452 AAS07253.1 Oryza sativa 62857204 BAD95881.1 Ipomoeanil 62857206 BAD95882.1 Ipomoea purperea 56550539 BAD77944.1 Bellisperennis 115454819 NP_001051010.1 Oryza sativa Japonica Group 115459312NP_001053256.1 Oryza sativa Japonica Group 115471069 NP_001059133.1Oryza sativa Japonica Group 115471071 NP_001059134.1 Oryza sativaJaponica Group 116310985 CAH67920.1 Oryza sativa Indica Group 116788066ABK24743.1 Picea sitchensis 122209731 Q2V6J9.1 Fragaria × ananassa125534461 EAY81009.1 Oryza sativa Indica Group 125559566 EAZ05102.1Oryza sativa Indica Group 125588307 EAZ28971.1 Oryza sativa JaponicaGroup 148907340 ABR16806.1 Picea sitchensis 148910082 ABR18123.1 Piceasitchensis 148910612 ABR18376.1 Picea sitchensis 15234195 NP_194486.1Arabidopsis thaliana 15239523 NP_200210.1 Arabidopsis thaliana 15239937NP_196793.1 Arabidopsis thaliana 1685005 AAB36653.1 Nicotiana tabacum183013903 ACC38471.1 Medicago truncatula 186478321 NP_172511.3Arabidopsis thaliana 187373030 ACD03249.1 Avena strigosa 194701936ACF85052.1 Zea mays 19743740 AAL92461.1 Solanum lycopersicum 212275846NP_001131009.1 Zea mays 222619587 EEE55719.1 Oryza sativa Japonica Group224055535 XP_002298527.1 Populus trichocarpa 224101569 XP_002334266.1Populus trichocarpa 224120552 XP_002318358.1 Populus trichocarpa224121288 XP_002330790.1 Populus trichocarpa 225444853 XP_002281094Vitis vinifera 225454342 XP_002275850.1 Vitis vinifera 225454475XP_002280923.1 Vitis vinifera 225461556 XP_002285222 Vitis vinifera225469540 XP_002270294.1 Vitis vinifera 226495389 NP_001148083.1 Zeamays 226502400 NP_001147674.1 Zea mays 238477377 ACR43489.1 Triticumaestivum 240254512 NP_565540.4 Arabidopsis thaliana 2501497 Q43716.1Petunia × hybrida 255555369 XP_002518721.1 Ricinus communis 26452040BAC43110.1 Arabidopsis thaliana 296088529 CBI37520.3 Vitis vinifera297611791 NP_001067852.2 Oryza sativa Japonica Group 297795735XP_002865752.1 Arabidopsis lyrata subsp. lyrata 297798502 XP_002867135.1Arabidopsis lyrata subsp. lyrata 297820040 XP_002877903.1 Arabidopsislyrata subsp. lyrata 297832276 XP_002884020.1 Arabidopsis lyrata subsp.lyrata 302821107 XP_002992218.1 Selaginella moellendorffii 30680413NP_179446.2 Arabidopsis thaliana 319759266 ADV71369.1 Pueraria montanavar. lobata 326507826 BAJ86656.1 Hordeum vulgare subsp. Vulgare343457675 AEM37036.1 Brassica rapa subsp. oleifera 350534960NP_001234680.1 Solanum lycopersicum 356501328 XP_003519477.1 Glycine max356522586 XP_003529927.1 Glycine max 356535480 XP_003536273.1 Glycinemax 357445733 XP_003593144.1 Medicago truncatula 357452783XP_003596668.1 Medicago truncatula 357474493 XP_003607531.1 Medicagotruncatula 357500579 XP_003620578.1 Medicago truncatula 357504691XP_003622634.1 Medicago truncatula 359477998 XP_003632051.1 Vitisvinifera 359487055 XP_002271587 Vitis vinifera 359495869 XP_003635104.1Vitis vinifera 387135134 AFJ52948.1 Linum usitatissimum 387135176AFJ52969.1 Linum usitatissimum 387135192 AFJ52977.1 Linum usitatissimum387135282 AFJ53022.1 Linum usitatissimum 387135302 AFJ53032.1 Linumusitatissimum 387135312 AFJ53037.1 Linum usitatissimum 388519407AFK47765.1 Medicago truncatula 393887646 AFN26668.1 Barbarea vulgarissubsp. arcuata 414888074 DAA64088.1 Zea mays 42572855 NP_974524.1Arabidopsis thaliana 449440433 XP_004137989.1 Cucumis sativus 449446454XP_004140986.1 Cucumis sativus 449449004 XP_004142255.1 Cucumis sativus449451593 XP_004143546.1 Cucumis sativus 449515857 XP_004164964.1Cucumis sativus 460382095 XP_004236775.1 Solanum lycopersicum 460409128XP_004249992.1 Solanum lycopersicum 460409461 XP_004250157.1 Solanumlycopersicum 460409465 XP_004250159.1 Solanum lycopersicum 462396388EMJ02187.1 Prunus persica 462402118 EMJ07675.1 Prunus persica 462409359EMJ14693.1 Prunus persica 462416923 EMJ21660.1 Prunus persica 46806235BAD17459.1 Oryza sativa Japonica Group 470104266 XP_004288529.1 Fragariavesca subsp. vesca 470142008 XP_004306714.1 Fragaria vesca subsp. vesca475432777 EMT01232.1 Aegilops tauschii 51090402 BAD35324.1 Oryza sativaJaponica Group

TABLE 2 Internal GI number Accession Origin reference 460409128XP.004249992.1 Solanum lycopersicum UGTSL 460386018 XP.004238697.1Solanum lycopersicum — 460409134 XP.004249995.1 Solanum lycopersicum —460410132 XP.004250485.1 Solanum lycopersicum UGTSL2 460410130XP.004250484.1 Solanum lycopersicum — 460410128 XP.004250483.1 Solanumlycopersicum — 460378310 XP.004234916.1 Solanum lycopersicum — 209954733BAG80557.1 Lycium barbarum UGTLB 209954725 BAG80553.1 Lycium barbarum —

In yet another embodiment, the UDP-glucosyltransferase is anyUDP-glucosyltransferase capable of adding at least one glucose unit torebaudioside D to form rebaudioside M and/or rebaudioside M2. TheUDP-glucosyltransferase may be, for example, UGT76G1. In preferredembodiments, conversion is at least greater than 50%, for examplegreater than 60%, greater than 70%, greater than 80% or greater than90%.

The UGT76G1 enzyme may also contain on or more point mutationsbeneficial for conversion of rebaudioside D to rebaudioside M. Suitablemutations include, for example, S42A, F46I, I190L, S274G, I295M, K303G,F314S, K316R, K393R, V394I, I407V, N409K, N409R, Q425E, Q432E, S447A andS456L. In preferred embodiments, utilization of UGT76G1 containing suchone or more point mutations results in increased rebaudioside Mconversion of at least about 5% compared to use of the non-mutatedUGT76G1 under the same conditions (wherein the results normalized). Inpreferred embodiments, conversion to rebaudioside M is increased fromabout 5% to about 50%, such as, for example, from about 10% to about50%, from about 20% to about 50%, from about 30% to about 50% or about40% to about 50%.

In some embodiments, a microorganism comprises an enzyme of the presentinvention, i.e. an enzyme capable of converting the organic compound tothe target steviol glycoside. Accordingly, some embodiments of thepresent method include contacting a microorganism with a mediumcontaining the starting composition to provide a medium comprising atleast one target steviol glycoside.

The microorganism can be any microorganism possessing the necessaryenzyme(s) for converting the organic compound to target steviolglycoside(s). These enzymes are encoded within the microorganism'sgenome.

Suitable microorganisms include, but are not limited to, E. coli,Saccharomyces sp., Aspergillus sp., Pichia sp., Bacillus sp., Yarrowiasp. etc.

In one embodiment, the microorganism is free when contacted with thestarting composition.

In another embodiment, the microorganism is immobilized when contactedwith the starting composition. For example, the microorganism may beimmobilized to a solid support made from inorganic or organic materials.Non-limiting examples of solid supports suitable to immobilize themicroorganism include derivatized cellulose or glass, ceramics, metaloxides or membranes. The microorganism may be immobilized to the solidsupport, for example, by covalent attachment, adsorption, cross-linking,entrapment or encapsulation.

In still another embodiment, the enzyme capable of converting theorganic compound to the target steviol glycoside is secreted out of themicroorganism and into the reaction medium.

The starting composition/organic compound is contacted with thebiocatalyst or microorganism in an aqueous medium comprising water, and,e.g. various components selected from the including carbon sources,energy sources, nitrogen sources, microelements, vitamins, nucleosides,nucleoside phosphates, nucleoside diphosphates, nucleosidetriphosphates, organic and inorganic salts, organic and mineral acids,bases etc. Carbon sources include glycerol, glucose, carbon dioxide,carbonates, bicarbonates. Nitrogen sources can include nitrates,nitrites, amino acids, peptides, peptones, or proteins.

In a particular embodiment, the medium comprises buffer. Suitablebuffers include, but are not limited to, PIPES buffer, acetate bufferand phosphate buffer. In a particular embodiment, the medium comprisesphosphate buffer.

In one embodiment, the medium can also include an organic solvent.

Optionally, the methods of the present invention further compriserecycling UDP to provide UDP-glucose. Accordingly, the methods compriseconcomitantly recycling UDP by providing a recycling catalyst, i.e., abiocatalyst capable of UDP-glucose overproduction, and a recyclingsubstrate, such that the conversion of the substrate steviol glycosideto the target steviol glycoside is carried out using catalytic amountsof UDP-glucosyltransferase and UDP-glucose (FIG. 2).

In one embodiment, the UDP-glucose recycling catalyst is sucrosesynthase.

In one embodiment, the recycling substrate is sucrose.

The target steviol glycoside is optionally purified from the resultingcomposition. Purification of the target steviol glycoside from thereaction medium can be achieved by at least one suitable method toprovide a highly purified target steviol glycoside composition. Suitablemethods include crystallization, separation by membranes,centrifugation, extraction (liquid or solid phase), chromatographicseparation, HPLC (preparative or analytical) or a combination of suchmethods.

In one embodiment, the present invention provides a method of producingstevioside by (a) contacting a medium containing a starting compositioncomprising rubusoside with UGT91D2 and UDP-glucose.

In a more particular embodiment, the present invention provides acatalytic method of producing stevioside by (a) contacting a mediumcontaining a starting composition comprising rubusoside with a catalyticamount of UGT91D2 and UDP-glucose, and (b) recycling UDP-glucose byproviding sucrose synthase and sucrose.

In another particular embodiment, the present invention provides afermentation method of producing stevioside by (a) contacting a mediumcontaining a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to stevioside.

In still another particular embodiment, the present invention provides afermentation method of producing stevioside by (a) contacting a mediumcontaining a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to stevioside and (b) recycling UDP-glucose by providingUDP-glucose, sucrose synthase and sucrose.

The methods above can further comprise purifying stevioside from themedium to provide a composition comprising highly purified stevioside.

In another embodiment, the present invention provides a method ofproducing rebaudioside E by (a) contacting a medium containing astarting composition comprising rubusoside with UGTSL2 and UDP-glucose.

In a more particular embodiment, the present invention provides acatalytic method of producing rebaudioside E by (a) contacting a mediumcontaining a starting composition comprising rubusoside with a catalyticamount of UGTSL2 and UDP-glucose, and (b) recycling UDP-glucose byproviding sucrose synthase and sucrose.

In another particular embodiment, the present invention provides afermentation method of producing rebaudioside E by (a) contacting amedium containing a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to rebaudioside E.

In still another particular embodiment, the present invention provides afermentation method of producing rebaudioside E by (a) contacting amedium containing a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to rebaudioside E and (b) recycling UDP-glucose by providingUDP-glucose, sucrose synthase and sucrose.

The methods above can further comprise purifying rebaudioside E from themedium to provide a composition comprising highly purified rebaudiosideE.

In still another embodiment, the present invention provides a method ofproducing rebaudioside D by (a) contacting a medium containing astarting composition comprising rebaudioside E with UGT76G1 andUDP-glucose.

In a more particular embodiment, the present invention provides acatalytic method of producing rebaudioside D by (a) contacting a mediumcontaining a starting composition comprising rebaudioside E with acatalytic amount of UGT76G1 and UDP-glucose, and (b) recyclingUDP-glucose by providing sucrose synthase and sucrose.

In another particular embodiment, the present invention provides afermentation method of producing rebaudioside D by (a) contacting amedium containing a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to rebaudioside D.

In still another particular embodiment, the present invention provides afermentation method of producing rebaudioside D by (a) contacting amedium containing a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to rebaudioside D and (b) recycling UDP-glucose by providingUDP-glucose, sucrose synthase and sucrose.

The methods above can further comprise purifying rebaudioside D from themedium to provide a composition comprising highly purified rebaudiosideD.

In yet another embodiment, the present invention provides a method ofproducing rebaudioside A by (a) contacting a medium containing astarting composition comprising stevioside with UGT76G1 and UDP-glucose.

In a more particular embodiment, the present invention provides acatalytic method of producing rebaudioside A by (a) contacting a mediumcontaining a starting composition comprising stevioside with a catalyticamount of UGT76G1 and UDP-glucose, and (b) recycling UDP-glucose byproviding sucrose synthase and sucrose.

In another particular embodiment, the present invention provides afermentation method of producing rebaudioside A by (a) contacting amedium containing a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to rebaudioside A.

In still another particular embodiment, the present invention provides afermentation method of producing rebaudioside A by (a) contacting amedium containing a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to rebaudioside A and (b) recycling UDP-glucose by providingUDP-glucose, sucrose synthase and sucrose.

The methods above can further comprise purifying rebaudioside A from themedium to provide a composition comprising highly purified rebaudiosideA.

In a still further embodiment, the present invention provides a methodof producing rebaudioside D, rebaudioside D2 and/or rebaudioside M2 by(a) contacting a medium containing a starting composition comprisingrebaudioside A with UGT91D2, UGTSL2 or EUGT11 and UDP-glucose.

In a more particular embodiment, the present invention provides acatalytic method of producing rebaudioside D, rebaudioside D2 and/orrebaudioside M2 by (a) contacting a medium containing a startingcomposition comprising rebaudioside A with a catalytic amount ofUGT91D2, UGTSL2 or EUGT11, and UDP-glucose, and (b) recyclingUDP-glucose by providing sucrose synthase and sucrose.

In another particular embodiment, the present invention provides afermentation method of producing rebaudioside D, rebaudioside D2 and/orrebaudioside M2 by (a) contacting a medium containing a startingcomposition comprising glucose with a microorganism comprising at leastone enzyme capable of converting glucose to rebaudioside D, rebaudiosideD2 and/or rebaudioside M2.

In still another particular embodiment, the present invention provides afermentation method of producing rebaudioside D, rebaudioside D2 and/orrebaudioside M2 by (a) contacting a medium containing a startingcomposition comprising glucose with a microorganism comprising at leastone enzyme capable of converting glucose to rebaudioside D, rebaudiosideD2 and/or rebaudioside M2 and (b) recycling UDP-glucose by providingUDP-glucose, sucrose synthase and sucrose.

The methods above can further comprise separating rebaudioside D,rebaudioside D2 and/or rebaudioside M2 from the medium to provide acomposition comprising highly purified rebaudioside D, rebaudioside D2and/or rebaudioside M2.

In yet another embodiment, the present invention provides a method ofproducing rebaudioside M by (a) contacting a medium containing astarting composition comprising rebaudioside D with UGT76G1 andUDP-glucose.

In a more particular embodiment, the present invention provides acatalytic method of producing rebaudioside M by (a) contacting a mediumcontaining a starting composition comprising rebaudioside D with acatalytic amount of UGT76G1 and UDP-glucose, and (b) recyclingUDP-glucose by providing sucrose synthase and sucrose.

In another particular embodiment, the present invention provides afermentation method of producing rebaudioside M by (a) contacting amedium containing a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to rebaudioside M.

In still another particular embodiment, the present invention provides afermentation method of producing rebaudioside M by (a) contacting amedium containing a starting composition comprising glucose with amicroorganism comprising at least one enzyme capable of convertingglucose to rebaudioside M and (b) recycling UDP-glucose by providingUDP-glucose, sucrose synthase and sucrose.

The methods above can further comprise separating rebaudioside M fromthe medium to provide a composition comprising highly purifiedrebaudioside M.

In some embodiment, multiple biocatalytic steps are performedsequentially to convert, e.g. (i) rebaudioside A to rebaudioside D, then(ii) rebaudioside D to rebaudioside M, or (i) stevioside to rebaudiosideA, then (ii) rebaudioside A to rebaudioside D, then (iii) rebaudioside Dto rebaudioside M, or (i) rubusoside to stevioside, then (ii) steviosideto rebaudioside A, then (iii) rebaudioside A to rebaudioside D, then(iv) rebaudioside D to rebaudioside M.

Alternatively, fermentation and biocatalytic steps can be usedsequentially. For example, fermentation of a starting compositioncomprising glucose with a microorganism containing at least one enzymecapable of converting glucose to a target steviol glycoside can beperformed first. The target steviol glycoside (which now becomes thestarting material for the purposes of the next bioconversion) can thenbe contacted with a biocatalyst capable of converting it to the nexttarget steviol glycoside.

Between each conversion the target steviol glycoside may optionally beseparated from the medium prior to contacting the steviol glycoside(which now becomes the starting steviol glycoside for the purposes ofthe next bioconversion) with the next biocatalyst.

Compounds and Methods

The present invention also provides isolated and highly purified reb D2.Reb D2 is an isomer of reb D and has the following structure:

13-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]ent-kaur-16-en-19-oic acid-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)ester]

In another embodiment, the present invention provides reb D2 having apurity greater than about 95% by weight on an anhydrous basis, such as,for example, greater than about 96% by weight, greater than about 97% byweight, greater than about 98% by weight or greater than about 99% byweight.

In still another embodiment, the present invention provides reb D2having a purity greater than about 95% by weight in a steviol glycosidemixture, such as, for example, greater than about 96% by weight, greaterthan about 97% by weight, greater than about 98% by weight or greaterthan about 99% by weight.

The present invention also provides compositions comprising reb D2.

The present invention also provides a method for preparing reb D2comprising:

-   -   a. contacting a starting composition comprising reb A with an        enzyme capable of transforming reb A to reb D2, UDP-glucose, and        optionally UDP-glucose recycling enzymes, to produce a        composition comprising reb D2; and    -   b. isolating the composition comprising reb D2.

In some embodiments, the enzyme capable of transforming reb A to reb D2is a UDP-glucosyltransferase, such as, for example, UGT91D2, UGTSL,UGTSL_Sc, UGTSL2 (GI No. 460410132 version XP_004250485.1), GI No.460409128 (UGTSL) version XP_004249992.1, GI No. 115454819 versionNP_001051010.1, GI No. 187373030, version ACD03249.1, GI No. 222619587version EEE55719.1, GI No. 297795735 version XP_002865752.1 or EUGT11.

In one embodiment, the enzyme can be provided in the form of one or morecells containing said enzyme.

In other embodiments, the enzyme can be provided in the form of a wholecell suspension, a crude lysate, a purified enzyme or a combinationthereof. In one embodiment, the enzyme is a purified enzyme. In anotherembodiment, the enzyme is provided in the form of a crude lysate. Instill another embodiment, the enzyme is provided in the form of a wholecell suspension.

The enzyme capable of transforming reb A to reb D2 can be immobilized.

In another embodiment, the enzyme is provided in a microorganism.

In one embodiment, the microorganism is free when contacted with thestarting composition.

In another embodiment, the microorganism is immobilized when contactedwith the starting composition. For example, the microorganism may beimmobilized to a solid support made from inorganic or organic materials.Non-limiting examples of solid supports suitable to immobilize themicroorganism include derivatized cellulose or glass, ceramics, metaloxides or membranes. The microorganism may be immobilized to the solidsupport, for example, by covalent attachment, adsorption, cross-linking,entrapment or encapsulation.

Suitable microorganisms include, but are not limited to, E. coli,Saccharomyces sp., Aspergillus sp., Pichia sp., Bacillus sp., Yarrowiasp.

In still another embodiment, the enzyme is secreted out of themicroorganism and into the reaction medium.

The starting composition is contacted with the enzyme or microorganismin an aqueous medium, comprising water, and various components selectedfrom the group including carbon sources, energy sources, nitrogensources, microelements, vitamins, nucleosides, nucleoside phosphates,nucleoside diphosphates, nucleoside triphosphates, organic and inorganicsalts, organic and mineral acids, bases etc. Carbon sources includeglycerol, glucose, carbon dioxide, carbonates, bicarbonates. Nitrogensources can include nitrates, nitrites, amino acids, peptides, peptones,or proteins.

In a particular embodiment, the medium comprises buffer. Suitablebuffers include, but are not limited to, PIPES buffer, acetate bufferand phosphate buffer. In a particular embodiment, the medium comprisesphosphate buffer.

In one embodiment the medium can also include an organic solvent.

In a particular embodiment, the enzyme is a UDP-glucosyltransferasecapable of transforming reb A to reb D2.

In a more particular embodiment, the enzyme is selected from UGT91D2,UGTSL, UGTSL_Sc, UGTSL2 (GI No. 460410132 version XP_004250485.1), GINo. 460409128 (UGTSL) version XP_004249992.1, GI No. 115454819 versionNP_001051010.1, GI No. 187373030, version ACD03249.1, GI No. 222619587version EEE55719.1, GI No. 297795735 version XP_002865752.1 or EUGT11and UGTs having substantial (>85%) sequence identity to these enzymes.

In a still more particular embodiment, the enzyme is UGTSL2 or itsimproved variant produced by directed evolution and having higheractivity.

In one embodiment, reb D2 is continuously removed from the medium whilethe conversion progresses. In yet another embodiment, reb D2 isseparated and, optionally, purified from the reaction medium aftercompletion of the reaction.

Isolation of reb D2 from the reaction medium can be achieved by anysuitable method to provide a composition comprising reb D2. Suitablemethods include, but are not limited to, lysis, crystallization,separation by membranes, centrifugation, extraction (liquid or solidphase), chromatographic separation, HPLC (preparative or analytical) ora combination of such methods. In a particular embodiment, isolation canbe achieved by lysis and centrifugation.

In some embodiments, isolation may result in a reb D2 purity less thanabout 95% by weight on an anhydrous basis, and the composition maycontain, e.g., steviol glycosides and/or residual reaction products. Thecomposition comprising reb D2 can be further purified to provide highlypurified reb D2, i.e. reb D2 having a purity greater than about 95% byweight on an anhydrous basis. In some embodiments, the compositionscomprising reb D2 can be further purified to provide reb D2 having apurity greater than about 96%, greater than about 97%, greater thanabout 98% or greater than about 99% by weight on an anhydrous basis.

Purification can be affected by any means known to one of skill in theart including, but not limited to, crystallization, separation bymembranes, centrifugation, extraction (liquid or solid phase),chromatographic separation, HPLC (preparative or analytical) or acombination of such methods. In a particular embodiment, HPLC is used topurify reb D2. In a more particular embodiment, semi-preparative HPLC isused to purify reb D2.

For example, a two-step semi-preparative HPLC purification can be used.The first step utilizes a C18 column with a mobile phase containing A(25% MeCN in water) and B (30% MeCN in water) with the followinggradient:

Time (min) % A % B 0.0-5.0 100 0 20 20 80 25 20 80 30 100 0

The secondary step utilizes the same column and conditions, but withonly an isocratic mobile phase: 20% MeCN in water.

Those of skill in the art will recognize that the particular column,mobile phases, injection volumes and other HPLC parameters can vary.

The present invention provides isolated and highly purified reb M2. RebM2 is an isomer of reb M and has the following structure:

(13-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]ent-kaur-16-en-19-oicacid-[(2-O-β-D-glucopyranosyl-6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)ester])

In another embodiment, the present invention provides reb M2 having apurity greater than about 95% by weight on an anhydrous basis, such as,for example, greater than about 96% by weight, greater than about 97% byweight, greater than about 98% by weight or greater than about 99% byweight.

In still another embodiment, the present invention provides reb M2having a purity greater than about 95% by weight in a steviol glycosidemixture, such as, for example, greater than about 96% by weight, greaterthan about 97% by weight, greater than about 98% by weight or greaterthan about 99% by weight.

In yet another embodiment, the present invention provides reb M2 havinga purity greater than about 95% by weight in a stevia extract, such as,for example, greater than about 96% by weight, greater than about 97% byweight, greater than about 98% by weight or greater than about 99% byweight.

The present invention also provides compositions comprising reb M2.

It has been found that reb M2 is produced during biotransformation ofreb A to reb D. As noted above, biotransformation of reb A to reb D alsoproduces reb D2. Accordingly, the present invention also provides amethod for preparing reb M2 comprising:

-   -   a. contacting a starting composition comprising reb A and/or reb        D2 with an enzyme capable of transforming reb A and/or reb D2 to        reb M2, UDP-glucose, and optionally UDP-glucose recycling        enzymes to produce a composition comprising reb M2; and    -   b. isolating a composition comprising reb M2.

Not wishing to be bound by theory, it is currently believed that thepathway begins with transformation of reb A to reb D2, followed bytransformation of reb D2 to reb M2. Accordingly, the present inventionprovides a method for preparing reb M2 comprising:

-   -   a. contacting a starting composition comprising reb D2 with an        enzyme capable of transforming reb D2 to reb M2, UDP-glucose,        and optionally UDP-glucose recycling enzymes to produce a        composition comprising reb M2; and    -   b. isolating a composition comprising reb M2.

In yet another embodiment, a method for preparing reb M2 comprises:

-   -   a. contacting a starting composition comprising reb A with an        enzyme capable of transforming reb A to reb D2, UDP-glucose, and        optionally UDP-glucose recycling enzymes to produce a        composition comprising reb D2;    -   b. optionally, isolating a composition comprising reb D2;    -   c. contacting the composition comprising reb D2 with an enzyme        capable of transforming reb D2 to reb M2, UDP-glucose, and        optionally UDP-glucose recycling enzymes to produce a        composition comprising reb M2; and    -   d. isolating a composition comprising reb M2.

The enzyme can be a UDP-glucosyltransferase, such as, for example,UGT91D2, UGTSL, UGTSL_Sc, UGTSL2 (GI No. 460410132 versionXP_004250485.1), GI No. 460409128 (UGTSL) version XP_004249992.1, GI No.115454819 version NP_001051010.1, GI No. 187373030, version ACD03249.1,GI No. 222619587 version EEE55719.1, GI No. 297795735 versionXP_002865752.1 or EUGT11.

In one embodiment, the enzyme can be provided in the form of one or morecells containing said enzyme.

In other embodiments, the enzyme can be provided in the form of a wholecell suspension, a crude lysate, a purified enzyme or a combinationthereof. In one embodiment, the enzyme is a purified enzyme. In anotherembodiment, the enzyme is provided in the form of a crude lysate. Instill another embodiment, the enzyme is provided in the form of a wholecell suspension.

In some embodiments, the enzyme can be immobilized.

In another embodiment, the enzyme is provided in a r microorganism.

In one embodiment, the microorganism is free when contacted with thestarting composition.

In another embodiment, the microorganism is immobilized when contactedwith the starting composition. For example, the microorganism may beimmobilized to a solid support made from inorganic or organic materials.Non-limiting examples of solid supports suitable to immobilize themicroorganism include derivatized cellulose or glass, ceramics, metaloxides or membranes. The microorganism may be immobilized to the solidsupport, for example, by covalent attachment, adsorption, cross-linking,entrapment or encapsulation.

Suitable microorganisms include, but are not limited to, E. coli,Saccharomyces sp., Aspergillus sp., Pichia sp., Bacillus sp., Yarrowiasp.

In still another embodiment, the enzyme is secreted out of themicroorganism and into the reaction medium.

The starting composition is contacted with the enzyme or microorganismin aqueous medium, comprising water, and various components selectedfrom the group including carbon sources, energy sources, nitrogensources, microelements, vitamins, nucleosides, nucleoside phosphates,nucleoside diphosphates, nucleoside triphosphates, organic and inorganicsalts, organic and mineral acids, bases etc. Carbon sources includeglycerol, glucose, carbon dioxide, carbonates, bicarbonates. Nitrogensources can include nitrates, nitrites, amino acids, peptides, peptones,or proteins.

In a particular embodiment, the medium comprises buffer. Suitablebuffers include, but are not limited to, PIPES buffer, acetate bufferand phosphate buffer. In a particular embodiment, the medium comprisesphosphate buffer.

In one embodiment the medium can also include an organic solvent.

In a particular embodiment, the enzyme is a UDP-glucosyltransferasecapable of transforming reb A and/or reb D2 to reb M2 and is containedin E. coli.

In a more particular embodiment, the enzyme is selected from UGT91D2,UGTSL, UGTSL_Sc, UGTSL2 (GI No. 460410132 version XP_004250485.1), GINo. 460409128 (UGTSL) version XP_004249992.1, GI No. 115454819 versionNP_001051010.1, GI No. 187373030, version ACD03249.1, GI No. 222619587version EEE55719.1, GI No. 297795735 version XP_002865752.1 or EUGT11.

In a still more particular embodiment, the enzyme is UGTSL2 or itsimproved variant produced by directed evolution and having higheractivity.

In one embodiment, reb M2 can be continuously removed from the mediumwhile the conversion progresses. In yet another embodiment, reb M2 isseparated, and optionally purified, from the reaction medium after thecompletion of the reaction.

Isolation of reb M2 from the reaction medium can be achieved by anysuitable method to provide a composition comprising reb M2. Suitablemethods include, but are not limited to, lysis, crystallization,separation by membranes, centrifugation, extraction (liquid or solidphase), chromatographic separation, HPLC (preparative or analytical) ora combination of such methods. In a particular embodiment, isolation canbe achieved by lysis and centrifugation.

In some embodiments, isolation may result in a reb M2 purity less thanabout 95% by weight on an anhydrous basis, and the composition maycontain, e.g., steviol glycosides and/or residual reaction products.

The composition comprising reb M2 can be further purified to providehighly purified reb M2, i.e. reb M2 having a purity greater than about95% by weight on an anhydrous basis. In some embodiments, thecompositions comprising reb M2 can be further purified to provide reb M2having a purity greater than about 96%, greater than about 97%, greaterthan about 98% or greater than about 99% by weight on an anhydrousbasis.

Purification can be affected by any means known to one of skill in theart including, but not limited to, crystallization, separation bymembranes, centrifugation, extraction (liquid or solid phase),chromatographic separation, HPLC (preparative or analytical) or acombination of such methods. In a particular embodiment, HPLC is used topurify reb M2. In a more particular embodiment, semi-preparative HPLC isused to purify reb M2.

For example, a two-step semi-preparative HPLC purification can be used.The first step utilizes a C18 column with a mobile phase containing A(25% MeCN in water) and B (30% MeCN in water) with the followinggradient:

Time (min) % A % B 0.0-5.0 100 0 20 20 80 25 20 80 30 100 0

The secondary step utilizes the same column and conditions, but withonly an isocratic mobile phase: 20% MeCN in water.

Those of skill in the art will recognize that the particular column,mobile phases, injection volumes and other HPLC parameters can vary.

Purified steviol glycosides, prepared in accordance with the presentinvention, may be used in a variety of consumable products including,but not limited to, foods, beverages, pharmaceutical compositions,tobacco products, nutraceutical compositions, oral hygiene compositions,and cosmetic compositions.

The high purity reb M obtained in this invention, having a molecularweight of 1291.29, a molecular formula of C₅₆H₉₀O₃₃, CAS registry number1220616-44-3, and the structure presented in FIG. 1, is in the form of awhite and odorless powder. The compound is about 200 times sweeter thansugar when compared to a 10% sucrose solution.

Other properties of the pure reb M compound include a melting point of249-250° C., and a specific rotation of [α]_(D) ²⁵−19.0° in 50% ethanol(C=1.0). The solubility of reb Min water is around 0.3%, and increaseswith an increase in temperature.

Reb M is soluble in diluted solutions of methanol, ethanol, n-propanol,and isopropanol. However, it is insoluble in acetone, benzene,chloroform, and ether.

Reb M obtained in accordance with the present invention is heat andpH-stable.

Highly purified target glycoside(s) particularly, reb D, reb D2, reb Mand/or reb M2 obtained according to this invention can be used “as-is”or in combination with other sweeteners, flavors, food ingredients andcombinations thereof.

Non-limiting examples of flavors include, but are not limited to, lime,lemon, orange, fruit, banana, grape, pear, pineapple, mango, berry,bitter almond, cola, cinnamon, sugar, cotton candy, vanilla andcombinations thereof.

Non-limiting examples of other food ingredients include, but are notlimited to, acidulants, organic and amino acids, coloring agents,bulking agents, modified starches, gums, texturizers, preservatives,antioxidants, emulsifiers, stabilizers, thickeners, gelling agents andcombinations thereof.

Highly purified target glycoside(s) particularly, reb D, reb D2, reb Mand/or reb M2 obtained according to this invention can be prepared invarious polymorphic forms, including but not limited to hydrates,solvates, anhydrous, amorphous forms and combinations thereof.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M and/or reb M2 obtained according to this invention may beincorporated as a high intensity natural sweetener in foodstuffs,beverages, pharmaceutical compositions, cosmetics, chewing gums, tabletop products, cereals, dairy products, toothpastes and other oral cavitycompositions, etc.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M and/or reb M2 as a sweetening compound may be employed as thesole sweetener, or it may be used together with one another or with atleast one other naturally occurring high intensity sweeteners such asstevia, stevia extract, steviolmonoside, steviolbioside, stevioside, rebA, reb B, reb C, reb E, reb F, reb G, reb I, reb E, reb H, reb L, reb K,reb J, reb N, reb 0, steviolbioside, dulcoside A, dulcoside B,rubusoside, or other glycosides of steviol found in Stevia rebaudiana,mogrosides, brazzein, neohesperidin dihydrochalcone, glycyrrhizic acidand its salts, thaumatin, perillartine, pernandulcin, mukuroziosides,baiyunoside, phlomisoside-I, dimethyl-hexahydrofluorene-dicarboxylicacid, abrusosides, periandrin, carnosiflosides, cyclocarioside,pterocaryosides, polypodoside A, brazilin, hernandulcin, phillodulcin,glycyphyllin, phlorizin, trilobatin, dihydroflavonol,dihydroquercetin-3-acetate, neoastilibin, trans-cinnamaldehyde, monatinand its salts, selligueain A, hematoxylin, monellin, osladin,pterocaryoside A, pterocaryoside B, mabinlin, pentadin, miraculin,curculin, neoculin, chlorogenic acid, cynarin, Luo Han Guo sweetener,mogroside V, mogroside VI, grosmomomside, siamenoside, or otherglycoside of mogrol found in Siraitia grosvenorii and combinationsthereof.

In a particular embodiment, reb D2 and/or reb M2 can be used together ina sweetener composition comprising a compound selected from the groupconsisting of reb A, reb B, reb D, NSF-02, Mogroside V, Luo Han Guo,allulose, allose, D-tagatose, erythritol and combinations thereof.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M and/or reb M2 may also be used in combination with synthetichigh intensity sweeteners such as sucralose, potassium acesulfame,aspartame, alitame, saccharin, neohesperidin dihydrochalcone, cyclamate,neotame, dulcin, suosan advantame, salts thereof, and combinationsthereof.

Moreover, highly purified target steviol glycoside(s), particularly, rebD, reb D2, reb M and/or reb M2 can be used in combination with naturalsweetener suppressors such as gymnemic acid, hodulcin, ziziphin,lactisole, and others. Reb D, reb D2, reb M and/or reb M2 may also becombined with various umami taste enhancers. Reb D, reb D2, reb M and/orreb M2 can be mixed with umami tasting and sweet amino acids such asglutamate, aspartic acid, glycine, alanine, threonine, proline, serine,glutamate, lysine, tryptophan and combinations thereof.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M can be used in combination with one or more additive selectedfrom the group consisting of carbohydrates, polyols, amino acids andtheir corresponding salts, poly-amino acids and their correspondingsalts, sugar acids and their corresponding salts, nucleotides, organicacids, inorganic acids, organic salts including organic acid salts andorganic base salts, inorganic salts, bitter compounds, flavorants andflavoring ingredients, astringent compounds, proteins or proteinhydrolysates, surfactants, emulsifiers, flavonoids, alcohols, polymersand combinations thereof.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M and/or reb M2 may be combined with polyols or sugar alcohols.The term “polyol” refers to a molecule that contains more than onehydroxyl group. A polyol may be a diol, triol, or a tetraol whichcontain 2, 3, and 4 hydroxyl groups, respectively. A polyol also maycontain more than four hydroxyl groups, such as a pentaol, hexaol,heptaol, or the like, which contain 5, 6, or 7 hydroxyl groups,respectively. Additionally, a polyol also may be a sugar alcohol,polyhydric alcohol, or polyalcohol which is a reduced form ofcarbohydrate, wherein the carbonyl group (aldehyde or ketone, reducingsugar) has been reduced to a primary or secondary hydroxyl group.Examples of polyols include, but are not limited to, erythritol,maltitol, mannitol, sorbitol, lactitol, xylitol, inositol, isomalt,propylene glycol, glycerol, threitol, galactitol, hydrogenatedisomaltulose, reduced isomalto-oligosaccharides, reducedxylo-oligosaccharides, reduced gentio-oligosaccharides, reduced maltosesyrup, reduced glucose syrup, hydrogenated starch hydrolyzates,polyglycitols and sugar alcohols or any other carbohydrates capable ofbeing reduced which do not adversely affect the taste of the sweetenercomposition.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M and/or reb M2 may be combined with reduced calorie sweetenerssuch as, for example, D-tagatose, L-sugars, L-sorbose, L-arabinose andcombinations thereof.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M and/or reb M2 may also be combined with various carbohydrates.The term “carbohydrate” generally refers to aldehyde or ketone compoundssubstituted with multiple hydroxyl groups, of the general formula(CH₂O)_(n), wherein n is 3-30, as well as their oligomers and polymers.The carbohydrates of the present invention can, in addition, besubstituted or deoxygenated at one or more positions. Carbohydrates, asused herein, encompass unmodified carbohydrates, carbohydratederivatives, substituted carbohydrates, and modified carbohydrates. Asused herein, the phrases “carbohydrate derivatives”, “substitutedcarbohydrate”, and “modified carbohydrates” are synonymous. Modifiedcarbohydrate means any carbohydrate wherein at least one atom has beenadded, removed, or substituted, or combinations thereof. Thus,carbohydrate derivatives or substituted carbohydrates includesubstituted and unsubstituted monosaccharides, disaccharides,oligosaccharides, and polysaccharides. The carbohydrate derivatives orsubstituted carbohydrates optionally can be deoxygenated at anycorresponding C-position, and/or substituted with one or more moietiessuch as hydrogen, halogen, haloalkyl, carboxyl, acyl, acyloxy, amino,amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino,alkoxy, aryloxy, nitro, cyano, sulfo, mercapto, imino, sulfonyl,sulfenyl, sulfinyl, sulfamoyl, carboalkoxy, carboxamido, phosphonyl,phosphinyl, phosphoryl, phosphino, thioester, thioether, oximino,hydrazino, carbamyl, phospho, phosphonato, or any other viablefunctional group provided the carbohydrate derivative or substitutedcarbohydrate functions to improve the sweet taste of the sweetenercomposition.

Examples of carbohydrates which may be used in accordance with thisinvention include, but are not limited to, psicose, turanose, allose,tagatose, trehalose, galactose, rhamnose, various cyclodextrins, cyclicoligosaccharides, various types of maltodextrins, dextran, sucrose,glucose, ribulose, fructose, threose, arabinose, xylose, lyxose, allose,altrose, mannose, idose, lactose, maltose, invert sugar, isotrehalose,neotrehalose, isomaltulose, erythrose, deoxyribose, gulose, idose,talose, erythrulose, xylulose, psicose, turanose, cellobiose,amylopectin, glucosamine, mannosamine, fucose, glucuronic acid, gluconicacid, glucono-lactone, abequose, galactosamine, beet oligosaccharides,isomalto-oligosaccharides (isomaltose, isomaltotriose, panose and thelike), xylo-oligosaccharides (xylotriose, xylobiose and the like),xylo-terminated oligosaccharides, gentio-oligosaccharides (gentiobiose,gentiotriose, gentiotetraose and the like), sorbose,nigero-oligosaccharides, palatinose oligosaccharides,fructooligosaccharides (kestose, nystose and the like), maltotetraol,maltotriol, malto-oligosaccharides (maltotriose, maltotetraose,maltopentaose, maltohexaose, maltoheptaose and the like), starch,inulin, inulo-oligosaccharides, lactulose, melibiose, raffinose, ribose,isomerized liquid sugars such as high fructose corn syrups, couplingsugars, and soybean oligosaccharides. Additionally, the carbohydrates asused herein may be in either the D- or L-configuration.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M and/or reb M2 obtained according to this invention can be usedin combination with various physiologically active substances orfunctional ingredients. Functional ingredients generally are classifiedinto categories such as carotenoids, dietary fiber, fatty acids,saponins, antioxidants, nutraceuticals, flavonoids, isothiocyanates,phenols, plant sterols and stanols (phytosterols and phytostanols);polyols; prebiotics, probiotics; phytoestrogens; soy protein;sulfides/thiols; amino acids; proteins; vitamins; and minerals.

Functional ingredients also may be classified based on their healthbenefits, such as cardiovascular, cholesterol-reducing, andanti-inflammatory. Exemplary functional ingredients are provided inWO2013/096420, the contents of which is hereby incorporated byreference.

Highly purified target steviol glycoside(s), particularly, reb D, rebD2, reb M and/or reb M2 obtained according to this invention may beapplied as a high intensity sweetener to produce zero calorie, reducedcalorie or diabetic beverages and food products with improved tastecharacteristics. It may also be used in drinks, foodstuffs,pharmaceuticals, and other products in which sugar cannot be used. Inaddition, highly purified target steviol glycoside(s), particularly, rebD, reb D2, reb M and/or reb M2 can be used as a sweetener not only fordrinks, foodstuffs, and other products dedicated for human consumption,but also in animal feed and fodder with improved characteristics.

Examples of consumable products in which highly purified target steviolglycoside(s), particularly, reb D, reb D2, reb M and/or reb M2 may beused as a sweetening compound include, but are not limited to, alcoholicbeverages such as vodka, wine, beer, liquor, and sake, etc.; naturaljuices; refreshing drinks; carbonated soft drinks; diet drinks; zerocalorie drinks; reduced calorie drinks and foods; yogurt drinks; instantjuices; instant coffee; powdered types of instant beverages; cannedproducts; syrups; fermented soybean paste; soy sauce; vinegar;dressings; mayonnaise; ketchups; curry; soup; instant bouillon; powderedsoy sauce; powdered vinegar; types of biscuits; rice biscuit; crackers;bread; chocolates; caramel; candy; chewing gum; jelly; pudding;preserved fruits and vegetables; fresh cream; jam; marmalade; flowerpaste; powdered milk; ice cream; sorbet; vegetables and fruits packed inbottles; canned and boiled beans; meat and foods boiled in sweetenedsauce; agricultural vegetable food products; seafood; ham; sausage; fishham; fish sausage; fish paste; deep fried fish products; dried seafoodproducts; frozen food products; preserved seaweed; preserved meat;tobacco; medicinal products; and many others. In principle it can haveunlimited applications.

During the manufacturing of products such as foodstuffs, drinks,pharmaceuticals, cosmetics, table top products, and chewing gum, theconventional methods such as mixing, kneading, dissolution, pickling,permeation, percolation, sprinkling, atomizing, infusing and othermethods may be used.

Moreover, the highly purified target steviol glycoside(s), particularly,reb D, reb D2, reb M and/or reb M2 obtained in this invention may beused in dry or liquid forms. In one embodiment, a tabletop sweetenercomprising reb D2 is provided. In another embodiment, a tabletopsweetener comprising reb M2 is provided.

The highly purified target steviol glycoside can be added before orafter heat treatment of food products. The amount of the highly purifiedtarget steviol glycoside(s), particularly, reb D, reb D2, reb M and/orreb M2 depends on the purpose of usage. As discussed above, it can beadded alone or in combination with other compounds.

The present invention is also directed to sweetness enhancement inbeverages using reb D2 and/or reb M2. Accordingly, the present inventionprovides a beverage comprising a sweetener and reb D2 and/or reb M2 as asweetness enhancer, wherein reb D2 and/or reb M2 is present in aconcentration at or below their respective sweetness recognitionthresholds.

As used herein, the term “sweetness enhancer” refers to a compoundcapable of enhancing or intensifying the perception of sweet taste in acomposition, such as a beverage. The term “sweetness enhancer” issynonymous with the terms “sweet taste potentiator,” “sweetnesspotentiator,” “sweetness amplifier,” and “sweetness intensifier.” Theterm “sweetness recognition threshold concentration,” as generally usedherein, is the lowest known concentration of a sweet compound that isperceivable by the human sense of taste, typically around 1.0% sucroseequivalence (1.0% SE). Generally, the sweetness enhancers may enhance orpotentiate the sweet taste of sweeteners without providing anynoticeable sweet taste by themselves when present at or below thesweetness recognition threshold concentration of a given sweetnessenhancer; however, the sweetness enhancers may themselves provide sweettaste at concentrations above their sweetness recognition thresholdconcentration. The sweetness recognition threshold concentration isspecific for a particular enhancer and can vary based on the beveragematrix. The sweetness recognition threshold concentration can be easilydetermined by taste testing increasing concentrations of a givenenhancer until greater than 1.0% sucrose equivalence in a given beveragematrix is detected. The concentration that provides about 1.0% sucroseequivalence is considered the sweetness recognition threshold.

In some embodiments, sweetener is present in the beverage in an amountfrom about 0.5% to about 12% by weight, such as, for example, about 1.0%by weight, about 1.5% by weight, about 2.0% by weight, about 2.5% byweight, about 3.0% by weight, about 3.5% by weight, about 4.0% byweight, about 4.5% by weight, about 5.0% by weight, about 5.5% byweight, about 6.0% by weight, about 6.5% by weight, about 7.0% byweight, about 7.5% by weight, about 8.0% by weight, about 8.5% byweight, about 9.0% by weight, about 9.5% by weight, about 10.0% byweight, about 10.5% by weight, about 11.0% by weight, about 11.5% byweight or about 12.0% by weight.

In a particular embodiment, the sweetener is present in the beverage inan amount from about 0.5% of about 10%, such as for example, from about2% to about 8%, from about 3% to about 7% or from about 4% to about 6%by weight. In a particular embodiment, the sweetener is present in thebeverage in an amount from about 0.5% to about 8% by weight. In anotherparticular embodiment, the sweetener is present in the beverage in anamount from about 2% to about 8% by weight.

In one embodiment, the sweetener is a traditional caloric sweetener.Suitable sweeteners include, but are not limited to, sucrose, fructose,glucose, high fructose corn syrup and high fructose starch syrup.

In another embodiment, the sweetener is erythritol.

In still another embodiment, the sweetener is a rare sugar. Suitablerare sugars include, but are not limited to, D-allose, D-psicose,L-ribose, D-tagatose, L-glucose, L-fucose, L-arbinose, D-turanose,D-leucrose and combinations thereof.

It is contemplated that a sweetener can be used alone, or in combinationwith other sweeteners.

In one embodiment, the rare sugar is D-allose. In a more particularembodiment, D-allose is present in the beverage in an amount of about0.5% to about 10% by weight, such as, for example, from about 2% toabout 8%.

In another embodiment, the rare sugar is D-psicose. In a more particularembodiment, D-psicose is present in the beverage in an amount of about0.5% to about 10% by weight, such as, for example, from about 2% toabout 8%.

In still another embodiment, the rare sugar is D-ribose. In a moreparticular embodiment, D-ribose is present in the beverage in an amountof about 0.5% to about 10% by weight, such as, for example, from about2% to about 8%.

In yet another embodiment, the rare sugar is D-tagatose. In a moreparticular embodiment, D-tagatose is present in the beverage in anamount of about 0.5% to about 10% by weight, such as, for example, fromabout 2% to about 8%.

In a further embodiment, the rare sugar is L-glucose. In a moreparticular embodiment, L-glucose is present in the beverage in an amountof about 0.5% to about 10% by weight, such as, for example, from about2% to about 8%.

In one embodiment, the rare sugar is L-fucose. In a more particularembodiment, L-fucose is present in the beverage in an amount of about0.5% to about 10% by weight, such as, for example, from about 2% toabout 8%.

In another embodiment, the rare sugar is L-arabinose. In a moreparticular embodiment, L-arabinose is present in the beverage in anamount of about 0.5% to about 10% by weight, such as, for example, fromabout 2% to about 8%.

In yet another embodiment, the rare sugar is D-turanose. In a moreparticular embodiment, D-turanose is present in the beverage in anamount of about 0.5% to about 10% by weight, such as, for example, fromabout 2% to about 8%.

In yet another embodiment, the rare sugar is D-leucrose. In a moreparticular embodiment, D-leucrose is present in the beverage in anamount of about 0.5% to about 10% by weight, such as, for example, fromabout 2% to about 8%.

The addition of the sweetness enhancer at a concentration at or belowits sweetness recognition threshold increases the detected sucroseequivalence of the beverage comprising the sweetener and the sweetnessenhancer compared to a corresponding beverage in the absence of thesweetness enhancer. Moreover, sweetness can be increased by an amountmore than the detectable sweetness of a solution containing the sameconcentration of the at least one sweetness enhancer in the absence ofany sweetener.

Accordingly, the present invention also provides a method for enhancingthe sweetness of a beverage comprising a sweetener comprising providinga beverage comprising a sweetener and adding a sweetness enhancerselected from reb D2, reb M2 or a combination thereof, wherein reb D2and reb M2 are present in a concentration at or below their sweetnessrecognition thresholds.

Addition of reb D2 and/or reb M2 in a concentration at or below thesweetness recognition threshold to a beverage containing a sweetener mayincrease the detected sucrose equivalence from about 1.0% to about 5.0%,such as, for example, about 1.0%, about 1.5%, about 2.0%, about 2.5%,about 3.0%, about 3.5%, about 4.0%, about 4.5% or about 5.0%.

The following examples illustrate preferred embodiments of the inventionfor the preparation of highly purified target steviol glycoside(s),particularly, reb D, reb D2, reb M and/or reb M2. It will be understoodthat the invention is not limited to the materials, proportions,conditions and procedures set forth in the examples, which are onlyillustrative.

Example 1 In-Vivo Production of UGT76G1

NcoI and NdeI restriction sides were added to the original nucleicsequence as described in Genbank accession no. AAR06912.1. After codonoptimization the following nucleic sequence was obtained:

(SEQ ID NO: 1) CCATGGCCCATATGGAAAACAAAACCGAAACCACCGTTCGTCGTCGTCGCCGTATTATTCTGTTTCCGGTTCCGTTTCAGGGTCATATTAATCCGATTCTGCAGCTGGCAAATGTGCTGTATAGCAAAGGTTTTAGCATTACCATTTTTCATACCAATTTTAACAAACCGAAAACCAGCAATTATCCGCATTTTACCTTTCGCTTTATTCTGGATAATGATCCGCAGGATGAACGCATTAGCAATCTGCCGACACATGGTCCGCTGGCAGGTATGCGTATTCCGATTATTAACGAACATGGTGCAGATGAACTGCGTCGTGAACTGGAACTGCTGATGCTGGCAAGCGAAGAAGATGAAGAAGTTAGCTGTCTGATTACCGATGCACTGTGGTATTTTGCACAGAGCGTTGCAGATAGCCTGAATCTGCGTCGTCTGGTTCTGATGACCAGCAGCCTGTTTAACTTTCATGCACATGTTAGCCTGCCGCAGTTTGATGAACTGGGTTATCTGGATCCGGATGATAAAACCCGTCTGGAAGAACAGGCAAGCGGTTTTCCGATGCTGAAAGTGAAAGATATCAAAAGCGCCTATAGCAATTGGCAGATTCTGAAAGAAATTCTGGGCAAAATGATTAAACAGACCAAAGCAAGCAGCGGTGTTATTTGGAATAGCTTTAAAGAACTGGAAGAAAGCGAACTGGAAACCGTGATTCGTGAAATTCCGGCACCGAGCTTTCTGATTCCGCTGCCGAAACATCTGACCGCAAGCAGCAGCAGCCTGCTGGATCATGATCGTACCGTTTTTCAGTGGCTGGATCAGCAGCCTCCGAGCAGCGTTCTGTATGTTAGCTTTGGTAGCACCAGCGAAGTTGATGAAAAAGATTTTCTGGAAATTGCCCGTGGTCTGGTTGATAGCAAACAGAGCTTTCTGTGGGTTGTTCGTCCGGGTTTTGTTAAAGGTAGCACCTGGGTTGAACCGCTGCCGGATGGTTTTCTGGGTGAACGTGGTCGTATTGTTAAATGGGTTCCGCAGCAAGAAGTTCTGGCACACGGCGCAATTGGTGCATTTTGGACCCATAGCGGTTGGAATAGCACCCTGGAAAGCGTTTGTGAAGGTGTTCCGATGATTTTTAGCGATTTTGGTCTGGATCAGCCGCTGAATGCACGTTATATGAGTGATGTTCTGAAAGTGGGTGTGTATCTGGAAAATGGTTGGGAACGTGGTGAAATTGCAAATGCAATTCGTCGTGTTATGGTGGATGAAGAAGGTGAATATATTCGTCAGAATGCCCGTGTTCTGAAACAGAAAGCAGATGTTAGCCTGATGAAAGGTGGTAGCAGCTATGAAAGCCTGGAAAGTCTGGTTAGCTATATTAGCAGCCTGTAATAACTCGAG.

After synthesis of the gene and subcloning into pET30A+ vector usingNdeI and XhoI cloning sites, the UGT76G1_pET30a+ plasmid was introducedin E. coli B121(DE3) and E. coli EC100 by electroporation. The obtainedcells were grown in petri-dishes in the presence of Kanamycin andsuitable colonies were selected and allowed to grow in liquid LB medium(erlenmeyer flasks). Glycerol was added to the suspension ascryoprotectant and 400 μL aliquots were stored at −20° C. and at −80° C.

The storage aliquots of E. coli BL21(DE3) containing the pET30A+_UGT76G1plasmid were thawed and added to 30 mL of LBGKP medium (20 g/L LuriaBroth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM Phosphate buffer pH7.00; 2.5 g/L glucose and 50 mg/L of Kanamycin). This culture wasallowed to shake at 135 rpm at 30° C. for 8 h.

The production medium contained 60 g/L of overnight express instant TBmedium (Novagen), 10 g/L of glycerol and 50 mg/L of Kanamycin. Themedium was allowed to stir at 20° C. while taking samples to measure theOD and pH. The cultures gave significant growth and a good OD wasobtained. After 40 h, the cells were harvested by centrifugation andfrozen to yield 12.7 g of cell wet weight.

Lysis was performed by addition of Bugbuster Master mix (Novagen) andthe lysate was recovered by centrifugation and kept frozen. Activitytests were performed with thawed lysate.

Example 2 In-Vitro Production of UGT76G1

The S30 T7 High Yield Protein expression system kit from Promega wasused. 4 μg of UGT76G1_pET30a+ plasmid from E. coli EC100 was mixed with80 μL of S30 premix plus and 72 μL of S30 T7 extract was added.Nuclease-free water was added in order to obtain a total volume of 200μL and the resulting solution was incubated for 2 h at 30° C. 180 μL wasused in the catalytic test reaction.

Example 3 In-Vitro Production of UGT91D2

NcoI and NdeI restriction sides were added to the original nucleicsequence as described in Genbank accession no. ACE87855.1. After codonoptimization the following nucleic sequence was obtained:

(SEQ ID NO: 2) CCATGGCACATATGGCAACCAGCGATAGCATTGTTGATGATCGTAAACAGCTGCATGTTGCAACCTTTCCGTGGCTGGCATTTGGTCATATTCTGCCGTATCTGCAGCTGAGCAAACTGATTGCAGAAAAAGGTCATAAAGTGAGCTTTCTGAGCACCACCCGTAATATTCAGCGTCTGAGCAGCCATATTAGTCCGCTGATTAATGTTGTTCAGCTGACCCTGCCTCGTGTTCAAGAACTGCCGGAAGATGCCGAAGCAACCACCGATGTTCATCCGGAAGATATTCCGTATCTGAAAAAAGCAAGTGATGGTCTGCAGCCGGAAGTTACCCGTTTTCTGGAACAGCATAGTCCGGATTGGATCATCTATGATTATACCCATTATTGGCTGCCGAGCATTGCAGCAAGCCTGGGTATTAGCCGTGCACATTTTAGCGTTACCACCCCGTGGGCAATTGCATATATGGGTCCGAGCGCAGATGCAATGATTAATGGTAGTGATGGTCGTACCACCGTTGAAGATCTGACCACCCCTCCGAAATGGTTTCCGTTTCCGACCAAAGTTTGTTGGCGTAAACATGATCTGGCACGTCTGGTTCCGTATAAAGCACCGGGTATTAGTGATGGTTATCGTATGGGTCTGGTTCTGAAAGGTAGCGATTGTCTGCTGAGCAAATGCTATCATGAATTTGGCACCCAGTGGCTGCCGCTGCTGGAAACCCTGCATCAGGTTCCGGTTGTTCCGGTGGGTCTGCTGCCTCCGGAAGTTCCGGGTGATGAAAAAGATGAAACCTGGGTTAGCATCAAAAAATGGCTGGATGGTAAACAGAAAGGTAGCGTGGTTTATGTTGCACTGGGTAGCGAAGTTCTGGTTAGCCAGACCGAAGTTGTTGAACTGGCACTGGGTCTGGAACTGAGCGGTCTGCCGTTTGTTTGGGCATATCGTAAACCGAAAGGTCCGGCAAAAAGCGATAGCGTTGAACTGCCGGATGGTTTTGTTGAACGTACCCGTGATCGTGGTCTGGTTTGGACCAGCTGGGCACCTCAGCTGCGTATTCTGAGCCATGAAAGCGTTTGTGGTTTTCTGACCCATTGTGGTAGCGGTAGCATTGTGGAAGGTCTGATGTTTGGTCATCCGCTGATTATGCTGCCGATTTTTGGTGATCAGCCGCTGAATGCACGTCTGCTGGAAGATAAACAGGTTGGTATTGAAATTCCGCGTAATGAAGAAGATGGTTGCCTGACCAAAGAAAGCGTTGCACGTAGCCTGCGTAGCGTTGTTGTTGAAAAAGAAGGCGAAATCTATAAAGCCAATGCACGTGAACTGAGCAAAATCTATAATGATACCAAAGTGGAAAAAGAATATGTGAGCCAGTTCGTGGATTATCTGGAAAAAAACACCCGTGCAGTTGCCATTGATCACGAAAGCTAATGACTCGAG

After synthesis of the gene and subcloning into pET30A+ vector usingNcoI and XhoI cloning sites, the UGT91D2_pET30a+ plasmid was introducedinto E. coli EC100 by electroporation. The obtained cells were grown inthe presence of Kanamycin and suitable colonies were selected andallowed to grow in liquid LB medium (erlenmeyer flasks). Glycerol wasadded to the suspension as cryoprotectant and 400 μL aliquots werestored at −20° C. and at −80° C.

The S30 T7 High Yield Protein expression system kit from Promega wasused for the in-vitro synthesis of the protein.

4 μg of UGT91D2_pET30a+ plasmid was mixed with 80 μL of S30 premix plusand 72 μL of S30 T7 extract was added. Nuclease-free water was added inorder to obtain a total volume of 200 μL and the resulting solution wasincubated for 2 h at 30° C. 5 μL was used for SDS-page analysis whilethe remaining 45 μL was used in the catalytic test reaction.

Example 4 Catalytic Reaction with In-Vivo Produced UGT76G1

The total volume of the reaction was 5.0 mL with the followingcomposition: 50 mM sodium phosphate buffer pH 7.2, 3 mM MgCl₂, 2.5 mMUDP-glucose, 0.5 mM Stevioside and 500 μL of UGT76G1 thawed lysate. Thereactions were run at 30° C. on an orbitary shaker at 135 rpm. For eachsample, 460 μL of the reaction mixture was quenched with 40 μL of 2NH₂SO₄ and 420 μL of methanol/water (6/4). The samples were immediatelycentrifuged and kept at 10° C. before analysis by HPLC (CAD). HPLCindicated almost complete conversion of stevioside to rebaudioside A(FIG. 4).

Example 5 Catalytic Reaction with In-Vitro Produced UGT91D2

The total volume of the reaction was 0.5 mL with the followingcomposition: 50 mM sodium phosphate buffer pH 7.2, 3 mM MgCl₂, 3.8 mMUDP-glucose, 0.1 mM Rebaudioside A and 180 μL of in-vitro producedUGT91D2. The reactions were run at 30° C. on an orbitary shaker at 135rpm. For each sample, 450 μL of reaction mixture was quenched with 45 μLof 2N H₂SO₄ and 405 μL of 60% MeOH. After centrifugation, thesupernatant was analyzed by HPLC (CAD). HPLC indicated a 4.7% conversionof rebaudioside A to rebaudioside D after 120 h.

Example 6 Catalytic Reaction with In-Vitro Produced UGT76G1

The total volume of the reaction was 2 mL with the followingcomposition: 50 mM sodium phosphate buffer pH 7.2, 3 mM MgCl₂, 3.8 mMUDP-glucose, 0.5 mM Rebaudioside D and 180 μL of in-vitro producedUGT76G1. The reactions were run at 30° C. on an orbitary shaker at 135rpm. For each sample, 400 μL of reaction mixture was quenched with 40 μLof 2N H₂SO₄ and 360 μL of 60% MeOH. After centrifugation, thesupernatant was analyzed by HPLC (CAD). HPLC indicated 80% conversion ofrebaudioside D to rebaudioside M after 120 h (FIG. 5).

For examples 7 to 12, the following abbreviations are used:

LBGKP medium: 20 g/L Luria Broth Lennox; 50 mM PIPES buffer pH 7.00; 50mM Phosphate buffer pH 7.00; 2.5 g/L glucose and 50 mg/L of Kanamycin orAmpicillin LB medium: (20 g/L Luria Broth Lennox)

Example 7 Preparation and Activity of UGT76G1 Prepared by pET30a+Plasmid and BL21 (DE3) Expression Strain

The pET30a+_UGT76G1 plasmid was transformed into BL21(DE3) expressionstrain (Lucigen E. Cloni® EXPRESS Electrocompetent Cells). The obtainedcells were grown on LB Agar medium in petri-dishes in the presence ofKanamycin. Suitable colonies were selected and allowed to grow in liquidLBGKP medium containing Kanamycin. Glycerol was added and 400 μLaliquots were stored at −20° C. and at −80° C.

A storage aliquot was thawed and added to 30 mL of LBGKP medium. Thisculture was allowed to shake at 30° C. for 8 h. and subsequently used toinoculate 400 mL of production medium containing 60 g/L of “Overnightexpress instant TB medium” (Novagen, reference 71491-5), 10 g/L ofglycerol and 50 mg/L of Kanamycin. The medium was allowed to stir at 20°C. while taking samples to measure the OD (600 nm) and pH. After 40 h,the cells were harvested by centrifugation and frozen. The obtained cellwet weight was 10.58 g.

3.24 g of obtained pellet was lysed by addition of 8.1 mL of “BugbusterMaster mix” (Novagen, reference 71456) and 3.5 mL of water. The lysatewas recovered by centrifugation and kept frozen.

Example 8 Preparation and Activity of UGT76G1 Prepared by pET30a+Plasmid and Tuner (DE3) Expression Strain

The pET30a+_UGT76G1 plasmid was transformed into Tuner (DE3) expressionstrain (Novagen Tuner™ (DE3) Competent cells) by heat shock treatment.The obtained cells were grown on LB Agar medium in petri-dishes in thepresence of Kanamycin. Suitable colonies were selected and allowed togrow in liquid LBGKP medium containing Kanamycin). Glycerol was addedand 400 μL aliquots were stored at −20° C. and at −80° C.

A storage aliquot was thawed and added to 100 mL of LB medium containing50 mg/L of Kanamycin. This culture allowed to shake at 30° C. for 15 h.4.4 mL of this culture was used to inoculate 200 mL of production mediumcontaining LB. This medium was allowed to stir at 37° C. until an OD(600 nm) of 0.9 was obtained, after which 400 μL of a 100 mM IPTGsolution was added and the medium was allowed to stir at 30° C. for 4 h.The cells were harvested by centrifugation and frozen. The obtained cellwet weight was 1.38 g.

The obtained pellet was lysed by addition of 4.9 mL of “Bugbuster Mastermix” (Novagen, reference 71456) and 2.1 mL of water. The lysate wasrecovered by centrifugation and kept frozen.

Example 9 Preparation and Activity of UGT76G1 Prepared by pMAL Plasmidand BL21 Expression Strain

After subcloning the synthetic UGT76G1 gene into the pMAL plasmid usingNdeI and Sal1 cloning sites, the pMAL_UGT76G1 plasmid was transformedinto BL21 expression strain (New England Biolabs BL21 Competent E. coli)by heat shock treatment. The obtained cells were grown on LB Agar mediumin petri-dishes in the presence of Ampicillin. Suitable colonies wereselected and allowed to grow in liquid LBGKP medium containingAmpicillin). Glycerol was added and 400 μL aliquots were stored at −20°C. and at −80° C.

A storage aliquot was thawed and added to 30 mL of LBGKP medium. Thisculture was allowed to shake at 30° C. for 8 h. and subsequently used toinoculate 400 mL of production medium containing 60 g/L of “Overnightexpress instant TB medium” (Novagen, reference 71491-5), 10 g/L ofglycerol and 50 mg/L of Ampicillin. The medium was allowed to stir at20° C. while taking samples to measure the OD and pH. After 40 h, thecells were harvested by centrifugation and frozen. The obtained cell wetweight was 5.86 g.

2.74 g of obtained pellet was lysed by addition of 9.6 mL of “BugbusterMaster Mix” (Novagen, reference 71456) and 4.1 mL of water. The lysatewas recovered by centrifugation and kept frozen.

Example 10 Preparation and Activity of UGT76G1 Prepared by pMAL Plasmidand ArcticExpress Expression Strain

The pMAL_UGT76G1 plasmid was transformed into ArticExpress expressionstrain (Agilent ArcticExpress competent cells) by heat shock treatment.The obtained cells were grown on LB Agar medium in petri-dishes in thepresence of Ampicillin and Geneticin. Suitable colonies were selectedand allowed to grow in liquid LBGKP medium containing of Ampicillin andGeneticin. Glycerol was added and 400 μL aliquots were stored at −20° C.and at −80° C.

A storage aliquot was thawed and added to 30 mL of LBGKP medium(containing Ampicillin and Geneticin). This culture was allowed to shakeat 30° C. for 8 h. and subsequently used to inoculate 400 mL ofproduction medium containing 60 g/L of “Overnight express instant TBmedium” (Novagen, reference 71491-5), 10 g/L of glycerol and 50 mg/L ofAmpicillin. The medium was allowed to stir at 12° C. while takingsamples to measure the OD (600 nm) and pH. After 68 h, the cells wereharvested by centrifugation and frozen. The obtained cell wet weight was8.96 g.

2.47 g of the obtained pellet was lysed by addition of 8.73 mL of“Bugbuster Master Mix” (Novagen, reference 71456) and 3.79 mL of water.The lysate was recovered by centrifugation and kept frozen.

Example 11 Preparation and Activity of UGT76G1 Prepared by pCOLDIIIPlasmid and ArcticExpress Expression Strain

After subcloning the synthetic UGT76G1 gene into the pCOLDIII plasmidusing NdeI and XhoI cloning sites, the pCOLDIII_UGT76G1 plasmid wastransformed into ArcticExpress expression strain (Agilent ArcticExpresscompetent cells) by heat shock treatment. The obtained cells were grownon LB Agar medium in petri-dishes in the presence of Ampicillin andGeneticin. Suitable colonies were selected and allowed to grow in liquidLBGKP medium containing Ampicillin and Geneticin. Glycerol was added and400 μL aliquots were stored at −20° C. and at −80° C.

A storage aliquot was thawed and added to 30 mL of LBGKP medium(containing Ampicillin and Geneticin). This culture was allowed to shakeat 30° C. for 8 h. and subsequently used to inoculate 400 mL ofproduction medium containing 60 g/L of “Overnight express instant TBmedium” (Novagen, reference 71491-5), 10 g/L of glycerol and 50 mg/L ofKanamycin. The medium was allowed to stir at 12° C. while taking samplesto measure the OD (600 nm) and pH. After 63 h, the cells were harvestedby centrifugation and frozen. The obtained cell wet weight was 6.54 g.

2.81 g of the obtained pellet was lysed by addition of 9.8 mL of“Bugbuster Master Mix” (Novagen, reference 71456) and 4.2 mL of water.The lysate was recovered by centrifugation and kept frozen.

Example 12 Preparation and Activity of UGT76G1 Prepared by pCOLDIIIPlasmid and Origami2 (DE3) Expression Strain

The pCOLDIII_UGT76G1 plasmid was transformed into Origami2 (DE3)expression strain (Novagen Origami™2 (DE3) Competent Cells) by heatshock treatment. The obtained cells were grown on LB Agar medium inpetri-dishes in the presence of Ampicillin. Suitable colonies wereselected and allowed to grow in liquid LBGKP medium containingAmpicillin. Glycerol was added and 400 μL aliquots were stored at −20°C. and at −80° C.

A storage aliquot was thawed and added to 30 mL of LBGKP medium(containing Ampicillin). This culture was allowed to shake at 30° C. for8 h. and subsequently used to inoculate 400 mL of production mediumcontaining 60 g/L of “Overnight express instant TB medium” (Novagen,reference 71491-5), 10 g/L of glycerol and 50 mg/L of Kanamycin. Themedium was allowed to stir at 12° C. while taking samples to measure theOD (600 nm) and pH. After 68 h, the cells were harvested bycentrifugation and frozen. The obtained cell wet weight was 2.53 g.

1.71 g of the obtained pellet was lysed by addition of 6.0 mL of“Bugbuster Master mix” (Novagen, reference 71456) and 1.9 mL of water.The lysate was recovered by centrifugation and kept frozen.

Example 13 Determination of Activity

Activity tests were performed on a 5 mL scale with 500 μL of thawedlysate for the transformation of Stevioside to Rebaudioside A andRebaudioside D to Rebaudioside M using 0.5 mM of substrate, 2.5 mM ofUDP-Glucose and 3 mM MgCl₂ in 50 mM Sodium Phosphate buffer at pH 7.2.Samples were taken and analyzed by HPLC. The results for the differentpreparations of UGT76G1 are summarized in the following table.

Transformation activity* Expression Stevioside to Rebaudioside D toExample Plasmid strain Rebaudioside A Rebaudioside M 7 pET30a+ BL21(DE3) 29 U mL⁻¹ 0.31 U mL⁻¹ 8 pET30a+ Tuner (DE3) 33 U mL⁻¹ 0.40 U mL⁻¹9 pMAL BL21 20 U mL⁻¹ 0.15 U mL⁻¹ 10 pMAL ArticExpress 15 U mL⁻¹ 0.25 UmL⁻¹ 11 pCOLDIII ArticExpress 15 U mL⁻¹ 0.11 U mL⁻¹ 12 pCOLDIII Origami2(DE3) 37 U mL⁻¹ 0.20 U mL⁻¹ *Note The activities for the transformationof Stevioside and Rebaudioside M are mentioned per mL of lysate. 1 Uwill transform 1 μmol of substrate in 1 hour at 30° C. and pH 7.2

Example 14 50 mL Scale Reaction for the Transformation of Rebaudioside Dto Rebaudioside M

5 mL of the lysate of Example 12 was used to transform Rebaudioside D toRebaudioside M on a 50 mL scale. The reaction medium consisted of 50 mMSodium Phosphate buffer pH 7.2, 3 mM of MgCl₂, 2.5 mM of UDP-Glucose and0.5 mM of Rebaudioside D. After allowing the reaction to be shaken at30° C. for 90 h. 50 mL of ethanol was added and the resulting mixturewas allowed to stir at −20° C. for 1 h. After centrifugation at 5000 gfor 10 min. the supernatant was purified via ultrafiltration (VivaflowMWCO 30000). 78 mL of permeate was obtained and the 9 mL of retentatewas diluted with 9 mL of ethanol and resubjected to Ultrafiltration(Vivaflow MWCO 30000). Another 14 mL of filtrate was obtained, which wascombined with the first permeate. The combined permeates wereconcentrated under reduced pressure at 30° C. until 32 mL of a clearsolution was obtained.

The HPLC trace of the product mixture is shown in FIG. 3. HPLC wascarried out on an Agilent 1200 series equipped with a binary pump, autosampler, and thermostat column compartment. The method was isocratic,with a mobile phase composed of 70% water (0.1% formic acid): 30%acetonitrile. The flow rate was 0.1 μL/min. The column used wasPhenomenex Prodigy 5μ ODS (3) 100 A; 250×2 mm. The column temperaturewas maintained at 40° C. The injection volume was 20-40 μl.

The material eluting at 31.325 minutes was isolated. Comparison with aknown reb M standard via HPLC, ¹H NMR and HRMS confirmed the material asreb M.

Example 15 Preparation of UGT91D2 Using pMAL Plasmid and BL21 ExpressionStrain

After subcloning the synthetic UGT91D2 gene into the pMAL plasmid usingNdeI and Sal1 cloning sites, the pMAL_UGT91D2 plasmid was transformedinto BL21 expression strain (New England Biolabs BL21 Competent E. coli)by heat shock treatment. The obtained cells were grown on LB Agar mediumin petri-dishes in the presence of Ampicillin. Suitable colonies wereselected and allowed to grow in liquid LBGKP medium containingAmpicillin). Glycerol was added and 400 μL aliquots were stored at −20°C. and at −80° C.

A storage aliquot was thawed and added to 30 mL of LBGKP medium. Thisculture was allowed to shake at 30° C. for 8 h. and subsequently used toinoculate 400 mL of production medium containing 60 g/L of “Overnightexpress instant TB medium” (Novagen, reference 71491-5), 10 g/L ofglycerol and 50 mg/L of Ampicillin. The medium was allowed to stir at20° C. while taking samples to measure the OD and pH. After 40 h, thecells were harvested by centrifugation and frozen. The obtained cell wetweight is 12.32 g.

2.18 g of obtained pellet was lysed by addition of 7.7 mL of “BugbusterMaster Mix” (Novagen, reference 71456) and 3.2 mL of water. The lysatewas recovered by centrifugation and used directly for activity testing.

Example 16 Preparation of UGT91D2 Using pMAL Plasmid and ArcticExpressExpression Strain

The pMAL_UGT91D2 plasmid was transformed into ArcticExpress expressionstrain (Agilent ArcticExpress competent cells) by heat shock treatment.The obtained cells were grown on LB Agar medium in petri-dishes in thepresence of Ampicillin and Geneticin. Suitable colonies were selectedand allowed to grow in liquid LBGKP medium containing Ampicillin andGeneticin. Glycerol was added and 400 μL aliquots were stored at −20° C.and at −80° C.

A storage aliquot was thawed and added to 30 mL of LBGKP medium(containing Ampicillin and Geneticin). This culture was allowed to shakeat 30° C. for 8 h. and subsequently used to inoculate 400 mL ofproduction medium containing 60 g/L of “Overnight express instant TBmedium” (Novagen, reference 71491-5), 10 g/L of glycerol and 50 mg/L ofAmpicillin. The medium was allowed to stir at 20° C. for 16 h. followedby another 50 h. at 12° C. while taking samples to measure the OD (600nm) and pH. The cells were harvested by centrifugation and frozen. Theobtained cell wet weight is 15.77 g.

2.57 g of the obtained pellet was lysed by addition of 9.0 mL of“Bugbuster Master Mix” (Novagen, reference 71456) and 3.8 mL of water.The lysate was recovered by centrifugation and used directly foractivity testing.

Example 17 Preparation of UGT91D2 Using pET30a+ Plasmid and Tuner (DE3)Expression Strain

The pET30a+_UGT91D2 plasmid was transformed into Tuner (DE3) expressionstrain (Novagen Tuner™ (DE3) Competent cells) by heat shock treatment.The obtained cells were grown on LB Agar medium in petri-dishes in thepresence of Kanamycin. Suitable colonies were selected and allowed togrow in liquid LBGKP medium (containing Kanamycin). Glycerol was addedand 400 μL aliquots were stored at −20° C. and at −80° C.

A storage aliquot was thawed and added to 100 mL of LB medium containing50 mg/L of Kanamycin. This culture allowed to shake at 30° C. for 15 h.6.2 mL of this culture was used to inoculate 500 mL of production mediumcontaining LB. This medium was allowed to stir at 37° C. until an OD(600 nm) of 0.9 was obtained after which 500 μL of a 100 mM IPTGsolution was added (IPTG concentration in medium is 100 μM) and themedium was allowed to stir at 30° C. for 4 h, the cells were harvestedby centrifugation and frozen. The obtained cell wet weight is 4.02 g.1.92 g of the obtained pellet was lysed by addition of 6.8 mL of“Bugbuster Master mix” (Novagen, reference 71456) and 2.8 mL of water.The lysate was recovered by centrifugation and tested directly foractivity.

Example 18 Preparation of UGT91D2 Using pET30a+ Plasmid andArcticExpress Expression Strain

The pET30a+_UGT91D2 plasmid was transformed into ArcticExpress (DE3)expression strain (Agilent ArcticExpress competent cells) by heat shocktreatment. The obtained cells were grown on LB Agar medium inpetri-dishes in the presence of Kanamycin and Geneticin. Suitablecolonies were selected and allowed to grow in liquid LBGKP mediumcontaining of Kanamycin and Geneticin. Glycerol was added and 400 μLaliquots were stored at −20° C. and at −80° C.

A storage aliquot was thawed and added to 30 mL of LBGKP medium(containing Kanamycin and Geneticin). This culture was allowed to shakeat 30° C. for 8 h. and subsequently used to inoculate 400 mL ofproduction medium containing 60 g/L of “Overnight express instant TBmedium” (Novagen, reference 71491-5), 10 g/L of glycerol and 50 mg/L ofAmpicillin. The medium was allowed to stir at 20° C. for 16 h. followedby another 50 h. at 12° C. while taking samples to measure the OD (600nm) and pH. After 60 h, the cells were harvested by centrifugation andfrozen. The obtained cell wet weight is 16.07 g.

3.24 g of the obtained pellet was lysed by addition of 11.4 mL of“Bugbuster Master Mix” (Novagen, reference 71456) and 4.8 mL of water.The lysate was recovered by centrifugation and used directly foractivity testing.

Example 19 Determination of Activity of In-Vivo Preparations of UGT91D2

Activity tests were performed at 5 mL scale with 1000 μL of lysate forthe transformation of Rubusoside to Stevioside using 0.5 mM ofsubstrate, 2.5 mM of UDP-Glucose and 3 mM MgCl₂ in 50 mM SodiumPhosphate buffer at pH 7.2. Samples were taken and analyzed by HPLC. Theresults for the different preparations of UGT91D2 are summarized in thefollowing table.

Transformation activity* Example Plasmid Expression strain Rubusoside toStevioside 15 pMAL BL21  9 mU mL⁻¹ 16 pMAL ArcticExpress 60 mU mL⁻¹ 17pET30a+ Tuner (DE3) 28 mU mL⁻¹ 18 pET30a+ ArcticExpress (DE3) 21 mU mL⁻¹*Note: The activities are mentioned per mL of lysate. 1 U will transform1 μmol of substrate in 1 hour at 30° C. and pH 7.2

Example 20 Other Enzymes for Rebaudioside A to Rebaudioside D Conversion

The following genes of UDP-glucosyltransferases were identified frompublic databases, synthesized by DNA2.0 and subsequently subcloned inpET30a+ vector.

Internal Conversion Microplate Position Gene Name reference RebA to RebDC908201 A1 gi115454819_NP_001051010.1 S115N01 A1 Active C908201 G2gi187373030_ACD03249.1 S115N01 G2 Active C908201 A7gi460409128_XP_004249992.1 S115N05 A7 Active C912666 E1gi222619587_EEE55719.1 S115N06 E1 Active C912666 C2gi297795735_XP_002865752.1 S115N06 C2 Active

The amino acid sequences are as follows:

>gi|115454819|ref|NP_001051010.1|Os03g0702500[Oryza sativa Japonica Group] (SEQ ID NO: 3)MDDAHSSQSPLHVVIFPWLAFGHLLPCLDLAERLAARGHRVSFVSTPRNLARLPPVRPELAELVDLVALPLPRVDGLPDGAEATSDVPFDKFELHRKAFDGLAAPFSAFLDTACAGGKRPDWVLADLMEIHWVALASQERGVPCAMILPCSAAVVASSAPPTESSADQREAIVRSMGTAAPSFEAKRATEEFATEGASGVSIMTRYSLTLQRSKLVAMRSCPELEPGAFTILTRFYGKPVVPFGLLPPRPDGARGVSKNGKHDAIMQWLDAQPAKSVVYVALGSEAPMSADLLRELAHGLDLAGTRFLWAMRKPAGVDADSVLPAGFLGRTGERGLVTTRWAPQVSILAHAAVCAFLTHCGWGSVVEGLQFGHPLIMLPILGDQGPNARILEGRKLGVAVPRNDEDGSFDRGGVAGAVRAVVVEEEGKTFFANARKLQEIVADREREERCIDEFVQHLTSWNELKNNSDGQYP. >gi|187373030|gb|ACD03249.1| UDP-glycosyl-transferase [Avena strigosa] (SEQ ID NO: 4)MAVKDEQQSPLHILLFPFLAPGHLIPIADMAALFASRGVRCTILTTPVNAAIIRSAVDRANDAFRGSDCPAIDISVVPFPDVGLPPGVENGNALTSPADRLKFFQAVAELREPFDRFLADNHPDAVVSDSFFHWSTDAAAEHGVPRLGFLGSSMFAGSCNESTLHNNPLETAADDPDALVSLPGLPHRVELRRSQMMDPKKRPDHWALLESVNAADQKSFGEVFNSFHELEPDYVEHYQTTLGRRTWLVGPVALASKDMAGRGSTSARSPDADSCLRWLDTKQPGSVVYVSFGTLIRFSPAELHELARGLDLSGKNFVWVLGRAGPDSSEWMPQGFADLITPRGDRGFIIRGWAPQMLILNHRALGGFVTHCGWNSTLESVSAGVPMVTWPRFADQFQNEKLIVEVLKVGVSIGAKDYGSGIENHDVIRGEVIAESIGKLMGSSEESDAIQRKAKDLGAEARSAVENGGSSYNDVGRLMDELMARRSSVKVGEDIIPTNDGL. >gi|460409128|ref|XP 004249992.1| PREDICTED:cyanidin-3-O-glucoside 2-O-glucuronosyltrans-ferase-like [Solanum lycopersicum] (SEQ ID NO: 5)MSPKLHKELFFHSLYKKTRSNHTMATLKVLIVIFPFLAYGHISPYLNVAKKLADRGFLIYFCSTPINLKSTIEKIPEKYADSIHLIELHLPELPQLPPHYHTTNGLPPNLNQVLQKALKMSKPNFSKILQNLKPDLVIYDILQRWAKHVANEQNIPAVKLLTSGAAVFSYFFNVLKKPGVEFPFPGIYLRKIEQVRLSEMMSKSDKEKELEDDDDDDDLLVDGNMQIMLMSTSRTIEAKYIDFCTALTNWKVVPVGPPVQDLITNDVDDMELIDWLGTKDENSTVFVSFGSEYFLSKEDMEEVAFALELSNVNFIWVARFPKGEERNLEDALPKGFLERIGERGRVLDKFAPQPRILNHPSTGGFISHCGWNSAMESIDFGVPIIAMPMHLDQPMNARLIVELGVAVEIVRDDDGKIHRGEIAETLKGVITGKTGEKLRAKVRDISKNLKTIRDEEMDAAAEELIQLCRNGN. >gi|222619587|gb|EEE55719.1|hypothetical protein OsJ_04191 [Oryza sativa Japonica Group](SEQ ID NO: 6) MHVVMLPWLAFGHILPFAEFAKRVARQGHRVTLFSTPRNTRRLIDVPPSLAGRIRVVDIPLPRVEHLPEHAEATIDLPSNDLRPYLRRAYDEAFSRELSRLLQETGPSRPDWVLADYAAYWAPAAASRHGVPCAFLSLFGAAALCFFGPAETLQGRGPYAKTEPAHLTAVPEYVPFPTTVAFRGNEARELFKPSLIPDESGVSESYRFSQSIEGCQLVAVRSNQEFEPEWLELLGELYQKPVIPIGMFPPPPPQDVAGHEETLRWLDRQEPNSVVYAAFGSEVKLTAEQLQRIALGLEASELPFIWAFRAPPDAGDGDGLPGGFKERVNGRGVVCRGWVPQVKFLAHASVGGFLTHAGWNSIAEGLANGVRLVLLPLNIFEQGLNARQLAEKKVAVEVARDEDDGSFAANDIVDALRRVMVGEEGDEFGVKVKELAKVFGDDEVNDRYVRDFLKCLSEYKMQRQG. >gi|297795735|ref|XP_002865752.1| UDP-glucoronosyl/UDP-glucosyl transferase familyprotein [Arabidopsis lyrata sub sp. lyrata] (SEQ ID NO: 7)MDDKKEEVMHIAMFPWLAMGHLLPFLRLSKLLAQKGHKISFISTPRNILRLPKLPSNLSSSITFVSFPLPSISGLPPSSESSMDVPYNKQQSLKAAFDLLQPPLTEFLRLSSPDWITYDYASHWLPSIAKELGISKAFFSLFNAATLCFMGPSSSLIEESRSTPEDFTVVPPWVPFKSTIVFRYHEVSRYVEKTDEDVTGVSDSVRFGYTIDGSDAVFVRSCPEFEPEWFSLLQDLYRKPVFPIGFLPPVIEDDDDDTTWVRIKEWLDKQRVNSVVYVSLGTEASLRREELTELALGLEKSETPFFWVLRNEPQIPDGFEERVKGRGMVHVGWVPQVKILSHESVGGFLTHCGWNSVVEGIGFGKVPIFLPVLNEQGLNTRLLQGKGLGVEVLRDERDGSFGSDSVADSVRLVMIDDAGEEIREKVKLMKGLFGNMDENIRYVDELVGFMRNDESSQLKEEEEEDDCSDDQSSEVSSETDEKELNLDLKEEKRRISVYKS LSSEFDDYVANEKMG.

The tested plasmids were received in a microtiter plate containing aplasmid as freeze-dried solid in each separate well.

Suspension of Plasmids.

To each well was added 24 μL of ultra-pure sterile water and themicrotiter plate was shaken for 30 minutes at Room Temperature.Subsequently, the plate was incubated at 4° C. for 1 hour. The contentof each well were further mixed by pipetting up and down. The plasmidquantification was performed by Qubit2.0 analysis using 1 μL ofsuspension. Determined quantities of plasmids were:

Microtiter plate Position Internal reference [Plasmid] ng/μL C908201 A1S115N01 A1 32.8 C908201 G2 S115N01 G2 41.0 C908201 A7 S115N05 A7 56.6C912666 E1 S115N06 E1 64.0 C912666 C2 S115N06 C2 31.4

Transformation of Competent Cells with Plasmids.

Aliquots of chemically competent EC100 cells were taken from freezer at−80° C. and stored on ice. The cells were allowed to thaw on ice for 10minutes. 10 μL of a dilution of above described plasmid solution wasadded to a sterile microtube of 1.5 mL (in order to transform each cellwith 50 pg of DNA) and stored on ice. 100 μL of chemically competentcells was added to each microtube. After incubation of the chemicallycompetent cells plasmid mixtures on ice for 20 min a thermal shock of 30seconds at 42° C. was performed.

Further incubation was performed on ice for 2 minutes. To each microtube300 μL of SOC medium was added and the resulting mixture was transferredto a sterile 15 mL tube. After incubate for 1 hour at 37° C. whileshaking at 135 rpm, the mixture is spread on solid Luria Broth mediumcontaining Kanamycin 50 μg/mL. The petri-dishes are allowed to incubatefor 16 hours at 37° C.

Preparation of Stock Solutions in Glycerol and Purification of Plasmids.

To a 50 mL sterile Falcon Tube 10 mL of Luria Broth medium containing 50μg/mL of Kanamycin was added. The medium was seeded with an isolatedcolony from the above described Petri dish and the cultures were allowedto incubate for 16 hours at 37° C. while shaking at 135 rpm.

To sterile microtube of 1.5 mL containing 300 μL of a 60% sterileglycerol solution, 600 μL of the culture was added. The stock solutionwas stored at −80° C.

The remainder of the culture was centrifuged at 5,525 g for 10 minutesat 10° C. and after removal of the supernatant, the pellet was stored onice. The produced plasmids were purified according to the Qiagen QiaprepSpin Miniprep kit (ref: 27106) and the plasmid yield was measured at 260nm. The plasmid solution was stored at 4° C. Plasmid quantities weredetermined as follows:

Microtiter plate Position Internal reference of test [Plasmid] ng/μLC908201 A1 S115N01 A1 115.7 C908201 G2 S115N01 G2 120.4 C908201 A7S115N05 A7 293.8 C912666 E1 S115N06 E1 126.1 C912666 C2 S115N06 C2 98.8

In-Vitro Expression of Enzymes.

18 μL of plasmid solution (containing approximately 1.5 μg of plasmid)was used for in-vitro expression according to the Promega S30 T7High-Yield Protein Expression System (ref: L1110) kit. The expressionmedium was produced as follows:

S30 Premix Plus T7 S30 Extract Total Trials 30 μL 27 μL 57 μL reference20 μL 18 μL 38 μL

The prepared expression medium mix was added to the plasmid solution andthe solution was allowed to incubate at 30° C. for 3 hours while mixingthe mixture every 45 minutes. 5 μL of the mixture was frozen whereas theremainder was used for the catalytic test for the conversion ofRebaudioside A to Rebaudioside D.

Catalytic Test for Transformation of Rebaudioside A to Rebaudioside D.

430 μL of a reaction mixture containing 0.5 mM Rebaudioside A, 3 mMMgCl₂, 50 mM phosphate buffer (pH7.2) and 2.5 mM UDP-glucose was addedto a 1.5 mL sterile microtube. 52 μL of the enzyme expression medium wasadded and the resulting mixture was allowed to react at 30° C. for 24hours. 125 μL samples were taken after 2 hours, 16 hours and 24 hoursand added to a 115 μL of 60% methanol and 10 μL of 2 N H₂SO₄. Thequenched sample was centrifuged at 18,000 g for 2 minutes at RT. 200 μLwas transferred to an HPLC vial and analyzed.

HPLC Analysis

The HPLC assay was performed as follows:

Apparatus Equipment Supplier Reference Lot# Elite Hitachi L-2130 NAPhotodiode Array Hitachi L-2455 NA Corona CAD detector ESA 70-6186ACO-2044 Injector 100 μL Hitachi NA Column Synergy 4 u Phenomenex00G-4375-E0 588582-12 Hydro-RP 80 A (250 × 4.60 mm)

Instrument conditions Column Temperature 55° C. Detection UV 205 nm; bw400 nm CAD detection Analysis duration 15 min Injected volume 10 μL Flowrate 1 mL/min

Mobil phase gradient program % Water containing Time (min) 0.04% aceticacid % methanol 0 40 60 8 25 75 10 25 75 11 40 60 15 40 60

The enzyme S115N05 A7 had the highest activity for Reb A to Reb Dconversion (ca. 22.4%). At least three enzymes produced a significantamount of an unknown glycoside (marked as Reb UNK; later identified asreb D2) along with reb D. An unknown peak at ˜4.5 min was lateridentified as reb M2.

The HPLC assay results are provided below:

Steviol glycoside conversion in reaction mixture (% area) Enzyme Reb DReb UNK Reb A Internal (Retention (Retention (Retention reference Time~5.8 min) Time ~6.7 min) Time ~9.1 min) S115N01 A1 2.1 ND 96.7 S115N01G2 0.6 ND 99.4 S115N05 A7 22.4 23.3 46.7 S115N06 E1 0.14 7.0 92.8S115N06 C2 0.28 3.9 95.8

Example 21 Activity of In-Vitro Produced EUGT11

EUGT11 gene, described in WO/2013/022989A2, was synthesized by DNA2.0and subsequently subcloned in pET30a+ vector.

Conversion GI Internal RebA to Microplate Position number Versionreference RebD C912666 G4 41469452 AAS07253.1 S115N08 Active G4

The amino-acid sequence is as follows:

>gi|41469452|gb|AAS07253.1| putative UDP-glucoronosyl and UDP-glucosyl transferase [Oryza sativa Japonica Group]EUGT11 enzyme from patent application WO/2013/022989A2 (SEQ ID NO: 8)MHVVICPLLAFGHLLPCLDLAQRLACGHRVSFVSTPRNISRLPPVRPSLAPLVSFVALPLPRVEGLPNGAESTHNVPHDRPDMVELHLRAFDGLAAPFSEFLGTACADWVMPTSSAPRQTLSSNIHRNSSRPGTPAPSGRLLCPITPHSNTLERAAEKLVRSSRQNARARSLLAFTSPPLPYRDVFRSLLGLQMGRKQLNIAHETNGRRTGTLPLNLCRWMWKQRRCGKLRPSDVEFNTSRSNEAISPIGASLVNLQSIQSPNPRAVLPIASSGVRAVFIGRARTSTPTPPHAKPARSAAPRAHRPPSSVMDSGYSSSYAAAAGMHVVICPWLAFGHLLPCLDLAQRLASRGHRVSFVSTPRNISRLPPVRPALAPLVAFVALPLPRVEGLPDGAESTNDVPHDRPDMVELHRRAFDGLAAPFSEFLGTACADWVIVDVFHHWAAAAALEHKVPCAMMLLGSAHMIASIADRRLERAETESPAAAGQGRPAAAPTFEVARMKLIRTKGSSGMSLAERFSLTLSRSSLVVGRSCVEFEPETVPLLSTLRGKPITFLGLMPPLHEGRREDGEDATVRWLDAQPAKSVVYVALGSEVPLGVEKVHELALGLELAGTRFLWALRKPTGVSDADLLPAGFEERTRGRGVVATRWVPQMSILAHAAVGAFLTHCGWNSTIEGLMFGHPLIMLPIFGDQGPNARLIEAKNAGLQVARNDGDGSFDREGVAAAIRAVAVEEESSKVFQAKAKKLQEIVADMACHERYIDGFIQQLRSYKD.

The tested plasmid was received in a microtiter plate containing aplasmid as freeze-dried solid in a separate well.

Suspension of Plasmid

To the well was added 24 μL of ultra-pure sterile water and themicrotiter plate was shaken for 30 minutes at Room Temperature.Subsequently, the plate was incubated at 4° C. for 1 hour. The contentof the well was further mixed by pipetting up and down. The plasmidquantification was performed by Qubit2.0 analysis using 1 μL ofsuspension. Plasmid quantity was determined as follows:

Microtiter plate Position Internal reference of test [Plasmid] ng/μLC912666 G4 S115N08 G4 19.2

Transformation of Competent Cells with Plasmid.

An aliquot of chemically competent EC100 cells was taken from freezer at−80° C. and stored on ice. The cells were allowed to thaw on ice for 10minutes. 10 μL of a dilution of above described plasmid solution wasadded to a sterile microtube of 1.5 mL (in order to transform each cellwith 50 pg of DNA) and stored on ice. 100 μL of chemically competentcells was added to the microtube. After incubation of the chemicallycompetent cells/plasmid mixture on ice for 20 min a thermal shock of 30seconds at 42° C. was performed.

Further incubation was performed on ice for 2 minutes. To the microtube300 μL of SOC medium was added and the resulting mixture was transferredto a sterile 15 mL tube. After incubate for 1 hour at 37° C. whileshaking at 135 rpm, the mixture is spread on solid Luria Broth mediumcontaining Kanamycin 50 μg/mL. The Petri dish is allowed to incubate for16 hours at 37° C.

Preparation of Stock Solutions in Glycerol and Purification of Plasmid.

To a 50 mL sterile Falcon Tube 10 mL of Luria Broth medium containing 50μg/mL of Kanamycin was added. The medium was seeded with an isolatedcolony from the above described Petri dish and the cultures were allowedto incubate for 16 hours at 37° C. while shaking at 135 rpm.

To sterile microtube of 1.5 mL containing 300 μL of a 60% sterileglycerol solution, 600 μL of the culture was added. The stock solutionwas stored at −80° C.

The remainder of the culture was centrifuged at 5,525 g for 10 minutesat 10° C. and after removal of the supernatant, the pellet was stored onice. The produced plasmids were purified according to the Qiagen QiaprepSpin Miniprep kit (ref: 27106) and the plasmid yield was measured at 260nm. The plasmid solution was stored at 4° C. Plasmid quantity wasdetermined as follows:

Microtiter plate Position Internal reference of test [Plasmid] ng/μLC912666 G4 S115N08 G4 38.4

In-Vitro Expression of EUGT11

18 μL of a diluted plasmid solution (containing approximately 1.5 μg ofplasmid) was used for in-vitro expression according to the Promega S30T7 High-Yield Protein Expression System (ref: L1110) kit. The expressionmedium was produced as follows:

S30 Premix Plus T7 S30 Extract DNA template Total Trials 30 μL 27 μL 18μL (~1.5 μg) 75 μL reference 20 μL 18 μL 12 μL (~1.0 μg) 50 μL

The prepared expression medium mix was added to the plasmid solution andthe solution was allowed to incubate at 30° C. for 3 hours while mixingthe mixture every 45 minutes. 5 μL of the mixture was frozen whereas theremainder was used for the catalytic test for the conversion ofRebaudioside A to Rebaudioside D.

Catalytic Test for Transformation of Rebaudioside A to Rebaudioside D.

430 μL of a reaction mixture containing 0.5 mM Rebaudioside A, 3 mMMgCl₂, 50 mM phosphate buffer (pH7.2) and 2.5 mM UDP-glucose was addedto a 1.5 mL sterile microtube. 52 μL of the enzyme expression medium wasadded and the resulting mixture was allowed to react at 30° C. for 24hours. 125 μL samples were taken after 2 hours, 16 hours and 24 hoursand added to a 115 μL of 60% methanol and 10 μL of 2 N H₂SO₄. Thequenched sample was centrifuged at 18,000 g for 2 minutes at RT. 200 μLwas transferred to HPLC vial and analyzed.

HPLC Analysis.

The HPLC assay was performed as described in EXAMPLE 20.

Compound Retention time Integration (area) Rebaudioside D 5.79754,654,810 Rebaudioside A 9.157 633,926,835 Total 688,581,645

Example 22 In-Vivo Production of Enzymes

The enzymes described in EXAMPLE 20 were produced in vivo.

The pET30A+ vector containing the gene corresponding to the enzyme wasintroduced in E. coli BL21(DE3) by heat shock. The obtained cells weregrown in Petri dishes in the presence of Kanamycin and suitable colonieswere selected and allowed to grow in liquid LB medium (Erlenmeyerflasks). Glycerol was added to the suspension as cryoprotector and 400μL aliquots were stored at −20° C. and at −80° C.

The storage aliquots of E. coli BL21(DE3) containing the pET30A+_UGTplasmids were thawed and added to 30 mL of LBGKP medium (20 g/L LuriaBroth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM Phosphate buffer pH7.00; 2.5 g/L glucose and 50 mg/L of Kanamycine). This culture wasallowed to shake at 135 rpm at 30° C. for 8 hrs.

The production medium contained 60 g/L of overnight express instant TBmedium (Novagen), 10 g/L of glycerol and 50 mg/L of Kanamycine. Thepreculture was added to 400 mL of this medium and the solution wasallowed to stir at 20° C. while taking samples to measure the OD and pH.The cultures gave significant growth and a good OD was obtained. After40 hrs, the cells were harvested by centrifugation and frozen. Thefollowing yields of cell wet weights (CWW) are mentioned below.

GI number Version CWW 115454819 NP_001051010.1 9.2 g 187373030ACD03249.1 7.4 g 460409128 XP_004249992.1 6.8 g 222619587 EEE55719.1 7.5g 297795735 XP_002865752.1 8.8 g

Lysis was performed by addition of Bugbuster Master mix (Novagen) andthe lysate was recovered by centrifugation and used fresh.

Determination of Activity.

Activity tests were performed at 5 mL scale with 1,000 L of thawedlysate for the transformation of Rebaudioside A using 0.5 mM ofsubstrate, 2.5 mM of UDP-Glucose and 3 mM MgCl₂ in 50 mM SodiumPhosphate buffer at pH 7.2. Samples were taken and analyzed by HPLC.

HPLC Analysis.

The HPLC assay was performed as described in EXAMPLE 20.

The results for the different enzymes are provided below.

Conversion GI Number Version after 45 hrs. Reb D selectivity 115454819NP_001051010.1 1.1% 100% 187373030 ACD03249.1 0.8% 100% 460409128XP_004249992.1 62.1% 43.6%  222619587 EEE55719.1 2.9% Reb D Not detected297795735 XP_002865752.1 0.0% Reb D Not detected

HPLC analysis also showed two unknown peaks. The peak at ˜4.5 min waslater identified as reb M2. The peak at ˜7.6 min was later identified asreb D2.

Example 23 Identification of Glycosides

The reaction mixtures representing GI No. 460409128 of EXAMPLE 20(hereinafter S115N05A7) and t EXAMPLE 22 (hereinafter S129N04) wereadditionally assayed by LC-MS to identify the unknown glycosides. AnAgilent 1200 series HPLC system, equipped with binary pump (G1312B),autosampler (G1367D), thermostatted column compartment (G1316B), DADdetector (G1315C), connected with Agilent 6110A MSD, and interfaced with“LC/MSD Chemstation” software, was used.

Instrument conditions Column Phenomenex Kinetex 2.6 u C18 100 A, 4.6 mm× 150 mm, 2.6 μm Column Temperature 55° C. Detection DAD at 210 nm bw360 nm MSD (Scan and SIM mode) Mode: ES-API, Negative Polarity Dryinggas flow: 13.0 L/min Nebulizer pressure: 30 psig Drying gas temperature:270° C. Analysis duration 25 min Injected volume 2 μL Flow rate 1 mL/min

Mobile phase gradient program Time (min) A (%): Formic acid 0.1% B (%):Acetonitrile 0 75 25 8.5 75 25 10.0 71 29 16.5 70 30

The compound observed on LCMS system at 3.5 min, corresponds to theunknown peak at ˜4.5 min in EXAMPLES 20 and 22. The LCMS data suggeststhat this compound has six glucosidic residues (C₅₆H₉₀O₃₃) in itsstructure, and was found to be an isomer form of reb M, namely reb M2(see Example 40 for discussion).

The compound observed on LCMS system at 7.6 min, corresponds to theunknown peak at ˜7.6 min in EXAMPLES 20 and 22. The LCMS data suggeststhat this compound has five glucosidic residues (C₅₀H₈₀O₂₈) in itsstructure, and was found to be an isomer form of reb D, namely reb D2(see Example 39 for discussion). The ratio of these compounds areprovided below.

Steviol glycoside conversion in reaction mixture (% area) Unknown@Sample RT3.5 Reb D Unknown@RT7.6 Reb A S115N05A7 6.47 20.35 19.93 53.24S129N04 6.05 23.73 21.22 49.00

Example 24 Identification of Glycosides

The reaction mixture representing GI No. 460409128 of EXAMPLE 22(hereinafter S129N04) were additionally assayed by LC-MS along withStevia rebaudiana Bertoni leaf extract “MLD1” produced by PureCircle SdnBhd (Malaysia) to determine the occurrence of S129N04 glycosides innature.

The assay showed that the compound observed on LCMS system at 3.5 min,in EXAMPLE 23 (C₅₆H₉₀O₃₃; later confirmed as reb M2), and the compoundobserved on LCMS system at 7.6 min, in EXAMPLE 23 (C₅₀H₈₀O₂₈; reb UNK;later confirmed as reb D2) occur in the extract of Stevia rebaudianaBertoni plant.

Example 25 Conversion of Rebaudioside E to Rebaudioside D

The total volume of the reaction was 5.0 mL with the followingcomposition: 100 mM potassium phosphate buffer pH 7.5, 3 mM MgCl₂, 2.5mM UDP-glucose, 0.5 mM Rebaudioside E and 500 μL of UGT76G1 thawedlysate UGT76G1 gene was cloned in pET30a+ vector and expressed in E.coli BL21 (DE3)). The reactions were run at 30° C. on an orbitary shakerat 135 rpm. For sampling 300 μL of the reaction mixture was quenchedwith 30 μL of 2N H₂SO₄ and 270 μL of methanol/water (6/4). The sampleswere immediately centrifuged and kept at 10° C. before analysis by HPLC(CAD detection). The following reaction profile was obtainedcorresponding to a complete conversion of Rebaudioside E to RebaudiosideD.

Example 26 Directed Evolution of UGT76G1 for the Conversion ofRebaudioside D to Rebaudioside M

Starting from the amino acid sequence of UGT76G1, as is described inGenbank (AAR06912.1), different mutations at various amino acidpositions were identified that could alter the activity of the enzymefor the transformation of Rebaudioside D (Reb D) to Rebaudioside M (RebM). This list of mutations, designed by DNA2.0 ProteinGPS™ strategy, wassubsequently used to synthesize 96 variant genes that contained 3, 4 or5 of these mutations that were codon-optimized for expression in E.coli. The genes were subcloned in the pET30a+ plasmid and used fortransformation of E. coli BL21 (DE3) chemically competent cells. Theobtained cells were grown in Petri-dishes on solid LB medium in thepresence of Kanamycin. Suitable colonies were selected and allowed togrow in liquid LB medium in tubes. Glycerol was added to the suspensionas cryoprotectant and 400 μL aliquots were stored at −20° C. and at −80°C.

These storage aliquots of E. coli BL21(DE3) containing thepET30a+_UGT76G1var plasmids were thawed and added to LBGKP medium (20g/L Luria Broth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM Phosphatebuffer pH 7.00; 2.5 g/L glucose and 50 mg/L of Kanamycine). This culturewas allowed to shake in a 96 microtiter plate at 135 rpm at 30° C. for 8h.

3.95 mL of production medium containing 60 g/L of Overnight Express™Instant TB medium (Novagen®), 10 g/L of glycerol and 50 mg/L ofKanamycin was inoculated with 50 μL of above described culture. In a 48deepwell plate the resulting culture was allowed to stir at 20° C. Thecultures gave significant growth and a good OD (600 nm; 1 cm) wasobtained. After 44 h, the cells were harvested by centrifugation andfrozen.

Lysis was performed by addition of Bugbuster® Master mix (Novagen®) tothe thawed cells and the lysate was recovered by centrifugation.Activity tests were performed with 100 μL of fresh lysate that was addedto a solution of Rebaudioside D (final concentration 0.5 mM), MgCl₂(final concentration 3 mM) and UDP-Glucose (final concentration 2.5 mM)in 50 mM phosphate buffer pH 7.2.

The reaction was allowed to run at 30° C. and samples were taken after2, 4, 7 and 24 h. to determine conversion and initial rate by HPLC (CADdetection) using the analytical method that was described above for thetransformation of Rebaudioside D to Rebaudioside M. The results aredepicted in the following table.

conversion Reb D initial rate Clone Mutations* to Reb M after 24 h (%)(Reb M area/min) UGT76G1var1 E224A_F314S_R334K 51.8 5.5E+07 UGT76G1var2S274G_T284I_L379G 49.3 4.7E+07 UGT76G1var3 I295T_S357C_V366I 9.6 1.6E+06UGT76G1var4 E224D_E231A_F265I 14.7 8.6E+06 UGT76G1var5 F22Y_I373L_P382M3.5 2.3E+06 UGT76G1var6 Q266S_S357N_I373L 0.5 1.8E+06 UGT76G1var7F22L_I43V_A239V 0.2 −6.0E+04 UGT76G1var8 E224A_Q266S_Q342E 0.5 2.3E+04UGT76G1var9 E231A_D301N_G348P 52.0 4.9E+07 UGT76G1var10 A33G_L246F_Q342E0.3 −7.7E+02 UGT76G1var11 F22L_A33G_V310I 0.4 3.8E+04 UGT76G1var12L243P_K303G_A352G 0.5 8.7E+04 UGT76G1var13 L243A_S357C_A385T 0.2−3.3E+04 UGT76G1var14 A239I_F265I_V396F 5.3 1.5E+06 UGT76G1var15F41L_L246F_Q425E 5.6 1.5E+06 UGT76G1var16 F265I_P272A_I335V 18.6 5.8E+06UGT76G1var17 F265L_Q266E_Q342K 0.7 7.2E+05 UGT76G1var18L243P_S274G_N409R 1.9 5.0E+05 UGT76G1var19 E224D_E229A_Q432E 10.55.5E+06 UGT76G1var20 S375M_K393G_Y397E 1.8 1.9E+06 UGT76G1var21A239V_V300A_K303G 41.9 3.3E+07 UGT76G1var22 E231A_V310I_R334K 34.42.4E+07 UGT76G1var23 T263S_G348P_A352G 47.8 4.1E+07 UGT76G1var24A239I_P272A_Q425E 31.0 2.1E+07 UGT76G1var25 T284L_Q342K_Y397Q 0.96.3E+04 UGT76G1var26 S241I_F265L_F377C 1.8 7.5E+05 UGT76G1var27A239I_L379A_V394I 29.0 1.5E+07 UGT76G1var28 L243A_S274G_P382M 6.12.4E+06 UGT76G1var29 F22Y_V279I_N409R 41.0 2.9E+07 UGT76G1var30I43V_E224A_S241I 13.6 5.6E+06 UGT76G1var31 E224D_L243P_V300A 0.4 2.4E+05UGT76G1var32 A239V_L243A_S375M 0.0 −4.4E+04 UGT76G1var33A33G_R334H_Y397Q 1.0 7.5E+06 UGT76G1var34 I43V_T284I_I295T 3.4 1.5E+06UGT76G1var35 T284L_F314S_S357N 0.5 1.8E+05 UGT76G1var36F265L_L379A_V396F 20.0 8.8E+06 UGT76G1var37 E229A_L379G_I407V 39.12.8E+07 UGT76G1var38 F41L_I295M_F377C 8.2 3.7E+06 UGT76G1var39F22Y_F41L_V366I 7.2 3.3E+06 UGT76G1var40 T263S_Q266E_S375R 47.6 3.3E+07UGT76G1var41 L246F_A385T_K393G 0.8 1.4E+06 UGT76G1var42T263S_Q266S_R334H 34.6 2.2E+07 UGT76G1var43 S241I_P272A_V279I 19.99.4E+06 UGT76G1var44 I335V_S375R_I407V 35.3 2.3E+07 UGT76G1var45V279I_D301N_S389E 38.6 2.3E+07 UGT76G1var46 F22L_Q266E_I295M 0.6 9.8E+05UGT76G1var47 E229A_T284I_S389E 4.8 2.7E+06 UGT76G1var48V394I_Y397E_Q432E 47.6 3.8E+07 UGT76G1var49 F41L_Q266E_T284I_Y397Q 2.61.1E+06 UGT76G1var50 F22Y_V310I_S375M_F377C 1.9 7.9E+05 UGT76G1var51K303G_S357C_S389E_V396F 18.7 9.5E+06 UGT76G1var52D301N_I373L_F377C_I407V 12.9 4.6E+06 UGT76G1var53R334K_A352G_P382M_S389E 9.3 4.1E+06 UGT76G1var54 E229A_T284L_R334K_Q342E0.7 4.3E+05 UGT76G1var55 I295M_Q342E_V366I_N409R 1.0 2.2E+05UGT76G1var56 L246F_A352G_S357N_Q432E 0.4 4.1E+04 UGT76G1var57S241I_T263S_L379G_A385T 0.8 1.5E+05 UGT76G1var58 S357C_S375M_N409R_Q425E7.5 2.2E+06 UGT76G1var59 I335V_K393G_V394I_Y397Q 33.0 2.7E+07UGT76G1var60 E231A_L243A_V279I_S357N 0.5 9.5E+04 UGT76G1var61I43V_F265I_Q266S_L379A 6.4 2.0E+06 UGT76G1var62 L243P_P272A_V394I_V396F0.1 3.4E+04 UGT76G1var63 F314S_R334H_Q342K_L379G 3.4 1.2E+06UGT76G1var64 F22L_A239I_R334H_I407V 0.3 3.1E+04 UGT76G1var65A33G_A239V_P382M_Q425E 1.2 3.3E+05 UGT76G1var66 F265L_V310I_V366I_A385T0.8 3.7E+05 UGT76G1var67 E224D_F314S_S375R_Y397E −2.1 −5.6E+05UGT76G1var68 Q342K_G348P_I373L_Y397E −1.4 −1.1E+05 UGT76G1var69S274G_I295T_I335V_L379A 24.7 8.3E+06 UGT76G1var70E224A_I295T_V300A_G348P 24.0 8.4E+06 UGT76G1var71I295M_V300A_K393G_Q432E 42.9 2.1E+07 UGT76G1var72T284L_D301N_K303G_S375R 19.2 9.1E+06 UGT76G1var73F22Y_D301N_R334H_Q342E_V396F 0.8 8.7E+05 UGT76G1var74I295T_I373L_S375R_Y397Q_Q432E 0.6 9.6E+04 UGT76G1var75F41L_A239I_Q266S_S375M_P382M 0.8 −1.3E+05 UGT76G1var76F22Y_A239I_L246F_I295M_R334K 2.6 7.2E+05 UGT76G1var77A239V_F265I_I295T_D301N_K393G 1.9 4.4E+05 UGT76G1var78V279I_V300A_V310I_I335V_S357C 3.2 8.2E+05 UGT76G1var79E224D_T284I_V366I_I373L_K393G 8.5 3.8E+06 UGT76G1var80L243P_L379A_S389E_Q425E_Q432E 1.0 2.1E+05 UGT76G1var81A33G_T263S_S274G_V279I_Y397E 15.0 6.5E+06 UGT76G1var82E224D_L243A_F265L_R334H_A352G 1.1 2.5E+05 UGT76G1var83I43V_Q342E_S357N_S375R_L379G 0.5 4.3E+04 UGT76G1var84F22L_Q266S_F314S_A352G_S357C 1.2 2.3E+05 UGT76G1var85T284L_G348P_F377C_P382M_N409R 1.8 4.0E+05 UGT76G1var86E224A_T284L_V396F_Y397E_I407V 1.6 3.8E+05 UGT76G1var87S241I_L243A_V300A_F314S_N409R 35.7 2.1E+07 UGT76G1var88A239V_T284I_V310I_Q342K_L379A 1.6 3.8E+05 UGT76G1var89F41L_E229A_E231A_F265L_P272A 1.2 2.1E+05 UGT76G1var90E231A_S241I_S274G_Y397Q_Q425E 34.5 1.9E+07 UGT76G1var91E224A_L246F_T263S_F265I_Q342K 1.2 2.3E+05 UGT76G1var92K303G_S357N_V366I_V394I_I407V 1.6 3.6E+05 UGT76G1var93I43V_Q266E_S375M_S389E_V394I 1.8 4.5E+05 UGT76G1var94Q266E_P272A_R334K_G348P_L379G 72.0 7.9E+07 UGT76G1var95A33G_I295M_K303G_I335V_A385T −1.3 −1.7E+05 UGT76G1var96F22L_E229A_L243P_F377C_A385T 1.2 2.7E+05 *Mutations are noted asfollows: original amino acid-position-new amino acid: For example themutation of an alanine at position 33 to a glycine is noted as A33G.

Example 27 In-Vivo Production of UGTSL2

UGTSL2 (GI_460410132/XP_004250485.1) amino acid sequence: (SEQ ID NO: 9)MATNLRVLMFPWLAYGHISPFLNIAKQLADRGFLIYLCSTRINLESIIKKIPEKYADSIHLIELQLPELPELPPHYHTTNGLPPHLNPTLHKALKMSKPNFSRILQNLKPDLLIYDVLQPWAEHVANEQNIPAGKLLTSCAAVFSYFFSFRKNPGVEFPFPAIHLPEVEKVKIREILAKEPEEGGRLDEGNKQMMLMCTSRTIEAKYIDYCTELCNWKVVPVGPPFQDLITNDADNKELIDWLGTKHENSTVFVSFGSEYFLSKEDMEEVAFALELSNVNFIWVARFPKGEERNLEDALPKGFLERIGERGRVLDKFAPQPRILNHPSTGGFISHCGWNSAMESIDFGVPIIAMPIHNDQPINAKLMVELGVAVEIVRDDDGKIHRGEIAETLKSVVTGETGEILRAKVREISKNLKSIRDEEMDAVAEELIQLCRNSNKSK.

The pET30A+ vector containing the UGTSL2 gene was introduced in E. coliB121(DE3) by heat shock. The obtained cells were grown in petri-dishesin the presence of Kanamycin and suitable colonies were selected andallowed to grow in liquid LB medium (erlenmeyer flasks). Glycerol wasadded to the suspension as cryoprotecteur and 400 μL aliquots werestored at −20° C. and at −80° C.

The storage aliquots of E. coli BL21(DE3) containing the pET30A+_UGTSL2plasmids were thawed and added to 30 mL of LBGKP medium (20 g/L LuriaBroth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM Phosphate buffer pH7.00; 2.5 g/L glucose and 50 mg/L of Kanamycin). This culture wasallowed to shake at 135 rpm at 30° C. for 8 h.

The production medium contained 60 g/L of overnight express instant TBmedium (Novagen), 10 g/L of glycerol and 50 mg/L of Kanamycin. Thepreculture was added to 200 mL of this medium and the solution wasallowed to stir at 20° C. while taking samples to measure the OD and pH.The culture gave significant growth and a good OD was obtained. After 40h, the cells were harvested by centrifugation and frozen to obtain 6.22g of cell wet weight.

Lysis was performed on 1.4 g of cells by addition of Bugbuster Mastermix (Novagen) and the lysate was recovered by centrifugation and usedfresh.

Example 28 Determination of Activity for Stevioside to Rebaudioside EConversion with UGTSL and UGTSL2

UGTSL was prepared according to EXAMPLE 22, and UGTSL2 was preparedaccording to EXAMPLE 27.

Activity tests were performed at 3 mL scale with 600 μL of lysate forthe transformation of Stevioside using 0.5 mM of substrate, 2.5 mM ofUDP-Glucose and 3 mM MgCl₂ in 50 mM Sodium Phosphate buffer at pH 7.2.Samples were taken and analyzed by HPLC. HPLC Analysis. The HPLC assaywas performed as described in EXAMPLE 20.

The results for the different enzymes and the correspondingchromatograms are provided below.

Stevioside Enzyme internal conv.¹ Rebaudioside reference GI NumberVersion (reaction time) E formation¹ UGTSL 460409128 XP_004249992.1 74%(22 h.) 46% UGTSL2 460410132 XP_004250485.1 77% (2 h.) 50% Note: ¹Basedon initial concentration of Stevioside

Example 29 Determination of Activity for Rubusoside to Rebaudioside EConversion with UGTSL and UGTSL2

UGTSL was prepared according to EXAMPLE 22, and UGTSL2 was preparedaccording to EXAMPLE 27.

Activity tests were performed at 3 mL scale with 600 μL of lysate forthe transformation of Rubusoside using 0.5 mM of substrate, 2.5 mM ofUDP-Glucose and 3 mM MgCl₂ in 50 mM Sodium Phosphate buffer at pH 7.2.Samples were taken and analyzed by HPLC. The HPLC assay was performed asdescribed in EXAMPLE 20.

The results for the different enzymes and the correspondingchromatograms are provided below.

Rubusoside Enzyme internal GI conv.¹ (reaction Rebaudioside referenceNumber Version time) E formation¹ UGTSL 460409128 XP_004249992.1 70% (45h.) 27% UGTSL2 460410132 XP_004250485.1 80% (2 h.) 55% Note: ¹Based oninitial concentration of Rubusoside

Example 30 Determination of Activity for Rebaudioside A to RebaudiosideD Conversion with UGTSL2

UGTSL2 was prepared according to EXAMPLE 27.

Activity tests were performed at 3 mL scale with 60 μL of lysate for thetransformation of Rebaudioside A using 0.5 mM of substrate, 2.5 mM ofUDP-Glucose and 3 mM MgCl₂ in 50 mM Sodium Phosphate buffer at pH 7.2.Samples were taken and analyzed by HPLC. The HPLC assay was performed asdescribed in EXAMPLE 20.

The result after 23 h. of reaction are provided below.

Rebaudioside A Enzyme internal GI conv.¹ (reaction Rebaudiosidereference Number Version time) D formation¹ UGTSL2 460410132XP_004250485.1 78% (23 h.) 75% Note: ¹Based on initial concentration ofRebaudioside A

Example 31 Identification of Glycosides

The reaction mixtures prepared according to EXAMPLE 30 and incubated for45 hrs was analyzed by LC-MS, along with Stevia rebaudiana Bertoni leafextract “MLD1” produced by PureCircle Sdn Bhd (Malaysia), to determinethe occurrence of unknown formed glycosides (˜4.5 min, ˜6.7 min, ˜7.0min, ˜7.3 min and ˜7.7 min) in nature.

An Agilent 1200 series HPLC system, equipped with binary pump (G1312B),autosampler (G1367D), thermostatted column compartment (G1316B), DADdetector (G1315C), connected with Agilent 6110A MSD, and interfaced with“LC/MSD Chemstation” software, was used.

Instrument conditions Column Phenomenex Prodigy 3u C18 100 A, 4.6 mm ×250 mm, 3 μm Column Temperature 55° C. Detection DAD at 210 nm bw 360 nmMSD (Scan and SIM mode) Mode: ES-API, Negative Polarity Drying gas flow:13.0 L/min Nebulizer pressure: 30 psig Drying gas temperature: 270° C.Analysis duration 75 min Injected volume 10 μL Flow rate 0.5 mL/min

Mobile phase gradient program Time (min) A (%): Formic acid 0.1% B (%):Acetonitrile 0 75 25 30 75 25 33 68 32 75 68 32

The assay shows that the compound observed on LC-MS system at 11.77 minis the same as the compound at 3.5 min, in EXAMPLE 23 (C₅₆H₉₀O₃₃; laterconfirmed as reb M2), and the compound observed at 26.64 min is the sameas the compound at 7.6 min, in EXAMPLE 23 (C₅₀H₈₀O₂₈; reb UNK; laterconfirmed as reb D2). Other isomers of reb M were observed at 13.96 minand also another isomer form of reb D was observed at 25.06 min. Allobserved compounds occurred in the extract of Stevia rebaudiana Bertoniplant.

Example 32 In Vivo Preparation and Activity Determination of UGTLB

UGTLB (GI_209954733/BAG80557.1) amino acid sequence (SEQ ID NO: 10)MGTEVTVHKNTLRVLMFPWLAYGHISPFLNVAKKLVDRGFLIYLCSTAINLKSTIKKIPEKYSDSIQLIELHLPELPELPPHYHTTNGLPPHLNHTLQKALKMSKPNFSKILQNLKPDLVIYDLLQQWAEGVANEQNIPAVKLLTSGAAVLSYFFNLVKKPGVEFPFPAIYLRKNELEKMSELLAQSAKDKEPDGVDPFADGNMQVMLMSTSRIIEAKYIDYFSGLSNWKVVPVGPPVQDPIADDADEMELIDWLGKKDENSTVFVSFGSEYFLSKEDREEIAFGLELSNVNFIWVARFPKGEEQNLEDALPKGFLERIGDRGRVLDKFAPQPRILNHPSTGGFISHCGWNSVMESVDFGVPIIAMPIHLDQPMNARLIVELGVAVEIVRDDYGKIHREEIAEILKDVIAGKSGENLKAKMRDISKNLKSIRDEEMDTAAEELIQLCKNS PKLK.

The pET30A+ vector containing the UGTLB gene was introduced in E. coliB121(DE3) by heat shock. The obtained cells were grown in petri-dishesin the presence of Kanamycin and suitable colonies were selected andallowed to grow in liquid LB medium (erlenmeyer flasks). Glycerol wasadded to the suspension as cryoprotecteur and 400 μL aliquots werestored at −20° C. and at −80° C.

The storage aliquots of E. coli BL21(DE3) containing the pET30A+_UGTLBplasmids were thawed and added to 30 mL of LBGKP medium (20 g/L LuriaBroth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM Phosphate buffer pH7.00; 2.5 g/L glucose and 50 mg/L of Kanamycine). This culture wasallowed to shake at 135 rpm at 30° C. for 8 h.

The production medium contained 60 g/L of overnight express instant TBmedium (Novagen), 10 g/L of glycerol and 50 mg/L of Kanamycine. Thepreculture was added to 200 mL of this medium and the solution wasallowed to stir at 20° C. while taking samples to measure the OD and pH.The culture gave significant growth and a good OD was obtained. After 40h, the cells were harvested by centrifugation and frozen to obtain 5.7 gof cell wet weight.

Lysis was performed on 1.2 g of cells by addition of 6 mL BugbusterMaster mix (Novagen) and the lysate was recovered by centrifugation andused fresh.

Determination of Activity for Stevioside to Rebaudioside E Conversionwith UGTLB

Activity tests were performed at 3 mL scale with 600 μL of lysate forthe transformation of Stevioside using 0.5 mM of substrate, 2.5 mM ofUDP-Glucose and 3 mM MgCl₂ in 50 mM Sodium Phosphate buffer at pH 7.2.Samples were taken and analyzed by HPLC according to the method ofEXAMPLE 20. The results are provided below.

Stevioside conv.¹ Rebaudioside E (reaction time) formation¹ Enzyme(Retention (Retention internal Time Time reference GI Number Version~9.2 min) ~5.4 min) UGTLB 209954733 BAG80557.1 89% (22 h.) 3% Note:¹Based on initial concentration of SteviosideDetermination of Activity for Rubusoside to Rebaudioside E Conversionwith UGTLB

Activity tests were performed at 3 mL scale with 600 μL of lysate forthe transformation of Rubusoside using 0.5 mM of substrate, 2.5 mM ofUDP-Glucose and 3 mM MgCl₂ in 50 mM Sodium Phosphate buffer at pH 7.2.Samples were taken and analyzed by HPLC according to the method ofEXAMPLE 20. The results are provided below.

Rubusoside conv.¹ Rebaudioside E (reaction time) formation¹ Enzyme(Retention (Retention internal Time Time reference GI Number Version~11.2 min) ~5.4 min) UGTLB 209954733 BAG80557.1 65% (5 h.) 4% Note:¹Based on initial concentration of RubusosideDetermination of Activity for Rebaudioside A to Rebaudioside DConversion with UGTLB

Activity tests were performed at 3 mL scale with 600 μL of lysate forthe transformation of Rebaudioside A using 0.5 mM of substrate, 2.5 mMof UDP-Glucose and 3 mM MgCl₂ in 50 mM Sodium Phosphate buffer at pH7.2. Samples were taken and analyzed by HPLC according to the method ofEXAMPLE 20. The results after 23 h. of reaction are provided below.

Rebaudioside Enzyme A conv.¹ Rebaudioside internal (reaction D referenceGI Number Version time) formation¹ UGTLB 209954733 BAG80557.1 72% (22h.) 10% Note: ¹Based on initial concentration of Rebaudioside A

Example 33 Determination of Reaction Products for Rubusoside andStevioside Conversion with UGTSL, UGTSL2, and UGTLB

Conversion of stevioside with UGTSL and UGTSL2 was conducted in similarmanner to Example 28, and the conversion of rubusoside with UGTSL andUGTSL2 was conducted similarly to Example 29. Conversions of rubusosideand stevioside with UGTLB was conducted similarly to Example 32.

The reaction mixtures were analyzed by LCMS to determine all reactionproducts.

Rubusoside conversion products LC-MS, peak area ratio (%) Sample ID UGT(reaction time) Rub Stev Reb E Reb D S151N15 UGTSL2 (2 hrs) 3.54 2.1252.88 6.73 S151N17 UGTLB (5 hrs) 13.49 ND 9.21 1.29 S151N22 UGTSL (45hrs) 7.82 2.37 35.88 3.45

Stevioside conversion products LC-MS, peak area ratio (%) Sample ID UGT(reaction time) Stev Reb E Reb D S151N26 UGTSL2 (2 hrs) 20.01 42.56 1.70S151N28 UGTLB (2 hrs) 43.11 3.12 ND S151N33 UGTSL (22 hrs) 25.24 49.680.54

It can be seen that amongst Rubusoside conversion products, besidesstevioside, reb E and reb D, there are at least 3 additional compoundswith Molecular Weight of 804. The retention time of these compounds donot match with reb B (also known to have same Molecular Weight asstevioside).

Among stevioside conversion products, besides reb E and reb D, there areat least 3 additional compounds with Molecular Weight of 966. Theretention time of these compounds do not match with reb A (also known tohave same Molecular Weight as reb E).

Example 34 In Vivo Production of UGT76G1 in S. cerevisiae

UGT 76G1 [Stevia rebaudiana] (gi_37993653/ gb_AAR06912.1)(SEQ ID NO: 11) MENKTETTVRRRRRIILFPVPFQGHINPILQLANVLYSKGFSITIFHTNFNKPKTSNYPHFTFRFILDNDPQDERISNLPTHGPLAGMRIPIINEHGADELRRELELLMLASEEDEEVSCLITDALWYFAQSVADSLNLRRLVLMTSSLFNFHAHVSLPQFDELGYLDPDDKTRLEEQASGFPMLKVKDIKSAYSNWQILKEILGKMIKQTKASSGVIWNSFKELEESELETVIREIPAPSFLIPLPKHLTASSSSLLDHDRTVFQWLDQQPPSSVLYVSFGSTSEVDEKDFLEIARGLVDSKQSFLWVVRPGFVKGSTWVEPLPDGFLGERGRIVKWVPQQEVLAHGAIGAFWTHSGWNSTLESVCEGVPMIFSDFGLDQPLNARYMSDVLKVGVYLENGWERGEIANAIRRVMVDEEGEYIRQNARVLKQKADVSLMKGGSSYESLES LVSYISSL.

The above mentioned amino acid sequence was codon optimized forexpression in S. cerevisiae. Furthermore the yeast consensus sequenceAACACA was added before the ATG start codon. The synthetic gene wassubcloned in the pYES2 vector using Hind III and Xba I restrictionsites. The pYES2_UGT76G1_Sc vector was used to transform chemicallycompetent S. cerevisiae INVSc1 cells (Invitrogen).

The cells were grown on a solid synthetic minimal medium containing 2%glucose lacking Uracil and a single colony was picked and allowed togrow in liquid synthetic minimal medium lacking Uracil (SC-U containing2% glucose). After centrifugation, the cells were suspended with SC-U(containing 2% glucose) and 60% glycerol/water. Aliquots were stored at−80° C. and one aliquot was used to start a culture in SC-U (containing2% glucose) for 43 h at 30° C. Part of this culture was centrifuged andsuspended in induction medium (SC-U containing 2% galactose) for 19 h30at 30° C.

Cells were obtained by centrifugation and lysis with five volumes ofCelLytic™ Y Cell Lysis Reagent (Sigma). The lysates were used directlyfor activity testing (UGT76G1_Sc).

Example 35 Determination of Activity of UGT76G1_Sc for the Conversion ofRebaudioside D to Rebaudioside M

UGT76G1_Sc was prepared according to EXAMPLE 34. Activity tests wereperformed at 2 mL scale with 200 μL of lysate for the transformation ofRebaudioside D using 0.5 mM of substrate, 2.5 mM of UDP-Glucose and 3 mMMgCl₂ in 50 mM Sodium Phosphate buffer at pH 7.2. Samples were taken andanalyzed by HPLC according to the method of EXAMPLE 20. The results areshown below.

Rebaudioside M Enzyme Rebaudioside D conv.¹ selectivity¹ internalreference (reaction time) (Retention Time ~6.7 min) UGT76G1_Sc 85% (21h.) 100% Note: ¹Based on initial concentration of Rebaudioside D

Example 36 In Vivo Production of UGTSL in S. cerevisiae

UGTSL [Solanum lycopersicum] (gi_460409128/ XP_004249992.1(SEQ ID NO: 12) MSPKLHKELFFHSLYKKTRSNHTMATLKVLMFPFLAYGHISPYLNVAKKLADRGFLIYFCSTPINLKSTIEKIPEKYADSIHLIELHLPELPQLPPHYHTTNGLPPNLNQVLQKALKMSKPNFSKILQNLKPDLVIYDILQRWAKHVANEQNIPAVKLLTSGAAVFSYFFNVLKKPGVEFPFPGIYLRKIEQVRLSEMMSKSDKEKELEDDDDDDDLLVDGNMQIMLMSTSRTIEAKYIDFCTALTNWKVVPVGPPVQDLITNDVDDMELIDWLGTKDENSTVFVSFGSEYFLSKEDMEEVAFALELSNVNFIWVARFPKGEERNLEDALPKGFLERIGERGRVLDKFAPQPRILNHPSTGGFISHCGWNSAMESIDFGVPIIAMPMHLDQPMNARLIVELGVAVEIVRDDDGKIHRGEIAETLKGVITGKTGEKLRAKVRDISKNLKTI RDEEMDAAAEELIQLCRNGN.

The above mentioned amino acid sequence was codon optimized forexpression in S. cerevisiae. Furthermore the yeast consensus sequenceAACACA was added before the ATG start codon. The synthetic gene wassubcloned in the pYES2 vector using Hind III and Xba I restrictionsites. The pYES2_UGTSL_Sc vector was used to transform chemicallycompetent S. cerevisiae INVSc1 cells (Invitrogen).

The cells were grown on a solid synthetic minimal medium containing 2%glucose, lacking Uracil and a single colony was picked and allowed togrow in liquid synthetic minimal medium lacking Uracil (SC-U containing2% glucose). After centrifugation, the cells were suspended with SC-U(containing 2% glucose) and 60% glycerol/water. Aliquots were stored at−80° C. and one aliquot was used to start a culture in SC-U (containing2% glucose) for 43 h at 30° C. Part of this culture was centrifuged andsuspended in induction medium (SC-U containing 2% galactose) for 19 h30at 30° C.

Cells were obtained by centrifugation and lysis with five volumes ofCelLytic™ Y Cell Lysis Reagent (Sigma). The lysates were used directlyfor activity testing (UGTSL_Sc).

Example 37 Determination of Activity of UGTSL_Sc for the Conversion ofRebaudioside A to Rebaudioside D

UGTSL_Sc was prepared according to EXAMPLE 36. Activity tests wereperformed at 2 mL scale with 200 μL of lysate for the transformation ofRebaudioside A using 0.5 mM of substrate, 2.5 mM of UDP-Glucose and 3 mMMgCl₂ in 50 mM Sodium Phosphate buffer at pH 7.2. Samples were taken andanalyzed by HPLC according to the method of EXAMPLE 20. The results areprovided below.

Enzyme internal Rebaudioside A conv.¹ (reaction Rebaudioside D referencetime) selectivity¹ UGTSL_Sc 46% (4 h) 42% Note: ¹Based on initialconcentration of Rebaudioside A

Example 38 Isolation of Rebaudioside M

The amount of the product mixture of Example 14 was not large enough toseparate via preparative HPLC methods. Accordingly, analytical HPLC witha series of injections was used to separate the components of themixture. Separation was conducted according to the method describedabove in Example 14 to provide two fractions corresponding to the twomain peaks in the HPLC trace of FIG. 3: Fraction A (retention time24.165 minutes) and Fraction B (retention time 31.325 minutes).

The retention time of Fraction A was consistent with reb D, indicatingunreacted starting material from the biotransformation reaction.

The retention time of purified Fraction B was consistent with reb M,indicating successful biotransformation from reb D. The identity of thematerial collected in Fraction B as reb M was confirmed by co-injectionof purified Fraction B with a reb M standard (available fromPureCircle). Both Fraction B and the reb M standard were found to eluteat the same retention time (FIG. 7), indicating Fraction B was reb M.

The identity of Fraction B as reb M was also separately confirmed by NMRand HRMS. For sampling, Fraction B was concentrated under rotaryevaporator, freeze dried and dried for 40 h at 40° C.

The NMR sample was dissolved in deuterated pyridine (C₅D₅N) and spectrawere acquired on a Varian Unity Plus 600 MHz instrument using standardpulse sequences. The NMR spectra of Fraction B was compared to the NMRspectra of reb M. An overlay of the two spectra showed consistency ofpeaks of Fraction B with reb M. A table of the NMR assignments for reb Mis shown below:

¹H and ¹³C NMR spectral data for Rebaudioside M in C₅D₅N ^(a-c).Position ¹³C NMR ¹H NMR  1 40.3 0.75 t (13.2) 1.76 m  2 19.6 1.35 m 2.24m  3 38.4 1.01 m 2.30 d (13.3)  4 44.3 —  5 57.4 1.06 d (12.8)  6 23.52.23 m 2.41 q (13.2)  7 42.6 1.41 m 1.80 m  8 41.2 —  9 54.3 0.91 d(7.7) 10 39.7 — 11 20.2 1.65 m 1.75 m 12 38.5 1.86 m 2.73 m 13 87.6 — 1443.3 2.02 m 2.74 m 15 46.5 1.88 d (16.4) 2.03 m 16 153.3 — 17 104.9 4.90s 5.69 s 18 28.2 1.32 s 19 176.9 — 20 16.8 1.38 s   1′ 94.9 6.39 d (8.2)  2′ 76.9 4.51 t (8.5)   3′ 88.6 5.09 t (8.5)   4′ 70.1 4.18 m   5′ 78.44.13 m   6′ 61.8 4.20 m 4.31 m  1″ 96.2 5.46 d (7.1)  2″ 81.4 4.13 m  3″87.9 4.98 t (8.5)  4″ 70.4 4.07 t (9.6)  5″ 77.7 3.94 m  6″ 62.6 4.19 m4.32 m   1′″ 104.8 5.48 d (7.7)   2′″ 75.8 4.15 m   3′″ 78.6 4.13 m  4′″ 73.2 3.98 m   5′″ 77.6 3.74 ddd (2.8, 6.4, 9.9)   6′″ 64.0 4.27 m4.51 m   1″″ 103.9 5.45 d (7.5)   2″″ 75.6 3.98 m   3″″ 77.8 4.50 t(7.8)   4″″ 71.3 4.14 m   5″″ 78.0 3.99 m   6″″ 62.1 4.20 m 4.32 m   1′″″ 104.2 5.81 d (7.2)    2′″″ 75.5 4.20 m    3′″″ 78.4 4.20 m   4′″″ 73.6 4.10 m    5′″″ 77.8 3.90 ddd (2.8, 6.4, 9.9)    6′″″ 64.04.32 m 4.64 d (10.3)   1″″″ 104.1 5.31 d (8.0)   2″″″ 75.5 3.95 m   3″″″78.0 4.37 t (9.1)   4″″″ 71.1 4.10 m   5″″″ 78.1 3.85 ddd (1.7, 6.1,9.9)   6″″″ 62.1 4.10 m 4.32 m ^(a) assignments made on the basis ofCOSY, HMQC and HMBC correlations; ^(b) Chemical shift values are in δ(ppm); ^(c) Coupling constants are in Hz.

HRMS was generated with a Waters Premier Quadropole Time-of-Flight(Q-TOF) mass spectrometer equipped with an electrospray ionizationsource operated in the positive-ion mode. The sample was dissolved inmethanol and eluted in 2:2:1 methanol:acetonitrile:water and introducedvia infusion using the onboard syringe pump. The presence of reb M wasconfirmed by a [M+Na]⁺ adduct at m/z 1313.5265, which corresponds to amolecular formula of C₅₆H₉₀O₃₃

Example 39 Isolation and Characterization of Reb D2

Crude Reaction Sample.

The sample, Lot CB-2977-106, used for isolation, was prepared accordingto Example 22 with UGTSL (GI #460409128).

HPLC Analysis.

Preliminary HPLC analyses of samples were performed using a Waters 2695Alliance System with the following method: Phenomenex Synergi Hydro-RP,4.6×250 mm, 4 m (p/n 00G-4375-E0); Column Temp: 55° C.; Mobile Phase A:0.0284% ammonium acetate (NH₄OAc) and 0.0116% acetic acid (HOAc) inwater; Mobile Phase B: Acetonitrile (MeCN); Flow Rate: 1.0 mL/min;Injection volume: 10 μL. Detection was by UV (210 nm) and CAD.

Gradient:

Time (min) % A % B 0.0-8.5 75 25 10.0 71 29 16.5 70 30 18.5-24.5 66 3426.5-29.0 48 52 31-37 30 70 38   75 25

Analyses of semi-preparative purification fractions were performed withthe following method: Waters Atlantis dC18, 4.6×100 mm, 5 m (p/n186001340); Mobile Phase A: 25% MeCN in water; Mobile Phase B: 30% MeCNin water; Flow Rate: 1.0 mL/min; Injection volume: 10 μL. Detection wasby CAD.

Gradient:

Time (min) % A % B 0.0-5.0 100 0 20 20 80 25 20 80 30 100 0LC-MS.

Preliminary analysis of the semi-synthetic steviol glycoside mixture wascarried out on a Waters AutoPurification HPLC/MS System with a Waters3100 Mass Detector operating in negative ion mode. Analysis of thesample was performed using the following method: Phenomenex SynergiHydro-RP, 4.6×250 mm, 4 m (p/n 00G-4375-E0); Column Temp: 55° C.; MobilePhase A: 0.0284% NH₄OAc and 0.0116% HOAc in water; Mobile Phase B:Acetonitrile; Flow Rate: 1.0 mL/min; Injection volume: 10 μL. Detectionwas by UV (210 nm), and MSD (−ESI m/z 500-2000). Gradient conditionswere as listed above.

Isolation by HPLC.

The purification was performed in two steps. The first method used forthe semi-preparative purification is summarized below. Column: WatersAtlantis dC18, 30×100 mm, 5 m (p/n 186001375); Mobile Phase A: 25% MeCNin water; Mobile Phase B: 30% MeCN in water; Flow Rate: 45 mL/min;Injection load: 160 mg dissolved in 20 mL of water. Detection was by UV(205 nm).

Gradient:

Time (min) % A % B 0.0-5.0 100 0 20 20 80 25 20 80 30 100 0

The secondary purification used the same column and conditions, butisocratic mobile phase: 20% MeCN in water.

Purification from Natural Extracts.

The purification was performed in three steps. The first method used forthe preparative purification is summarized below. Primary Process:Waters Symmetry C18, 50×250 mm, 7 m (p/n WAT248000); Isocratic mobilephase: 50% methanol (MeOH) in water with 0.05% HOAc; Flow Rate: 85mL/min; Injection load: 6 g crude extract dissolved in 50 mL of mobilephase. Detection was by UV (210 nm). Following the elution of targetanalytes, the column was flushed with 85% MeOH in water.

Secondary Process: Waters Symmetry Shield RP18, 50×250 mm, 7 m (p/nWAT248000); Isocratic mobile phase: 20% MeCN in water; Flow Rate: 100mL/min; Injection load: 0.5 g primary fraction dissolved in 30 mL ofwater. Detection was by UV (210 nm).

Tertiary Process: Waters Symmetry Shield RP18, 50×250 mm, 7 m (p/nWAT248000); Isocratic mobile phase: 20% MeCN in water; Flow Rate: 100mL/min; Injection load: 0.5 g secondary fraction dissolved in 30 mL ofwater. Detection was by UV (210 nm).

MS and MS/MS.

MS and MS/MS data were generated with a Waters QT of Premier massspectrometer equipped with an electrospray ionization source. Sampleswere analyzed by negative ESI. Samples were diluted withH₂O:acetonitrile (1:1) by 50 fold and introduced via infusion using theonboard syringe pump. The samples were diluted to yield good s/n whichoccurred at an approximate concentration of 0.01 mg/mL.

NMR.

The sample was prepared by dissolving 1-2 mg in 150 μL of pyridine-d₅and NMR data were acquired on a Bruker Avance 500 MHz instrument with a2.5 mm inverse detection probe. The ¹H NMR spectrum was referenced tothe residual solvent signal (δ_(H) 8.74 and δ_(C) 150.35 forpyridine-d₅).

Results and Discussion

Isolation and Purification.

Isolation was performed on steviol glycoside mixture, Lot numberCB-2977-106, prepared according to Example 22 with UGTSL (GI #460409128)The material was analyzed by LC-MS using the method described above andresults are provided in FIG. 6. The targeted peak of interest was thatat 7.7 min in the TIC chromatogram. The mass spectrum of this peakprovided a [M-H]⁻ ion at m/z 1127.6. The provided sample waspreliminarily processed in a single injection (160 mg) using the firstmethod condition provided above. This method fractionated the materialinto ‘polar’ and ‘non-polar’ mixtures of glycosides. The ‘polar’ mixturewas then reprocessed using the second-step conditions above. From thissemi-preparative collection, the compound was isolated with apurity >99% (CAD, AUC). Following the purification, the combinedfractions were concentrated by rotary evaporation at 35° C. andlyophilized. Approximately 1-2 mg was obtained for characterization.

Mass Spectrometry.

The ESI-TOF mass spectrum acquired by infusing a sample showed a [M-H]⁻ion at m/z 1127.4709. The mass of the [M-H]⁻ ion was in good agreementwith the molecular formula C₅₀H₈₀O₂₈ (calcd for C₅₀H₇₉O₂₈: 1127.4758,error: −4.3 ppm). The MS data confirmed a nominal mass of 1128 Daltonswith the molecular formula, C₅₀H₈₀O₂₈.

The MS/MS spectrum (selecting the [M-H]⁻ ion at m/z 1127.5 forfragmentation) indicated the loss of two glucose units and sequentialloss of three glucose moieties at m/z 641.3187, 479.2655 and 317.2065.

NMR Spectroscopy.

A series of NMR experiments including ¹H NMR (FIG. 8), ¹³C NMR (FIGS. 9and 10), ¹H-¹H COSY (FIG. 11), HSQC-DEPT (FIG. 12), HMBC (FIGS. 13 and14), NOESY (FIG. 15) and 1D-TOCSY were performed to allow assignment ofthe compound. In the ¹H NMR acquired after ˜46 hrs of samplepreparation, the anomeric resonance at δ_(H) 5.04 is resolved which wasobscured by the solvent (HOD) in the original spectrum (FIG. 8)

The ¹H, ¹H-¹H COSY, ¹H-¹³C HSQC-DEPT and ¹H-¹³C HMBC NMR data indicatedthat the central core of the glycoside is a diterpene. The presence offive anomeric protons observed in the ¹H and ¹H-¹³C HSQC-DEPT spectraconfirm five sugar units in the structure. The methylene ¹³C resonanceat δ_(C) 69.9 in the ¹H-¹³C HSQC-DEPT spectrum indicated the presence ofa 1→6 sugar linkage in the structure. The linkages of sugar units wereassigned using ¹H-¹³C HMBC and 1D-TOCSY correlations.

A HMBC correlation from the methyl protons at δ_(H) 1.29 to the carbonylat δ_(C) 177.7 allowed assignment of one of the tertiary methyl groups(C-18) as well as C-19 and provided a starting point for the assignmentof the rest of the aglycone. Additional HMBC correlations from themethyl protons (H-18) to carbons at δ_(C) 38.9, 45.0, and 57.8 allowedassignment of C-3, C-4, and C-5. Analysis of the ¹H-¹³C HSQC-DEPT dataindicated that the carbon at δ_(C) 38.9 was a methylene group and thecarbon at δ_(C) 57.8 was a methine which were assigned as C-3 and C-5,respectively. This left the carbon at δ_(C) 45.0, which did not show acorrelation in the HSQC-DEPT spectrum, to be assigned as the quaternarycarbon, C-4. The ¹H chemical shifts for C-3 (δ_(H) 0.98 and 2j.36) andC-5 (δ_(H) 1.04) were assigned using the HSQC-DEPT data. A COSYcorrelation between one of the H-3 protons (δ_(H) 0.98) and a proton atδ_(H) 1.43 allowed assignment of one of the H-2 protons which in turnshowed a correlation with a proton at δ_(H) 0.75 which was assigned toC-1. The remaining ¹H and ¹³C chemical shifts for C-1 and C-2 were thenassigned on the basis of additional COSY and HSQC-DEPT correlations andare summarized in the table below.

¹H and ¹³C NMR (500 and 125 MHz, pyridine-d₅), Assignments of Reb D2.Reb D2 Position ¹³C ¹H 1 41.3 0.75 t (11.0) 1.76 m 2 19.9 1.43 m 2.20 m3 38.9 0.98 m 2.36 d (12.1) 4 45.0 — 5 57.8 1.04 d (12.5) 6 22.7 1.92 m2.43 m 7 42.2 1.22 m 1.30 m 8 43.1 — 9 54.5 0.88 brs 10 40.3 — 11 21.11.65 m 1.69 m 12 37.5 1.99 m 2.25 m 13 87.1 — 14 44.5 1.80 d (11.7) 2.65d (11.7) 15 48.3 1.31 m 2.04 brs 16 154.7 — 17 105.2 5.01 s 5.64 s 1828.8 1.29 s 19 177.7 — 20 16.0 1.30 s

The other tertiary methyl singlet, observed at δ_(H) 1.30 showed HMBCcorrelations to C-1 and C-5 and was assigned as C-20. The methyl protonsshowed additional HMBC correlations to a quaternary carbon (δ_(C) 40.3)and a methine carbon (δ_(C) 54.5) which were assigned as C-10 and C-9,respectively. COSY correlations between H-5 (δ_(H) 1.04) and protons atδ_(H) 1.92 and 2.43 then allowed assignment of the H-6 protons which inturn showed correlations to protons at δ_(H) 1.22 and 1.30 which wereassigned to C-7. The ¹³C chemical shifts for C-6 (δ_(C) 22.7) and C-7(δ_(C) 42.2) were then determined from the HSQC-DEPT data. COSYcorrelations between H-9 (δ_(H) 0.88) and protons at δ_(H) 1.65 and 1.69allowed assignment of the H-11 protons which in turn showed COSYcorrelations to protons at δ_(H) 1.99 and 2.25 which were assigned asthe H-12 protons. The HSQC-DEPT data was then used to assign C-11 (δ_(C)21.1) and C-12 (δ_(C) 37.5). HMBC correlations from the H-12 proton(δ_(H) 2.25) to carbons at δ_(C) 87.1 and 154.7 allowed assignment ofC-13 and C-16, respectively. The olefinic protons observed at δ_(H) 5.01and 5.64 showed HMBC correlations to C-13 and were assigned to C-17(δ_(C) 105.2 via HSQC-DEPT). The olefinic protons H-17 and the methineproton H-9 showed HMBC correlations to a carbon at δ_(C) 48.3 which wasassigned as C-15. An additional HMBC correlation from H-9 to a methylenecarbon at δ_(C) 44.5 then allowed assignment of C-14. The ¹H chemicalshifts at C-14 (δ_(H) 1.80 and 2.65) and C-15 (δ_(H) 1.31 and 2.04) wereassigned using the HSQC-DEPT data.

Correlations observed in the NOESY spectrum were used to assign therelative stereochemistry of the central diterpene core. In the NOESYspectrum, NOE correlations were observed between H-14 and H-20indicating that H-14 and H-20 are on the same face of the rings.Similarly, NOE correlations were observed between H-9 and H-5; H-9 andH-18 as well as H-5 and H-18 but NOE correlations were not observedbetween H-9 and H-14 indicating that H-5, H-9 and H-18 were on theopposite face of the rings compared to H-14 and H-20. These dataindicated that the relative stereochemistry in the central core wasretained during the glycosylation step.

The key HMBC and COSY correlations used to assign the aglycone regionare provided below:

Analysis of the ¹H-¹³C HSQC-DEPT data confirmed the presence of fiveanomeric protons. Three of the anomeric protons were well resolved atδ_(H) 6.02 (δ_(C) 96.1), 5.57 (δ_(C) 105.3), and 5.34 (δ_(C) 105.3) inthe ¹H NMR spectrum. The remaining two anomeric protons observed atδ_(H) 5.04 (δ_(C) 105.6) and 5.07 (δ_(C) 98.7) which were obscured bysolvent (HOD) resonance in the ¹H spectrum were identified by ¹H-¹³CHSQC-DEPT data. The anomeric proton observed at δ_(H) 6.02 showed HMBCcorrelation to C-19 which indicated that it corresponds to the anomericproton of Glc_(I). Similarly, the anomeric proton observed at δ_(H) 5.07showed an HMBC correlation to C-13 allowing it to be assigned as theanomeric proton of Glc_(II).

The Glc_(I) anomeric proton (δ_(H) 6.02) showed a COSY correlation to aproton at δ_(H) 4.07 was assigned as Glc_(I) H-2 which in turn showed aCOSY correlation to a proton at δ_(H) 4.22 (Glc_(I) H-3) which showed aCOSY correlation with a proton at δ_(H) 4.12 (Glc_(I) H-4). Due to dataoverlap, the COSY spectrum did not allow assignment of H-5 or the H-6protons. Therefore, a series of 1D-TOCSY experiments were performedusing selective irradiation of the Glc_(I) anomeric proton with severaldifferent mixing times. In addition to confirming the assignments forGlc_(I) H-2 through H-4, the 1D-TOCSY data showed a proton at δ_(H) 4.04assigned as Glc_(I) H-5 and a proton at δ_(H) 4.68 assigned as one ofthe Glc_(I) H-6 protons. The latter proton was also used for 1D-TOCSYexperiments. The selective irradiation of H-6 with several differentmixing times also confirmed the assignment of Glc_(I) H-1 to H-5 as wellas the remaining methylene proton of H-6 (δ_(H) 4.30). Assignment of the¹³C chemical shifts for Glc_(I) C-2 (δ_(C) 74.2), C-3 (δ_(C) 79.1), C-4(δ_(C) 72.1), C-5 (δ_(C) 78.5), and C-6 (δ_(C) 69.9) was determinedusing the ¹H-¹³C HSQC-DEPT data to complete the assignment of Glc_(I).Furthermore, the presence of a methylene ¹³C resonance at δ_(C) 69.9 inthe ¹H-¹³C HSQC-DEPT spectrum indicated a 1→6 sugar linkage of Glc_(I)in the structure.

Out of four remaining unassigned glucose moieties, one was assigned as asubstituent at C-6 of Glc_(I) on the basis of ¹H-¹³C HSQC-DEPT, HMBC,and 1D-TOCSY correlations. The relatively downfield shift of a methylene¹³C resonance of Glc_(I) at δ_(C) 69.9 in the HSQC-DEPT spectrumindicated a 1→6 sugar linkage of Glc_(I). The anomeric proton observedat δ_(H) 5.04 showed HMBC correlation to Glc_(I) C-6 and was assigned asthe anomeric proton of Glc_(V). Similarly, methylene protons of Glc_(I)showed HMBC correlations to anomeric carbon of Glc_(V) confirming thepresence of a 1→6 sugar linkage between Glc_(I) and Glc_(V). The Glc_(V)anomeric proton showed a COSY correlation to a proton at δ_(H) 4.00which was assigned as Glc_(V) H-2 which in turn showed a COSYcorrelation to a proton at δ_(H) 4.22 (Glc_(V) H-3). Due to dataoverlap, the COSY spectrum did not allow assignment of Glc_(V) H-4 basedon the COSY correlation of Glc_(V) H-3. However, in the HMBC spectrum,Glc_(V) H-3 showed a correlation to Glc_(V) C-5 (δ_(C) 78.9). InHSQC-DEPT spectrum, Glc_(V) C-5 showed a correlation to δ_(H) 3.89(Glc_(V) H-5). The Glc_(V) H-5 showed COSY correlations to δ_(H) 4.21,4.37, and 4.48. In the HSQC-DEPT spectrum, δ_(H) 4.21 showed acorrelation to δ_(C) 71.4 (Glc_(V) H-4), while δ_(H) 4.37 and 4.48showed a correlation to δ_(C) 63.1 and were assigned to Glc_(V) H-6a andH-6b, respectively. Assignment of the ¹³C chemical shifts for Glc_(V)C-2 (δ_(C) 75.7) and C-3 (δ_(C) 79.1) was determined using the ¹H-¹³CHSQC-DEPT data to complete the assignment of Glc_(V).

A summary of the ¹H and ¹³C chemical shifts for the glycoside at C-19are shown in the following table:

¹H and ¹³C NMR (500 and 125 MHz, pyridine-d₅), Assignments of the reb D2C-19 glycoside. Reb D2 Position ¹³C ¹H Glc_(I)-1 96.1 6.02 d (8.1)Glc_(I)-2 74.2 4.07 m Glc_(I)-3 79.1^(#) 4.22 m^(#) Glc_(I)-4 72.1 4.12m Glc_(I)-5 78.5 4.04 m Glc_(I)-6 69.9 4.30 m 4.68 d (10.7) Glc_(V)-1105.6 5.04 (8.1) Glc_(V)-2 75.7 4.00 m Glc_(V)-3 79.1^(#) 4.22 m^(#)Glc_(V)-4 71.4 4.21 m Glc_(V)-5 78.9 3.89 m Glc_(V)-6 63.1 4.37 m 4.48 m^(#1)H and ¹³C values can be exchangeable between positions Glc₁-3,Glc_(V)-3 and Glc_(IV)-3.

A summary of the key HMBC, COSY, and 1D-TOCSY correlations used toassign the C-19 glycoside region are provided below.

Assignment of Glc_(II) was carried out in a similar manner. The Glc_(II)anomeric proton (δ_(H) 5.07) showed a COSY correlation to a proton atδ_(H) 4.37, assigned as Glc_(II) H-2, which in turn showed a COSYcorrelation to a proton at δ_(H) 4.18 (Glc_(II) H-3). This latter protonshowed an additional correlation with a proton at δ_(H) 3.88 (Glc_(II)H-4) which also showed a COSY correlation to a proton at δ_(H) 3.79(Glc_(II) H-5). Glc_(II) H-5 also showed a COSY correlation to Glc_(II)H-6 protons (δ_(H) 4.08 and 4.46). Assignment of the ¹³C chemical shiftsfor Glc_(II) C-2 (δ_(C) 81.3), C-3 (δ_(C) 88.4), C-4 (δ_(C) 71.1), C-5(δ_(C) 77.9), and C-6 (δ_(C) 63.2) was determined using the HSQC-DEPTdata. HMBC correlations from Glc_(II) H-3 to C-2 and C-4 and also fromGlc_(II) H-4 to C-2 and C-5 confirmed the assignments made above.Additional HMBC correlations of Glc_(II) H-4 to Glc_(II) C-6 furthersupport to complete the assignment of Glc_(II).

Two of the remaining unassigned glucose moieties were assigned assubstituents at C-2 and C-3 of Glc_(II) on the basis of HMBCcorrelations. The anomeric proton observed at δ_(H) 5.57 showed a HMBCcorrelation to Glc_(II) C-2 and was assigned as the anomeric proton ofGlc_(III). The anomeric proton observed at δ_(H) 5.34 showed a HMBCcorrelation to Glc_(II) C-3 and was assigned as the anomeric proton ofGlc_(IV). The reciprocal HMBC correlations from Glc_(II) H-2 to theanomeric carbon of Glc_(III) and from Glc_(II) H-3 to the anomericcarbon of Glc_(IV) were also observed.

The anomeric proton of Glc_(III) (δ_(H) 5.57) showed a COSY correlationwith a proton at δ_(H) 4.19 which was assigned as Glc_(III) H-2. Due todata overlap, the COSY spectrum did not allow assignment of H-3 to H-6protons. Therefore, a series of 1D-TOCSY experiments were performedusing selective irradiation of the Glc_(III) anomeric proton withseveral different mixing times. In addition to confirming theassignments for Glc_(III) H-2, the 1D-TOCSY data showed protons at δ_(H)4.24 (Glc_(III) H-3), δ_(H) 4.27 (Glc_(III) H-4), and δ_(H) 3.94(Glc_(III) H-5). Once H-4 was assigned using 1D-TOCSY data, COSYcorrelations from H-4 to H-5 and in turn to H-6 were used to assign H-6.In the COSY spectrum, Glc_(III) H-4 showed a correlation to Glc_(III)H-5, which in turn showed COSY correlations to δ_(H) 4.41 and 4.50 ofGlc_(III) H-6a and H-6b, respectively. The ¹³C chemical shifts forGlc_(III) C-2 (δ_(C) 76.8), C-3 (δ_(C) 78.9), C-4 (δ_(C) 72.4), C-5(δ_(C) 78.8), and C-6 (δ_(C) 63.5) were then determined using the ¹H-¹³CHSQC-DEPT correlations to complete the assignment of Glc_(III).

The anomeric proton of Glc_(IV) (δ_(H) 5.34) showed a COSY correlationwith a proton at δ_(H) 4.06 which was assigned as Glc_(IV) H-2. Due todata overlap, the COSY spectrum did not allow assignment of H-3 to H-6protons. Therefore, a series of 1D-TOCSY experiments were performedusing selective irradiation of the Glc_(IV) anomeric proton with severaldifferent mixing times. In addition to confirming the assignments forGlc_(IV) H-2, the 1D-TOCSY data showed protons at δ_(H) 4.22 (Glc_(IV)H-3), δ_(H) 4.18 (Glc_(IV) H-4), and δ_(H) 4.10 (Glc_(IV) H-5). Once H-4was assigned using 1D-TOCSY data, COSY correlations from H-4 to H-5 andin turn to H-6 were used to assign H-6. In the COSY spectrum, Glc_(IV)H-4 showed a correlation to Glc_(IV) H-5, which in turn showed COSYcorrelations to δ_(H) 4.32 and 4.58, Glc_(IV) H-6a and H-6b,respectively. The ¹³C chemical shifts for Glc_(IV) C-2 (δ_(C) 75.8), C-3(δ_(C) 78.9), C-4 (δ_(C) 72.0), C-5 (δ_(C) 79.3), and C-6 (δ_(C) 62.9)were then determined using the ¹H-¹³C HSQC-DEPT correlations to completethe assignment of Glc_(IV).

The large coupling constants observed for the anomeric protons of theglucose moieties at δ_(H) 6.02 (d, J=8.1 Hz), 5.57 (d, J=7.6 Hz), 5.34(d, J=7.9 Hz) and δ_(H) 5.04 (d, J=8.1 Hz), suggested theirβ-orientation. While the remaining anomeric proton at δ_(H) 5.07 wasobscured by the solvent resonance (HDO) it's coupling constant (J=˜8 Hz)evident from 1D TOCSY data also indicated β-orientation.

A summary of the ¹H and ¹³C chemical shifts for the glycoside at C-13are shown in the table below:

¹H and ¹³C NMR (500 and 125 MHz, pyridine-d₅), Assignments of the Reb D2C-13 glycoside. Reb D2 Position ¹³C ¹H Glc_(II)-1 98.7 5.07 (~8)*Glc_(II)-2 81.3 4.37 m Glc_(II)-3 88.4 4.18 m Glc_(II)-4 71.1 3.88 mGlc_(II)-5 77.9 3.79 m Glc_(II)-6 63.2 4.08 m 4.47 m Glc_(III)-1 105.35.57 d (7.6) Glc_(III)-2 76.8 4.19 m Glc_(III)-3 78.9 4.24 m Glc_(III)-472.4 4.27 m Glc_(III)-5 78.8 3.94 m Glc_(III)-6 63.5 4.41 m 4.50 mGlc_(IV)-1 105.3 5.34 d (7.9) Glc_(IV)-2 75.8 4.06 m Glc_(IV)-3 78.9^(#)4.22 m^(#) Glc_(IV)-4 72.0 4.18 m Glc_(IV)-5 79.3 4.10 m Glc_(IV)-6 62.94.32 m 4.58 m *Anomeric proton was obscured by solvent (HDO) resonance,coupling constant value obtained from 1D-TOCSY data. ^(#1)H and ¹³Cvalues can be exchangeable between Glc₁-3, Glc_(V)-3 and Glc_(IV)-3.

A summary of the key HMBC, COSY, and 1D-TOCSY correlations used toassign the C-13 glycoside region are provided below:

The chemical name of the compound is13-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]ent-kaur-16-en-19-oic acid-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)ester] (rebaudioside D2 or reb D2). The compound is an isomer ofrebaudioside D.

Example 40 Isolation and Characterization of Reb M2

Crude Reaction Sample.

The sample, Lot CB-2977-106, used for isolation was prepared accordingto Example 22 with UGTSL (GI #460409128).

HPLC Analysis.

Preliminary HPLC analyses was performed using a Waters 2695 AllianceSystem with the following method: Phenomenex Synergi Hydro-RP, 4.6×250mm, 4 m (p/n 00G-4375-E0); Column Temp: 55° C.; Mobile Phase A: 0.0284%NH₄OAc and 0.0116% HOAc in water; Mobile Phase B: Acetonitrile (MeCN);Flow Rate: 1.0 mL/min; Injection volume: 10 μL. Detection was by UV (210nm) and CAD.

Gradient:

Time (min) % A % B 0.0-5.0 100 0 20 20 80 25 20 80 30 100 0

Analyses of semi-preparative purification fractions were performed withthe following method: Waters Atlantis dC18, 4.6×100 mm, 5 m (p/n186001340); Mobile Phase A: 25% MeCN in water; Mobile Phase B: 30% MeCNin water; Flow Rate: 1.0 mL/min; Injection volume: 10 μL. Detection wasby CAD.

Gradient:

Time (min) % A % B 0.0-8.5 75 25 10.0 71 29 16.5 70 30 18.5-24.5 66 3426.5-29.0 48 52 31-37 30 70 38   75 25LC-MS.

Preliminary analysis of the semi-synthetic steviol glycoside mixture wascarried out on a Waters AutoPurification HPLC/MS System with a Waters3100 Mass Detector operating in negative ion mode. Analysis of thesample was performed using the following method: Phenomenex SynergiHydro-RP, 4.6×250 mm, 4 m (p/n 00G-4375-E0); Column Temp: 55° C.; MobilePhase A: 0.0284% NH₄OAc and 0.0116% HOAc in water; Mobile Phase B: MeCN;Flow Rate: 1.0 mL/min; Injection volume: 10 μL. Detection was by UV (210nm), and MSD (−ESI m/z 500-2000). Gradient conditions were as listedabove.

Isolation by HPLC.

The purification was performed in two steps. The first method used forthe semi-preparative purification is summarized below. Column: WatersAtlantis dC18, 30×100 mm, 5 m (p/n 186001375); Mobile Phase A: 25% MeCNin water; Mobile Phase B: 30% MeCN in water; Flow Rate: 45 mL/min;Injection load: 160 mg dissolved in 20 mL of water. Detection was by UV(205 nm).

Gradient:

Time (min) % A % B 0.0-5.0 100 0 20 20 80 25 20 80 30 100 0

The secondary purification used the same column and conditions, butisocratic mobile phase: 20% MeCN in water.

MS and MS/MS.

MS and MS/MS data were generated with a Waters QTof Premier massspectrometer equipped with an electrospray ionization source. Sampleswere analyzed by negative ESI. Samples were diluted with H₂O:MeCN (1:1)by 50 fold and introduced via infusion using the onboard syringe pump.The samples were diluted to yield good s/n which occurred at anapproximate concentration of 0.01 mg/mL.

NMR.

The sample was prepared by dissolving ˜1.0 mg in 150 μL of D₂O and NMRdata were acquired on a Bruker Avance 500 MHz instrument with a 2.5 mminverse detection probe. The ¹H NMR and ¹³C NMR spectra were referencedto the residual solvent signal HDO (δ_(H) 4.79 ppm) and TSP (δ_(C) 0.00ppm), respectively.

Results and Discussion

Isolation and Purification.

Isolation was performed using on a steviol glycoside mixture, Lot numberCB-2977-106, prepared according to Example 22 with UGTSL (GI#460409128). The material was analyzed by LC-MS using the methoddescribed above (FIG. 6). The targeted peak of interest was that at 4.1min in the TIC chromatogram. The mass spectrum of this peak provided a[M-H]⁻ ion at m/z 1289.7. The provided sample was preliminarilyprocessed in a single injection (160 mg) using the first methodcondition provided above. This method fractionated the material into‘polar’ and ‘non-polar’ mixtures of glycosides. The ‘polar’ mixture wasthen reprocessed using the second-step conditions provided above. Fromthis semi-preparative collection, the peak was isolated with apurity >99% (CAD, AUC). Following the purification, the fractions wereconcentrated by rotary evaporation at 35° C. and lyophilized.Approximately 1 mg was obtained.

Mass Spectrometry.

The ESI-TOF mass spectrum acquired by infusing a sample of CC-00300showed a [M-H]⁻ ion at m/z 1289.5266. The mass of the [M-H]⁻ ion was ingood agreement with the molecular formula C₅₆H₉₀O₃₃ (calcd forC₅₆H8₉O₃₃: 1289.5286, error: −1.6 ppm) expected for reb M2. The MS dataconfirmed that CC-00300 has a nominal mass of 1290 Daltons with themolecular formula, C₅₆H₉₀O₃₃.

The MS/MS spectrum (selecting the [M-H]⁻ ion at m/z 1289.5 forfragmentation) indicated the loss of three glucose units at m/z 803.3688and sequential loss of three glucose moieties at m/z 641.3165, 479.2633and 317.2082.

NMR Spectroscopy.

A series of NMR experiments including ¹H NMR (FIG. 18), ¹³C NMR (FIGS.19 and 20), ¹H-¹H COSY (FIG. 21), HSQC-DEPT (FIG. 22), HMBC (FIGS. 23and 24), and 1D-TOCSY were performed to allow assignment of reb M2.

The ¹H, ¹H-¹H COSY, ¹H-¹³C HSQC-DEPT and ¹H-¹³C HMBC NMR data indicatedthat the central core of the glycoside is a diterpene. The presence ofsix anomeric protons observed in the ¹H and ¹H-¹³C HSQC-DEPT spectraconfirm six sugar units in the structure. The methylene ¹³C resonance atδ_(C) 70.9 in the ¹H-¹³C HSQC-DEPT spectrum indicated the presence of a1→6 sugar linkage in the structure. The linkages of sugar units wereassigned using ¹H-¹³C HMBC and 1D-TOCSY correlations.

A HMBC correlation from the methyl protons at δ_(H) 1.29 to the carbonylat δ_(C) 181.5 allowed assignment of one of the tertiary methyl groups(C-18) as well as C-19 and provided a starting point for the assignmentof the rest of the aglycone. Additional HMBC correlations from themethyl protons (H-18) to carbons at δ_(C) 39.8, 43.7, and 59.2 allowedassignment of C3, C4, and C5. Analysis of the ¹H-¹³C HSQC-DEPT dataindicated that the carbon at δ_(C) 39.8 was a methylene group and thecarbon at δ_(C) 59.2 was a methine which were assigned as C-3 and C-5,respectively. This left the carbon at δ_(C) 43.7, which did not show acorrelation in the HSQC-DEPT spectrum, to be assigned as the quaternarycarbon, C-4. The ¹H chemical shifts for C-3 (δ_(H) 1.16 and 2.28) andC-5 (δ_(H) 1.24) were assigned using the HSQC-DEPT data. A COSYcorrelation between one of the H-3 protons (δ_(H) 1.16) and a proton atδ_(H) 1.49 allowed assignment of one of the H-2 protons which in turnshowed a correlation with a proton at δ_(H) 0.92 which was assigned toC-1. The remaining ¹H and ¹³C chemical shifts for C-1 and C-2 were thenassigned on the basis of additional COSY and HSQC-DEPT correlations andare summarized in the table below.

¹H NMR (500 MHz, D₂O) and ¹³C NMR (125 MHz, D₂O/TSP) Assignments of theReb M2 aglycone. Position ¹³C ¹H 1 41.9 0.92 m 1.93 m 2 21.8 1.49 m 1.86m 3 39.8 1.16 m 2.28 d (13.4) 4 43.7 — 5 59.2 1.24 d (12.1) 6 24.4 1.73m 1.94 m 7 44.2 1.49 m 1.56 m 8 46.9 — 9 55.5 1.09 d (7.7) 10 42.4 — 1122.6 1.66 m 1.70 m 12 39.9 1.60 m 2.00 m 13 90.9 — 14 46.9 1.53 d (12.6)2.21 d (13.6) 15 49.4 2.15 d (17.2) 2.18 d (18.1) 16 164.0 — 17 107.04.98 s 5.16 s 18 31.0 1.29 s 19 181.5 — 20 19.1 0.92 s

The other tertiary methyl singlet, observed at δ_(H) 0.92 showed HMBCcorrelations to C-1 and C-5 and was assigned as C-20. The methyl protonsshowed additional HMBC correlations to a quaternary carbon (δ_(C) 42.4)and a methine (δ_(C) 55.5) which were assigned as C-10 and C-9,respectively. COSY correlations between H-5 (δ_(H) 1.24) and protons atδ_(H) 1.73 and 1.94 then allowed assignment of the H-6 protons which inturn showed correlations to protons at δ_(H) 1.49 and 1.56 which wereassigned to C-7. The ¹³C chemical shifts for C-6 (δ_(C) 24.4) and C-7(δ_(C) 44.2) were then determined from the HSQC-DEPT data. COSYcorrelations between H-9 (δ_(H) 1.09) and protons at δ_(H) 1.66 and 1.70allowed assignment of the H-11 protons which in turn showed COSYcorrelations to protons at δ_(H) 1.60 and 2.00 which were assigned asthe H-12 protons. The HSQC-DEPT data was then used to assign C-11 (δ_(C)22.6) and C-12 (δ_(C) 39.9). The olefinic protons observed at δ_(H) 4.98and 5.16 showed HMBC correlations to C-13 (δ_(C) 90.9) and were assignedto C-17 (δ_(C) 107.0 via HSQC-DEPT). The olefinic protons H-17 showedHMBC correlations to a carbon at δ_(C) 49.4 which was assigned as C-15.An additional HMBC correlation from H-9 to a methylene carbon at δ_(C)46.9 then allowed assignment of C-14. The ¹H chemical shifts at C-14(δ_(H) 1.53 and 2.21) and C-15 (δ_(H) 2.15 and 2.18) were assigned usingthe HSQC-DEPT data.

A summary of the key HMBC and COSY correlations used to assign theaglycone region are provided below:

Analysis of the ¹H-¹³C HSQC-DEPT data confirmed the presence of sixanomeric protons. Three of the anomeric protons were well resolved atδ_(H) 5.65 (δ_(C) 95.5), 4.92 (δ_(C) 104.9), and 4.50 (δ_(C) 105.7) inthe ¹H NMR spectrum. The remaining three anomeric protons observed atδ_(H) 4.85 (δ_(C) 98.4), 4.84 (δ_(C) 105.0), and 4.83 (δ_(C) 105.3) wereoverlapped by the residual solvent resonance in the ¹H spectrum. Theanomeric proton observed at δ_(H) 5.65 showed a HMBC correlation to C-19which indicated that it corresponds to the anomeric proton of Glc_(I).Similarly, the anomeric proton observed at δ_(H) 4.85 showed a HMBCcorrelation to C-13 allowing it to be assigned as the anomeric proton ofGlc_(II).

The Glc_(I) anomeric proton (δ_(H) 5.65) showed a COSY correlation to aproton at δ_(H) 3.96 which was assigned as Glc_(I) H-2 which in turnshowed a COSY correlation to a proton at δ_(H) 3.89 (Glc_(I) H-3) whichshowed a COSY correlation with a proton at δ_(H) 3.71 (Glc_(I) H-4). Dueto data overlap, the COSY spectrum did not allow assignment of the H-5or H-6 protons. Therefore, a series of 1D-TOCSY experiments wereperformed using selective irradiation of the Glc_(I) anomeric protonwith several different mixing times. In addition to confirming theassignments for Glc_(I) H-2 through H-4, the 1D-TOCSY data showed aproton at δ_(H) 3.73 assigned as Glc_(I) H-5 and a proton at δ_(H) 4.15assigned as one of the Glc_(I) H-6 protons. The latter proton was alsoused for 1D-TOCSY experiments. The selective irradiation of H-6 withseveral different mixing times also confirmed the assignment of Glc_(I)H-1 to H-5 as well as the remaining methylene proton of H-6 (δ_(H)4.00). Assignment of the ¹³C chemical shifts for Glc_(I) C-2 (δ_(C)80.5), C-3 (δ_(C) 79.0), C-4 (δ_(C) 71.5), C-5 (δ_(C) 79.0), and C-6(δ_(C) 70.9) was determined using the ¹H-¹³C HSQC-DEPT data to completethe assignment of Glc_(I). Furthermore, the presence of a methylene ¹³Cresonance at δ_(C) 70.9 in the ¹H-¹³C HSQC-DEPT spectrum indicated a 1→6sugar linkage of Glc_(I) in the structure.

Two of the unassigned glucose moieties were assigned as substituents atC-2 and C-6 of Glc_(I) on the basis of HMBC correlations. The anomericproton observed at δ_(H) 4.83 showed an HMBC correlation to Glc_(I) C-2and was assigned as the anomeric proton of Glc_(V). The anomeric protonobserved at δ_(H) 4.50 showed a HMBC correlation to Glc_(I) C-6 and wasassigned as the anomeric proton of Glc_(VI). The reciprocal HMBCcorrelations from Glc_(I) H-2 to the anomeric carbon of Glc_(V) and fromGlc_(I) H-6 to the anomeric carbon of Glc_(VI) were also observed.

The anomeric proton of Glc_(V) (δ_(H) 4.83) showed a COSY correlationwith a proton at δ_(H) 3.32 which was assigned as Glc_(V) H-2. TheGlc_(V) H-2 in turn showed a COSY correlation to a proton at δ_(H) 3.51(Glc_(V) H-3). This latter proton showed an additional correlation witha proton at δ_(H) 3.38 (Glc_(V) H-4). H-4 also showed a COSY correlationto a proton at δ_(H) 3.55 (Glc_(V) H-5) and Glc_(V) H-5 in turn showed aCOSY correlation to Glc_(V) H-6 protons (δ_(H) 3.76 and 3.97).Assignment of the ¹³C chemical shifts for Glc_(V) C-2 (δ_(C) 78.5), C-3(δ_(C) 78.7), C-4 (δ_(C) 72.9), C-5 (δ_(C) 78.8), and C-6 (δ_(C) 63.6)was determined using the HSQC-DEPT data. HMBC correlations from Glc_(V)H-3 to C-2 and C-4 and also from Glc_(V) H-4 to C-3 and C-6 confirmedthe assignments made above to complete the assignment of Glc_(V).

Another glucose moiety was assigned as a substituent at C-6 of Glc_(I)on the basis of ¹H-¹³C HSQC-DEPT and HMBC correlations. The relativelydownfield shift of a methylene ¹³C resonance of Glc_(I) at δ_(C) 70.9 inthe HSQC-DEPT spectrum indicated a 1→6 sugar linkage of Glc_(I). Theanomeric proton observed at δ_(H) 4.50 showed a HMBC correlation toGlc_(I) C-6 and was assigned as the anomeric proton of Glc_(VI).Similarly, methylene protons of Glc_(I) showed HMBC correlations to theanomeric carbon of Glc_(VI) and this confirmed the presence of a 1→6sugar linkage between Glc_(I) and Glc_(VI). The Glc_(VI) anomeric protonshowed a COSY correlation to a proton at δ_(H) 3.33 which was assignedas Glc_(VI) H-2 which in turn showed a COSY correlation to a proton atδ_(H) 3.49 (Glc_(VI) H-3). Due to data overlap, the COSY spectrum didnot allow assignment of Glc_(V) H-4 to H-6 based on the COSYcorrelations. Therefore, a series of 1D-TOCSY experiments were performedusing selective irradiation of the Glc_(VI) anomeric proton withdifferent mixing times. In addition to confirming the assignments forGlc_(VI) H-2 through H-3, the 1D-TOCSY data showed protons at δ_(H) 3.45(Glc_(VI) H-4) and δ_(H) 3.48 (Glc_(VI) H-5) and protons at δ_(H) 3.92and 3.94 assigned for Glc_(VI) H-6 protons. Assignment of the ¹³Cchemical shifts for Glc_(VI) C-2 (δ_(C) 78.1), C-3 (δ_(C) 78.6), C-4(δ_(C) 72.3), C-5 (δ_(C) 78.8), and C-6 (δ_(C) 64.1) was determinedusing the ¹H-¹³C HSQC-DEPT data to complete the assignment of Glc_(VI).

A summary of the ¹H and ¹³C chemical shifts for the glycoside at C-19are found in the table below:

¹H NMR (500 MHz, D₂O) and ¹³C NMR (125 MHz, D₂O/TSP) Assignments of theReb M2 glycoside. Position ¹³C ¹H Glc_(I)-1 95.5 5.65 d (7.6) Glc_(I)-280.5 3.96 m Glc_(I)-3 79.0 3.89 m Glc_(I)-4 71.5 3.71 m Glc_(I)-5 79.03.73 m Glc_(I)-6 70.9 4.00 m 4.15 d (11.7) Glc_(V)-1 105.3* 4.83* d(8.0) Glc_(V)-2 78.5 3.32 m Glc_(V)-3 78.7 3.51 m Glc_(V)-4 72.9 3.38 mGlc_(V)-5 78.8 3.55 m Glc_(V)-6 63.6 3.76 m 3.97 m Glc_(VI)-1 105.7 4.50d (7.9) Glc_(VI)-2 78.1 3.33 m Glc_(VI)-3 78.6 3.49 m Glc_(VI)-4 72.33.45 m Glc_(VI)-5 78.8 3.48 m Glc_(VI)-6 64.1 3.92 m 3.94 m *¹H and ¹³Cvalues can be exchangeable with Glc_(IV)-1 of the following table.

A summary of the key HMBC, COSY, and 1D-TOCSY correlations used toassign the C-19 glycoside region are provided below:

¹H NMR (500 MHz, D₂O) and ¹³C NMR (125 MHz, D₂O/TSP) Assignments of theReb M2 glycoside. Position ¹³C^(#) ¹H Glc_(II)-1 98.4 4.85 d (7.8)Glc_(II)-2 81.7 3.75 m Glc_(II)-3 88.0 3.98 m Glc_(II)-4 71.3 3.54 mGlc_(II)-5 80.5 3.96 m Glc_(II)-6 63.6 3.45 m 3.77 m Glc_(III)-1 104.94.92 d (7.9) Glc_(III)-2 76.3 3.32 m Glc_(III)-3 78.8 3.51 m Glc_(III)-473.3 3.26 t (9.5) Glc_(III)-5 78.8 3.44 m Glc_(III)-6 64.4 3.75 m 3.94 mGlc_(IV)-1 105.0 4.84 d (7.8) Glc_(IV)-2 76.1 3.41 m Glc_(IV)-3 78.83.46 m Glc_(IV)-4 72.5 3.45 m Glc_(IV)-5 81.7 3.75 m Glc_(IV)-6 65.83.55 m 3.78 m

Assignment of Glc_(II) was carried out in a similar manner. The Glc_(II)anomeric proton (δ_(H) 4.85) showed a COSY correlation to a proton atδ_(H) 3.75 which was assigned as Glc_(II) H-2 which in turn showed aCOSY correlation to a proton at δ_(H) 3.98 (Glc_(II) H-3). This latterproton showed an additional correlation with a proton at δ_(H) 3.54(Glc_(II) H-4). H-4 also showed a COSY correlation to a proton at δ_(H)3.96 (Glc_(II) H-5). Glc_(II) H-5 also showed a COSY correlation toGlc_(II) H-6 protons (δ_(H) 3.77 and 3.45). Assignment of the ¹³Cchemical shifts for Glc_(II) C-2 (δ_(C) 81.7), C-3 (δ_(C) 88.0), C-4(δ_(C) 71.3), C-5 (δ_(C) 80.5), and C-6 (δ_(C) 63.6) was determinedusing the HSQC-DEPT data. HMBC correlations from Glc_(II) H-3 to C-2 andC-4 and also from Glc_(II) H-4 to C-3 and C-6 confirmed the assignmentsmade above to complete the assignment of Glc_(II).

Two of the remaining unassigned glucose moieties were assigned assubstituents at C-2 and C-3 of Glc_(II) on the basis of HMBCcorrelations. The anomeric proton observed at δ_(H) 4.92 showed a HMBCcorrelation to Glc_(II) C-2 and was assigned as the anomeric proton ofGlc_(III). The anomeric proton observed at δ_(H) 4.84 showed a HMBCcorrelation to Glc_(II) C-3 and was assigned as the anomeric proton ofGlc_(IV). The reciprocal HMBC correlations between Glc_(II) H-2 and theanomeric carbon of Glc_(III) and between Glc_(II) H-3 and the anomericcarbon of Glc_(IV) were also observed.

The anomeric proton of Glc_(III) (δ_(H) 4.92) showed a COSY correlationwith a proton at δ_(H) 3.32 which was assigned as Glc_(III) H-2. Due todata overlap, the COSY spectrum did not allow assignment of H-3 to H-6protons. Therefore, a series of 1D-TOCSY experiments were performedusing selective irradiation of the Glc_(III) anomeric proton withdifferent mixing times. In addition to confirming the assignments forGlc_(III) H-2, the 1D-TOCSY data showed protons at δ_(H) 3.51 (Glc_(III)H-3), δ_(H) 3.26 (Glc_(III) H-4), and δ_(H) 3.44 (Glc_(III) H-5). OnceH-4 was assigned using 1D-TOCSY data, COSY correlations from H-4 to H-5and in turn to H-6 were used to assign H-6. In the COSY spectrum,Glc_(III) H-4 showed a correlation to Glc_(III) H-5, which in turnshowed COSY correlations to δ_(H) 3.94 and 3.75 of Glc_(III) H-6a andH-6b, respectively. The ¹³C chemical shifts for Glc_(III) C-2 (δ_(C)76.3), C-3 (δ_(C) 78.8), C-4 (δ_(C) 73.3), C-5 (δ_(C) 78.8), and C-6(δ_(C) 64.4) were then determined using the ¹H-¹³C HSQC-DEPTcorrelations to complete the assignment of Glc_(III).

The anomeric proton of Glc_(IV) (δ_(H) 4.84) which showed a COSYcorrelation to a proton at δ_(H) 3.41 was assigned as Glc_(IV) H-2 whichin turn showed a COSY correlation to a proton at δ_(H) 3.46 (Glc_(IV)H-3). This latter proton showed an additional correlation with a protonat δ_(H) 3.45 (Glc_(IV) H-4) which also showed a COSY correlation to aproton at δ_(H) 3.75 (Glc_(IV) H-5). Glc_(IV) H-5 also showed a COSYcorrelation to Glc_(IV) H-6 protons (δ_(H) 3.55 and 3.78). Assignment ofthe ¹³C chemical shifts for Glc_(IV) C-2 (δ_(C) 76.1), C-3 (δ_(C) 78.8),C-4 (δ_(C) 72.5), C-5 (δ_(C) 81.7), and C-6 (δ_(C) 65.8) was determinedusing the HSQC-DEPT data. HMBC correlations from Glc_(IV) H-3 to C-4 andC-5 and also from Glc_(IV) H-4 to C-3 and C-6 confirmed the assignmentsmade above to complete the assignment of Glc_(IV).

A summary of the ¹H and ¹³C chemical shifts for the glycoside at C-13are found in the following table:

¹H NMR (500 MHz, D₂O) and ¹³C NMR (125 MHz, D₂O/TSP) Assignments of theReb M2 glycoside. Position ¹³C^(#) ¹H Glc_(II)-1 98.4 4.85 d (7.8)Glc_(II)-2 81.7 3.75 m Glc_(II)-3 88.0 3.98 m Glc_(II)-4 71.3 3.54 mGlc_(II)-5 80.5 3.96 m Glc_(II)-6 63.6 3.45 m 3.77 m Glc_(III)-1 104.94.92 d (7.9) Glc_(III)-2 76.3 3.32 m Glc_(III)-3 78.8 3.51 m Glc_(III)-473.3 3.26 t (9.5) Glc_(III)-5 78.8 3.44 m Glc_(III)-6 64.4 3.75 m 3.94 mGlc_(IV)-1 105.0 4.84 d (7.8) Glc_(IV)-2 76.1 3.41 m Glc_(IV)-3 78.83.46 m Glc_(IV)-4 72.5 3.45 m Glc_(IV)-5 81.7 3.75 m Glc_(IV)-6 65.83.55 m 3.78 m

A summary of the key HMBC, COSY, and 1D-TOCSY correlations used toassign the C-13 glycoside region are provided below:

NMR and MS analyses allowed a full assignment of its structure, shownbelow. The chemical name of the compound is13-[(2-O-β-D-glucopyranosyl-3-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]ent-kaur-16-en-19-oicacid-[(2-O-β-D-glucopyranosyl-6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)ester] (rebaudioside M2 or reb M2). The compound is an isomer ofrebaudioside M.

Example 41 Directed Evolution of UGT76G1 for the Conversion ofRebaudioside D to Rebaudioside M (Round 2)

The most active clone from the first round of directed evolution ofUGT76G1 (see EXAMPLE 26 UGT76G1var94 containing mutations:Q266E_P272A_R334K_G348P_L379G) was chosen as baseline clone for round 2.A list of 53 mutations was established containing different identifiedpositive mutations from the first round and new mutations obtained byDNA2.0 ProteinGPS™ strategy. This list of mutations was subsequentlyused to design 92 variant genes that contained each 3 differentmutations. After codon-optimized for expression in E. coli the geneswere synthesized, subcloned in the pET30a+ plasmid and used fortransformation of E. coli BL21 (DE3) chemically competent cells. Theobtained cells were grown in Petri-dishes on solid LB medium in thepresence of Kanamycin. Suitable colonies were selected and allowed togrow in liquid LB medium in tubes. Glycerol was added to the suspensionas cryoprotectant and 400 μL aliquots were stored at −20° C. and at −80°C.

These storage aliquots of E. coli BL21(DE3) containing thepET30a+_UGT76G1var plasmids were thawed and added to LBGKP medium (20g/L Luria Broth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM Phosphatebuffer pH 7.00; 2.5 g/L glucose and 50 mg/L of Kanamycine). This culturewas allowed to shake in a 96 microtiter plate at 30° C. for 8 h.

3.95 mL of production medium containing 60 g/L of Overnight Express™Instant TB medium (Novagen®), 10 g/L of glycerol and 50 mg/L ofKanamycin was inoculated with 50 μL of above described culture. In a 48deepwell plate the resulting culture was allowed to stir at 20° C. Thecultures gave significant growth and a good OD (600 nm) was obtained.After 44 h, the cells were harvested by centrifugation and frozen.

Lysis was performed by addition of Bugbuster® Master mix (Novagen®) tothe thawed cells and the lysate was recovered by centrifugation.Activity tests were performed with 100 μL of fresh lysate that was addedto a solution of Rebaudioside D (final concentration 0.5 mM), MgCl₂(final concentration 3 mM) and UDP-Glucose (final concentration 2.5 mM)in 50 mM phosphate buffer pH 7.2.

The reaction was allowed to run at 30° C. and samples were taken after2, 4, 7 and 24 h. to determine conversion and initial rate by HPLC (CADdetection) using the analytical method that was described above for thetransformation of Rebaudioside D to Rebaudioside M. In parallel theexperiments were performed with baseline clone, Round1-Var94. Theconversion after 22 h. and initial rate for this baseline clone wasdefined as 100% and the normalized conversions and initial rates for theround 2 clones are depicted in the following table:

Normalized conversion Normalized initial Clone Mutations* Reb D to Reb Mafter 22 h. rate (0-4 h) Round1-Var94 UGT76G1 100%  100% (Q266E_P272A_R334K_G348P_L379G) baseline clone Round2-Var1 Round1-Var94(A213N_P348G_I411V) 70% 86% Round2-Var2 Round1-Var94 (K303G_I423M_Q425E)120%  134%  Round2-Var3 Round1-Var94 (V20L_N138K_S147G) 14% 15%Round2-Var4 Round1-Var94 (I16V_V133A_L299I) 37% 43% Round2-Var5Round1-Var94 (S241V_S274G_Q432E) 75% 72% Round2-Var6 Round1-Var94(I16V_L139V_I218V) 62% 68% Round2-Var7 Round1-Var94 (K334R_N409K_Q432E)104%  92% Round2-Var8 Round1-Var94 (I15L_R141T_I407V) 17% 26%Round2-Var9 Round1-Var94 (R141T_K303G_G379L) 31% 42% Round2-Var10Round1-Var94 (I190L_K303G_P348G) 131%  149%  Round2-Var11 Round1-Var94(E266Q_F314S_N409R) 106%  132%  Round2-Var12 Round1-Var94(V133A_I295V_K303G) 43% 49% Round2-Var13 Round1-Var94 (I16V_S241V_N409R)80% 79% Round2-Var14 Round1-Var94 (A239V_K334R_G379L) 58% 55%Round2-Var15 Round1-Var94 (I190L_K393R_V396L) 118%  126%  Round2-Var16Round1-Var94 (L101F_I295M_K393R) 84% 89% Round2-Var17 Round1-Var94(A239V_E266Q_Q425E) 96% 101%  Round2-Var18 Round1-Var94(V20L_I190L_I423M) 98% 98% Round2-Var19 Round1-Var94 (V20L_G379L_S456L)84% 81% Round2-Var20 Round1-Var94 (K334R_P348G_N409R) 73% 73%Round2-Var21 Round1-Var94 (E231A_S241V_E449D) 53% 50% Round2-Var22Round1-Var94 (K188R_L299I_V394I) 56% 59% Round2-Var23 Round1-Var94(E231A_S274G_V394I) 110%  124%  Round2-Var24 Round1-Var94(S42A_I295V_Q432E) 71% 78% Round2-Var25 Round1-Var94 (A213N_A272P_K334R)95% 80% Round2-Var26 Round1-Var94 (L158Y_S274K_N409K) 80% 50%Round2-Var27 Round1-Var94 (K188R_I295M_Q425E) 132%  116%  Round2-Var28Round1-Var94 (I15L_I295M_V394I) 53% 36% Round2-Var29 Round1-Var94(V133A_A239V_V394I) 47% 30% Round2-Var30 Round1-Var94(L158Y_F314S_K316R) 107%  72% Round2-Var31 Round1-Var94(L158Y_A239V_A272P) 54% 30% Round2-Var32 Round1-Var94 (F46I_D301N_V396L)109%  101%  Round2-Var33 Round1-Var94 (L101F_I218V_Q432E) 78% 54%Round2-Var34 Round1-Var94 (I16V_F46I_I295M) 110%  95% Round2-Var35Round1-Var94 (A213N_E266S_I407V) 98% 79% Round2-Var36 Round1-Var94(A239V_S274K_I295M) 102%  89% Round2-Var37 Round1-Var94(A239V_F314S_S450K) 105%  99% Round2-Var38 Round1-Var94(L139V_K188R_D301N) 66% 51% Round2-Var39 Round1-Var94 (I45V_I218V_S274K)87% 58% Round2-Var40 Round1-Var94 (S241V_K303G_V394I) 78% 57%Round2-Var41 Round1-Var94 (R141T_S274G_K334R) 41% 28% Round2-Var42Round1-Var94 (V217L_S274G_L299I) 47% 34% Round2-Var43 Round1-Var94(S274G_D301N_P348G) 98% 91% Round2-Var44 Round1-Var94(E231A_N409R_S450K) 87% 65% Round2-Var45 Round1-Var94 (R64H_E231A_K316R)88% 64% Round2-Var46 Round1-Var94 (V394I_N409K_I411V) 110%  100% Round2-Var47 Round1-Var94 (I45V_I295M_K303G) 113%  88% Round2-Var48Round1-Var94 (L101F_V396L_L398V) 46% 43% Round2-Var49 Round1-Var94(N27S_L101F_S447A) 54% 37% Round2-Var50 Round1-Var94 (S274G_F314S_L398V)129%  156%  Round2-Var51 Round1-Var94 (E266Q_L299I_K393R) 70% 51%Round2-Var52 Round1-Var94 (V217L_E266S_V394I) 62% 48% Round2-Var53Round1-Var94 (N138K_A272P_N409R) 118%  102%  Round2-Var54 Round1-Var94(E266S_F314S_Q432E) 124%  146%  Round2-Var55 Round1-Var94(D301N_G379L_L398V) 56% 45% Round2-Var56 Round1-Var94 (F46I_E266S_K334R)123%  142%  Round2-Var57 Round1-Var94 (A272P_V394I_Q432E) 133%  142% Round2-Var58 Round1-Var94 (V394I_I407V_S456L) 118%  114%  Round2-Var59Round1-Var94 (I218V_E266Q_I423M) 106%  98% Round2-Var60 Round1-Var94(A272P_G379L_I407V) 80% 63% Round2-Var61 Round1-Var94(E231A_K303G_S456L) 113%  110%  Round2-Var62 Round1-Var94(I190L_E266Q_I407V) 150%  167%  Round2-Var63 Round1-Var94(N27S_L139V_I295V) 43% 25% Round2-Var64 Round1-Var94 (V217L_I423M_S447A)67% 51% Round2-Var65 Round1-Var94 (L158Y_E266S_E449D) 68% 43%Round2-Var66 Round1-Var94 (S42A_F46I_I407V) 160%  203%  Round2-Var67Round1-Var94 (N138K_E231A_D301N) 118%  93% Round2-Var68 Round1-Var94(K188R_G379L_N409R) 52% 35% Round2-Var69 Round1-Var94 (I15L_E231A_V396L)38% 22% Round2-Var70 Round1-Var94 (E231A_Q425E_Q432E) 115%  119% Round2-Var71 Round1-Var94 (D301N_K316R_Q425E) 126%  121%  Round2-Var72Round1-Var94 (L139V_I295M_F314S) 76% 91% Round2-Var73 Round1-Var94(S147G_E266S_D301N) 30% 18% Round2-Var74 Round1-Var94 (R64H_S147G_S447A)23% 12% Round2-Var75 Round1-Var94 (S42A_K303G_L398V) 95% 110% Round2-Var76 Round1-Var94 (I45V_D301N_E449D) 62% 60% Round2-Var77Round1-Var94 (V133A_E266S_I411V) 37% 28% Round2-Var78 Round1-Var94(I45V_N409R_Q425E) 63% 59% Round2-Var79 Round1-Var94 (R141T_A272P_F314S)23% 10% Round2-Var80 Round1-Var94 (E266S_S274G_N409R) 81% 91%Round2-Var81 Round1-Var94 (N409K_Q425E_S450K) 81% 84% Round2-Var82Round1-Var94 (N27S_R64H_K393R) 47% 37% Round2-Var83 Round1-Var94(S42A_A213N_V217L) 62% 46% Round2-Var84 Round1-Var94 (N27S_S274K_I407V)49% 44% Round2-Var85 Round1-Var94 (I411V_Q425E_S456L) 75% 81%Round2-Var86 Round1-Var94 (A239V_K316R_E449D) 83% 72% Round2-Var87Round1-Var94 (S147G_A239V_P348G) 18%  7% Round2-Var88 Round1-Var94(V20L_S274G_S450K) 71% 68% Round2-Var89 Round1-Var94 (F314S_V394I_S447A)88% 123%  Round2-Var90 Round1-Var94 (R64H_E266Q_I295M) 45% 47%Round2-Var91 Round1-Var94 (N138K_I295V_I407V) 50% 51% Round2-Var92Round1-Var94 (I15L_P348G_Q432E) 18% 13% *Mutations are noted as follows:reference gene-original amino acid-position-new amino acid: For examplethe mutation of an alanine at position 33 to a glycine for variant 94from the first round of directed evolution of UGT76G1 is noted asRound1-Var94 (A33G)

Modeling of these results allowed to obtain a ranking of the effect ofeach mutation. The following mutations were determined as beingbeneficial for activity: S42A, F46I, I190L, S274G, I295M, K303G, F314S,K316R, K393R, V394I, I407V, N409K, N409R, Q425E, Q432E, S447A, S456L.

Example 42 In Vivo Production of AtSUS

AtSUS >gi|79328294|ref|NP_001031915.1| sucrose synthase1 [Arabidopsis thaliana] (SEQ ID NO: 13)MANAERMITRVHSQRERLNETLVSERNEVLALLSRVEAKGKGILQQNQIIAEFEALPEQTRKKLEGGPFFDLLKSTQEAIVLPPWVALAVRPRPGVWEYLRVNLHALVVEELQPAEFLHFKEELVDGVKNGNFTLELDFEPFNASIPRPTLHKYIGNGVDFLNRHLSAKLFHDKESLLPLLKFLRLHSHQGKNLMLSEKIQNLNTLQHTLRKAEEYLAELKSETLYEEFEAKFEEIGLERGWGDNAERVLDMIRLLLDLLEAPDPCTLETFLGRVPMVFNVVILSPHGYFAQDNVLGYPDTGGQVVYILDQVRALEIEMLQRIKQQGLNIKPRILILTRLLPDAVGTTCGERLERVYDSEYCDILRVPFRTEKGIVRKWISRFEVWPYLETYTEDAAVELSKELNGKPDLIIGNYSDGNLVASLLAHKLGVTQCTIAHALEKTKYPDSDIYWKKLDDKYHFSCQFTADIFAMNHTDFITTSTFQEIAGSKETVGQYESHTAFTLPGLYRVVHGIDVFDPKFNIVSPGADMSIYFPYTEEKRRLTKFHSEIEELLYSDVENKEHLCVLKDKKKPILFTMARLDRVKNLSGLVEWYGKNTRLRELANLVVVGGDRRKESKDNEEKAEMKKMYDLIEEYKLNGQFRWISSQMDRVRNGELYRYICDTKGAFVQPALYEAFGLTVVEAMTCGLPTFATCKGGPAEIIVHGKSGFHIDPYHGDQAADTLADFFTKCKEDPSHWDEISKGGLQRIEEKYTWQIYSQRLLTLTGVYGFWKHVSNLDRLEARRYLEMFYALKYRPLAQ AVPLAQDD.

The synthetic gene of AtSuS that was codon optimized for expression inE. coli and subcloned in the pET30a+ plasmid using the NdeI and XhoIrestriction sites. The pET30A+ vector containing the AtSUS gene was usedto transform electrocompetent E. coli B121(DE3) cells. The obtainedcells were grown in petri-dishes in the presence of Kanamycin andsuitable colonies were selected and allowed to grow in liquid LB medium(erlenmeyer flasks). Glycerol was added to the suspension ascryoprotectant and 400 μL aliquots were stored at −20° C. and at −80° C.

The storage aliquots of E. coli BL21(DE3) containing the pET30A+_AtSUSplasmids were thawed and added to 30 mL of LBGKP medium (20 g/L LuriaBroth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM Phosphate buffer pH7.00; 2.5 g/L glucose and 50 mg/L of Kanamycine). This culture wasallowed to shake at 135 rpm at 30° C. for 8 h.

The production medium contained 60 g/L of overnight express instant TBmedium (Novagen), 10 g/L of glycerol and 50 mg/L of Kanamycine. Thepreculture was added to 800 mL of this medium and the solution wasallowed to stir at 20° C. while taking samples to measure the OD and pH.The culture gave significant growth and a good OD was obtained. After 40h, the cells were harvested by centrifugation and frozen to obtain 30.1g of cell wet weight.

Lysis was performed by Fastprep (MP Biomedicals, Lysing matrix B, speed6.0, 3×40 sec) with a cell suspension of 200 mg of cells in 1.0 mL of 50mM Tris buffer pH 7.5. The lysate was recovered by centrifugation andused fresh.

Example 43 Conversion of Rebaudioside A to Rebaudioside M with In SituPrepared UDP-Glucose Using UGTSL2, UGT76G1-R1-F12 and AtSUS

The reaction was performed at 1 mL scale using 100 mM of sucrose, 3 mMof MgCl₂, 0.25 mM of UDP and 0.5 mM of Rebaudioside A in potassiumphosphate buffer (50 mM final concentration, pH 7.5). The reaction wasstarted by adding 15 μL of UGTSL2 (see EXAMPLE 27) lysate (2 U/mL), 150μL of UGT76G1var94 (see EXAMPLE 26) (2.5 U/mL) and 15 μL of AtSUS (seeEXAMPLE 42) (400 U/mL). The reaction was followed by HPLC afterquenching 125 μL samples with 10 μL of 2 N H₂SO₄ and 115 μL of 60%methanol. 68% of Rebaudioside M and 26% of Rebaudioside M2 were obtainedafter 21 h of reaction time.

We claim:
 1. A method for producing target steviol glycosiderebaudioside D2 (reb D2) having the following structure:

comprising the steps of: a. providing an aqueous solution comprising astarting composition comprising steviol glycosides and wherein thesteviol glycosides comprise rebaudioside A (reb A); b. providing amicroorganism selected from the group consisting of E. coli,Saccharomyces species, Aspergillus species, Pichia species, Bacillusspecies, and Yarrowia species; said microorganism comprising at leastone enzyme selected from the group consisting of: geranylgeranyldiphosphate synthase, copalyl diphosphate synthase, kaurene synthase,kaurene oxidase, kaurenoic acid 13-hydroxylase (KAH), steviolsynthetase, deoxyxylulose 5-phosphate synthase (DXS), D-1-deoxyxylulose5-phosphate reductoisomerase (DXR),4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (CMS),4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (CMK),4-diphosphocytidyl-2-Cmethyl-D-erythritol 2,4-cyclodiphosphate synthase(MCS), 1-hydroxy-2-methyl-2(E)butenyl 4-diphosphate synthase (HDS),1-hydroxy-2-methyl-2(E)-butenyl 4-diphosphate reductase (HDR),acetoacetyl-CoA thiolase, truncated HMG-CoA reductase, mevalonatekinase, phosphomevalonate kinase, mevalonate pyrophosphatedecarboxylase, cytochrome P450 reductase, and a combination thereof;said microorganism further comprising a UDP-glycosyltransferase capableof adding at least one glucose unit to the steviol glycoside to providethe target steviol glycoside; said microorganism further optionallycomprising a UDP-glucose recycling enzyme; c. contacting themicroorganism with a medium containing the starting composition totransform rebaudioside A to rebaudioside D2 to produce a mediumcomprising rebaudioside D2; and d. purifying the rebaudioside D2 fromthe medium to provide a highly purified rebaudioside D2 composition. 2.The method of claim 1, wherein the UDP-glycosyltransferase is selectedfrom the group consisting of UGT91D2, UGTSL2, UGT76G1, or UGT76G1containing one or more point mutations selected from S42A, F46I, I190L,S274G, I295M, K303G, F314S, K316R, K393R, V394I, I407V, N409K, N409R,Q425E, Q432E, S447A and S456L.
 3. The method of claim 1, wherein thehighly purified rebaudioside D2 composition has a rebaudioside D2 puritygreater than about 95% by weight on a dry basis.
 4. The method of claim1, further comprising: e. contacting the reb D2 with an enzyme selectedfrom the group consisting of enzymes capable of transforming reb D2 toreb M2, UDP-glucose, and optionally UDP-glucose recycling enzymes toproduce a composition comprising reb M2; and f. isolating, andoptionally, purifying the composition comprising reb M2.
 5. The methodof claim 4, wherein reb M2 has a purity greater than about 95% by weighton an anhydrous basis.